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Abstract
In a meta-analysis, diﬀerences in the design and conduct of studies may cause vari-
ation in eﬀects beyond what is expected from chance alone. This additional variation
is commonly known as heterogeneity, which is incorporated into a random-eﬀects
model. The heterogeneity variance parameter in this model is commonly estimated
by the DerSimonian-Laird method, despite being shown to produce negatively biased
estimates in simulated data. Many other methods have been proposed, but there
has been less research into their properties.
This thesis compares all methods to estimate the heterogeneity variance in both
empirical and simulated meta-analysis data. First, methods are compared in 12,894
empirical meta-analyses from the Cochrane Database of Systematic Reviews (CDSR).
These results showed high discordance in estimates of the heterogeneity variance
between methods, so investigating their properties in simulated meta-analysis data
is worthwhile. A systematic review of relevant simulation studies was then conducted
and identiﬁed 12 studies, but there was little consensus between them and conclusions
could only be considered tentative.
A new simulation study was conducted in collaboration with other statisticians. Res-
ults conﬁrmed that the DerSimonian-Laird method is negatively biased in scenarios
where within-study variances are imprecise and/or biased. On the basis of these res-
ults, the REML approach to heterogeneity variance estimation is recommended. A
secondary analysis combines simulated and empirical meta-analysis data and shows
all methods usually have poor properties in practice; only marginal improvements
are possible using REML.
In conclusion, caution is advised when interpreting estimates of the heterogeneity
variance and conﬁdence intervals should always be presented to express its uncer-
tainty. More promisingly, the Hartung-Knapp conﬁdence interval method is robust to
poor heterogeneity variance estimates, so sensitivity analysis is not usually required
for inference on the mean eﬀect.
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Chapter 1
Introduction
1
1.1 Principles of systematic reviews and
meta-analysis
A systematic review collates and synthesises all relevant evidence for a given research
question using transparent and comprehensive procedures. Health researchers may
be inundated with information in the absence of a systematic review [51], so may
be unconsciously selective and potentially come to biased conclusions. A systematic
review can identify gaps in knowledge, so that research can be more focused on areas
where little is known or evidence in inconclusive. They allow those making changes
to health policy to make better judgements based on all available evidence and can
provide conclusive answers that would not be possible using individual studies.
Guidance for conducting a systematic review has been published by the Cochrane
Collaboration [51], Cooper and Hedges [19] and the Centre for Reviews and Dissem-
ination (University of York, UK) [13]. These guidance documents recommend the
following common steps. First, a research question should be identiﬁed and formu-
lated which is focused and concise, giving the review a clear aim. The next step is to
carry out a search of all literature that may provide relevant evidence in answering
the research question. Evidence is then appraised and selected for inclusion based
on explicit criteria decided at the planning stage of the systematic review. Exclusion
criteria may include, for example, the exclusion of literature in a foreign language or
studies that are not randomised controlled trials. The PRISMA statement (Preferred
Reporting Items for Systematic reviews and Meta-Analyses) advises the inclusion of
a ﬂow diagram in the ﬁnal report that documents all searching and screening steps
[76]. Finally, evidence is synthesised in a manageable and digestible way that allows
readers to consider conclusions made by the reviewer and also investigate how these
conclusions were drawn [13, 71].
Glass [32] coined the term meta-analysis, referring to the statistical collation of
results of related studies for the purpose of integrating the ﬁndings. Since the aims
of a meta-analysis complement those of a systematic review, they are frequently
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included as a component of a systematic review. However, these two approaches
to evidence synthesis can also exist in isolation [4]. A meta-analysis is a statistical
synthesis or summary of studies, most commonly producing an 'average' result across
the studies. It is an increasingly popular type of analysis in medical research [69, 112],
and has also been used in other areas including social [31] and education research
[1].
Many of the reasons to conduct a meta-analysis stem from the reasons to conduct a
systematic review; they help to understand what is often a large and diverse base of
evidence. Furthermore, a meta-analysis usually has greater power to detect a stat-
istically signiﬁcant result than any one of the included studies [13]. A meta-analysis
can also help to reduce bias in a systematic review because of the transparency of
its method; this is particularly true if methods are deﬁned up-front and justiﬁed in
a review protocol.
1.2 The Cochrane Database of Systematic Reviews
(CDSR)
One of the most notable contributing factors in the increase of published systematic
reviews and meta-analyses is the formation of Cochrane (formerly The Cochrane
Collaboration). The collaboration was founded in 1993 [36] and has grown such that
there are now over 15,000 contributing members and have produced and continue
to maintain over 3000 open-access systematic reviews [51]. The main aim of col-
laboration is to provide researchers, or anyone with personal health concerns with
high-quality resources for making informed health decisions. Their systematic re-
views are published in the Cochrane Database of Systematic Reviews (CDSR) along
with review protocols and editorials. Meta-analyses are often are often included
within the reviews to statistically combine study results. Data from meta-analyses
published by the collaboration are used in thesis, as noted in the front matter.
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1.3 Types of study-level data
In this section, I deﬁne the type of study-level data required for meta-analysis.
Ideally, this can be extracted directly from published papers, but this isn't always
possible. Methods for meta-analysis using these data are given from section 1.5
onwards.
Required study-level data usually consist of an estimate of some parameter and its
variance, denoted by θˆi and σˆ
2
i respectively for a given study i. This parameter is
commonly referred to as an eﬀect size. In a health research setting, this parameter
often represents a measure of the diﬀerence between two groups, such as an active
treatment groups and a control/placebo group. For example, a study may meas-
ure the risk of myocardial infarction in a group of patients receiving intravenous
magnesium and in a control group [114]. In this case, θˆi represents an estimated
diﬀerence in the risk between these groups [46]. To increase generality, I refer to
them as groups one and two in this thesis. A number of measures can be used to
calculate θˆi depending on the type of study outcome, such as an odds ratio for a
binary outcome, or a standardised mean diﬀerence for a continuous outcome. I show
how these measures, among others, are calculated in the following two sections.
1.3.1 Summarising continuous outcome data
In studies with a continuous outcome, data from each group can be summarised by
its mean, standard deviation and sample size. µˆ1i and µˆ2i denote the observed means,
sˆd1i and sˆd2i denote the observed standard deviations and n1i and n2i denote the
sample sizes in groups 1 and 2 respectively. The mean diﬀerence and the standardised
mean diﬀerence are two commons ways to measure the diﬀerence in µˆ1i and µˆ2i, which
are calculated as follows.
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1.3.1.1 Mean diﬀerence (MD)
The mean diﬀerence (MD) can be calculated by [8]:
θˆi = µˆ1i − µˆ2i
If we assume the equal variances of µˆ1i and µˆ2i, the variance of θˆi is:
σˆ2i =
n1i + n2i
n1in2i
· S2i
where
S2i =
(n1i − 1) sˆd21i + (n2i − 1) sˆd22i
n1i + n2i − 2 (1.1)
Alternatively, without making the equal-variances assumption:
σˆ2i =
sˆd21i
n1i
+
sˆd22i
n2i
1.3.1.2 Standardised mean diﬀerence (SMD)
If MDs are comparable but on diﬀerent scales, it is not advisable to combine them
in a meta-analysis in their current form. For example, the continuous outcome of
physical functioning could be measured in rehabilitation studies using measures based
on diﬀerent questionnaires with diﬀerent scoring methods [130]. To address this
problem and allow studies to be pooled more meaningfully, we calculate standardised
mean diﬀerences (SMD) [8]:
θˆi =
µˆ1i − µˆ2i
Si
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where Si is the estimated standard deviation of the mean diﬀerence (see formula 1.1)
an assumes equal variances between groups.
When θˆi is on the SMD scale, a good approximation of its variance is:
σˆ2i =
n1i + n2i
n1in2i
+
θˆ2i
n1i + n2i
Hedges [43] proved that the SMD measure has positive bias in studies with small
sample sizes and therefore suggested applying a correction factor; the bias corrected
θˆi becomes Ji · θˆi and σˆ2i becomes J2i ·σˆ2i where Ji = 1−3/ (4 (n1i + n2i − 2)− 1). The
correction factor has since become widely used and suggested in many meta-analysis
texts [8, 19, 42, 128].
Continuous study outcomes are usually on the same scale, so the unstandardised
mean diﬀerence (MD) is more commonly used in practice [19, 88].
1.3.2 Summarising binary outcome data
In studies with a binary outcome, data can be presented in the form of a contingency
table (e.g. table 1.1). From this data, we can derive measures that compare the event
probability between groups such as the relative risk or odds ratio.
Event No event Total
Group 1 ai bi n1i = ai + bi
Group 2 ci di n2i = ci + di
Total ai + ci bi + di Ni = ai + bi + ci + di
Table 1.1: Standard contingency table notations for a study i with a binary
outcome
1.3.2.1 Relative risk (RR)
The risk of an event in groups one and two are ai/n1i and ci/n2i. The relative
risk (RR) is a comparison between the two groups and is thus (ai/n1i) / (ci/n2i)
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[8]. This measure is transformed onto the log scale for meta-analysis to make the
eﬀect estimate within a given study conform approximately to a normal sampling
distribution. Normality of study estimates is one of the assumptions in the standard
meta-analysis models introduced in section 1.5.1. The log RR (θˆi) and its variance
(σˆ2i ) in each study are therefore:
θˆi = log
(
ai/n1i
ci/n2i
)
σˆ2i =
1
ai
− 1
n1i
+
1
ci
− 1
n2i
θˆi and σˆ
2
i cannot be calculated in the above formulae when zero events are observed
in one or both groups. Throughout this thesis, a continuity correction is applied
when required by adding 0.5 to ai, bi, ci and di [10]. Other methods are available for
dealing with zero events [113].
1.3.2.2 Odds ratio (OR)
The odds of an event in study groups one and two are ai/bi and ci/di. From this,
the odds ratio (OR) is (ai/bi) / (ci/di). As with RRs, ORs are transformed onto the
log scale:
θˆi = log
(
ai/bi
ci/di
)
σˆ2i =
1
ai
+
1
bi
+
1
ci
+
1
di
As for RR, a continuity correction is required when zero events are observed.
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The OR measure has superior statistical properties over RR [5, 19]. First, estimated
ORs don't change when the cause and eﬀect is reversed (i.e. if the study groups
become the event of interest and vice versa). Second, logistic regression methodology
of binary data has developed using the odds ratio measure, so this gives added
convenience when conducting a logistic regression analysis [5]. Finally, ORs follow
the normal distribution more closely than RRs when transformed to the log scale.
These are perhaps some of the reasons why it is the most commonly used measure
in systematic reviews of health research (see chapter 4 for a summary of outcome
measures used in meta-analyses from Cochrane reviews).
1.4 Heterogeneity of true study eﬀects
Studies brought together in a meta-analysis usually diﬀer to some extent in how
they are designed and conducted. Therefore, observed study eﬀects (θˆi) in a meta-
analysis often have a higher dispersion than what is expected from their observed
variances (σˆ2i ) alone. This extra variability is known as heterogeneity and is the
central theme of this thesis. Meta-analyses containing heterogeneous studies should
not only combine studies into an average result, they should also estimate and explore
the plausible range of study eﬀects [8, 48]. This is particularly necessary, for instance,
in a meta-analysis where the intervention is proven eﬀective on average but may be
harmful in certain cases.
The Cochrane handbook suggests causes of heterogeneity can be split into two cat-
egories; methodological and clinical [51]. Methodological heterogeneity is the variab-
ility caused by diﬀerences in study design and risk of bias. Clinical heterogeneity is
the variability caused by diﬀerences in the participants, interventions and outcomes
studied. Clinical and methodological heterogeneity are both observed because of
diﬀerences in the study design and its conduct. The key diﬀerence is that for clinical
heterogeneity, diﬀerences in study design uncover heterogeneity that is ultimately
attributable to variation of intervention eﬀects in real settings. Thus, Glasziou and
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Sanders [33] alternatively deﬁnes these two distinct categories of heterogeneity as
artiﬁcial and real. The former is considered nuisance heterogeneity, exploring this
can tells us little about how an intervention works outside of the study setting.
The causes of heterogeneity can be numerous and diverse, which often makes identi-
fying them infeasible in practice. Alternatively, they may simply be unknown. To
address the presence of heterogeneity in such cases, we may (1) refrain from pool-
ing the studies together in a meta-analysis if extent of heterogeneity is too great,
(2) choose to ignore it or (3) account for this extra variability in the analysis stage
[51]. The latter two can be accomplished by implementing ﬁxed and random-eﬀects
models respectively, which I introduce in the next section.
In some cases, researchers may hypothesise that quantiﬁed study characteristics ex-
plain all or a proportion of the observed heterogeneity. These characteristics can be
used to carried out a sub-group analysis or added as a covariate in the meta-analysis
model [112, 115]. This can be accomplished by implementing a meta-regression
model, which I also introduce in the next section. Meta-regression typically only
works with few study characteristics because meta-analyses in health research con-
tain few studies [115].
1.5 Meta-analysis models
I ﬁrst introduce the ﬁxed-eﬀect model in section 1.5.1 which makes the assump-
tion that study eﬀects are homogeneous. In section 1.5.2, the random-eﬀects model
includes an added variance parameter to taken into account any observed, but un-
explained, heterogeneity. I show in section 1.5.3 how study covariates can be added
random eﬀects model when some heterogeneity can be explained. In section 1.5.4, I
introduce the Bayesian approach to random-eﬀects models.
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1.5.1 The standard ﬁxed-eﬀect model
The term 'ﬁxed-eﬀect' refers to the fact that all studies in the meta-analysis are as-
sumed to be estimating a common parameter value θ. Meta-analysis models usually
assume observed study eﬀects in a meta-analysis conform to the normal distribution:
θˆi ∼ N
(
θ, σ2i
)
where θ is the true ﬁxed summary eﬀect size in the meta-analysis and σ2i is the true
variance in studies i = 1, ..., k.
1.5.2 The standard random-eﬀects model
A random-eﬀects model accounts for the possibility that θˆi are estimates of diﬀerent
true study eﬀect parameters θi:
θˆi ∼ N
(
θi, σ
2
i
)
In this model, the distribution of θi has a mean θ and a heterogeneity variance
denoted by τ 2. Some meta-analysis methods assume the normal distribution for θi:
θi ∼ N
(
θ, τ 2
)
A crucial, but sometimes overlooked distinction [89], from a ﬁxed-eﬀect model is that
θˆ is an estimate of the average from a distribution of study eﬀects [48].
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1.5.3 Modelling with covariates
Study-level variables may be available that explain a proportion of the total het-
erogeneity. In this case, a meta-regression can be carried out by adding these as
parameters in the random-eﬀects model:
θˆi ∼ N
(
θi, σ
2
i
)
θi ∼ N
(
θ +
m∑
j=1
βj, τ
2
)
where βij is the jth variable in a model containing m covariates.
In this model, τ 2 can be considered the residual variance of the true eﬀects. The
same methods are available to estimate τ 2 in both models, which are introduced in
section 1.7.1 and detailed comprehensively in chapter 2.
1.5.4 Bayesian models
A Bayesian approach to meta-analysis may be taken using any of the above models
[106, 111]. The distinguishing feature of a Bayesian model is that parameters are
considered random quantities so we want to estimate its distribution rather than its
value. The approach also involves combining the meta-analysis data with our prior
beliefs about the parameters. For example, if we assume the random-eﬀects model
with no covariates, we can select prior distributions for the parameter values τ 2 and
θ. These prior distributions can be speciﬁed based on expert opinion or on similar
meta-analyses in the same research ﬁeld [49, 120]. Prior distributions can also be
vague if researchers can deduce little about the parameter value prior to conducting
the meta-analysis.
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Applying Bayes theorem results in the following joint posterior distribution, where
ϕ is the vector of parameters of interest (e.g. τ 2 and θ):
P (ϕ | data) ≈ P (ϕ)P (data | ϕ)
P (ϕ | data) is the posterior distribution based on a combination of the prior distri-
bution, P (ϕ), and the observed data P (data | ϕ).
Running a Bayesian analysis with many model parameters can be complicated and
involves high-dimensional integration. However, it is becoming easier with recent
technological advances. The posterior distribution is calculated using Markov Chain
Monte Carlo (MCMC) methods. MCMC works by simulating from the high dimen-
sional joint probability distribution, most commonly for the parameters θ and τ 2, to
ﬁnd a solution. Gibbs Sampling is used often in practice and is known to work well
in this setting [111].
1.6 The inverse-variance method
One of the main aims of a meta-analysis is to combine studies and produce an
average estimate for θ. Studies typically vary in terms of size and assuming studies
are all of equal quality, larger studies tend to estimate the parameter with more
precision. The inverse-variance method is commonly used to combine studies in a
meta-analysis, which gives more precise studies a larger weighting and thus more
inﬂuence on the average eﬀect size. Using this method, θ and its variance can be
estimated by:
θˆ =
∑k
i=1 wˆiθˆi∑k
i=1 wˆi
(1.2)
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V ar
(
θˆ
)
=
1∑k
i=1 wˆi
(1.3)
Study weights can only be estimated from the data and are denoted by wˆi, which
are calculated by the reciprocal of V ar
(
θˆi
)
. If we assume a common eﬀect, like the
ﬁxed-eﬀect model in section 1.5.1, the within-study variance is assumed to account
for all the variability of θˆi and therefore wˆi = 1/σˆ
2
i . If we allow for random eﬀects,
like the random-eﬀects model in section 1.5.2, wˆi = 1/ (σˆ
2
i + τˆ
2).
Conﬁdence intervals for θ are commonly calculated using the Wald-type method [25]
based on the above variance (1.3):
[
θˆ − Φ−1
(
1− α
2
)
·
√
V ar
(
θˆ
)
, θˆ + Φ−1
(
1− α
2
)
·
√
V ar
(
θˆ
)]
(1.4)
where Φ−1
(
1− α
2
)
is the
(
1− α
2
)
th percentile of the normal distribution and α is
the signiﬁcance level. α is usually 0.05, leading to a 95% conﬁdence interval.
Other conﬁdence interval methods are available, which I describe in chapter 3. Al-
ternative methods exist for combining studies that are speciﬁc to meta-analysis of
binary data, including Peto [81] and Mantel-Haenszel methods [75]. These methods
can only estimate the summary eﬀect if common eﬀects are assumed, but hetero-
geneity can still be estimated and incorporated in the conﬁdence interval for the
summary eﬀect [128].
1.7 Quantifying heterogeneity
I now outline a common method to estimate the heterogeneity variance parameter,
τ 2, as deﬁned in the standard random-eﬀects model in section 1.5.2. Then, I intro-
duce the I2 statistic, which estimates the proportion of study eﬀect inconsistency
that is attributable to heterogeneity.
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1.7.1 Estimating the heterogeneity variance
A common approach to estimating the heterogeneity variance parameter, τ 2, is that
proposed by DerSimonian and Laird [25]. The method is based on the Q-statistic:
Q =
k∑
i=1
wˆi(θˆi − θˆ)2
Q is also used as a test statistic for the presence of heterogeneity, a p-value for this
test is derived by referring Q to the χ2-distribution with k− 1 degrees of freedom. If
σˆ2i adequately account for the total observed variance and θˆi are normally distributed
around θi, then E [Q] = k − 1, i.e. the expected value of χ2k−1.
The DerSimonian-Laird method to estimate τ 2 is based on Q:
τˆ 2 = max
0, Q− (k − 1)∑k
i=1 wˆi −
∑k
i=1 wˆ
2
i∑k
i=1 wˆi

The numerator is a standardised measure of the extent that Q exceeds its expec-
ted value under the common eﬀect assumption. This measure is converted to the
same scale as θˆ by the denominator. The method estimates τ 2 with no distribution
assumption for θi.
When Q < k − 1, heterogeneity variance estimates are truncated at zero as shown
in the formula above. Other methods to estimate τ 2 are available; these are detailed
in chapter 2.
1.7.2 The I2 statistic
I2 represents the proportion of the total variance that can be attributed to hetero-
geneity of true study eﬀects and is more intuitive to interpret than τ 2. This is derived
by transforming the Q-statistic [47]:
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I2 =
Q− (k − 1)
Q
· 100% (1.5)
Unlike τ 2, I2 is independent of the scale of measurement (i.e. I2 can be compared
between meta-analyses with SMD and OR outcome measures). An alternative for-
mula for I2 is also given in the original paper [47], where its interpretation becomes
more apparent:
I2 =
τˆ 2
τˆ 2 + σˆ2
· 100% (1.6)
where σˆ2 is an estimate of the typical within-study variance:
σˆ2 =
(k − 1)∑ki=1 wˆi(∑k
i=1 wˆi
)2
−∑ki=1 wˆ2i
and wˆi = 1/σˆ
2
i
σˆ2 is a measure mainly proposed to calculate I2 via formula 1.6 and represents the
estimated within-study variance if studies have equal σ2i . In reality, σ
2
i vary from
study-to-study and therefore formula 1.6 is not considered a true deﬁnition of I2 [8].
I2 is more commonly calculated from Q-based formula 1.5 for this reason and because
of its convenient relationship with the DerSimonian-Laird method for estimating τ 2.
1.8 Prediction intervals
A prediction interval is used to measure the spread of true eﬀect sizes (θi) in a meta-
analysis with heterogeneous studies [48]. The interval can also predict the eﬀect
size of a new study to be included in the meta-analysis, hence the name 'prediction
interval'. The prediction interval, as proposed by Higgins et al. [48], is:
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[
θˆ − t1−(α/2)k−2 ·
√
τˆ 2 + V
(
θˆ
)
, θˆ + t
1−(α/2)
k−2 ·
√
τˆ 2 + V
(
θˆ
)]
where θˆ is estimated as in equation 1.2 with random-eﬀects weights and t
1−(α/2)
k−2
represents the
(
1− α
2
)
th percentile of the t-distribution with k−2 degrees of freedom.
α is usually 0.05, leading to a 95% prediction interval.
The interval should not be confused with the conﬁdence interval for θˆ, which I
introduced in section 1.5.1.
1.9 Fixed eﬀect vs. random-eﬀects models
Using a ﬁxed-eﬀect model is appropriate when there is a contextual reason to believe
study results are homogeneous. However, there is usually doubt whether the common
eﬀect assumption holds due to diﬀerences in study design or sampling population.
Until recently, a common approach in such cases was to test for the presence of
heterogeneity using the method based on the Q-statistic (section 1.7.1). The decision
to use a ﬁxed eﬀect or random-eﬀects model is then based on whether evidence for
heterogeneity is statistically signiﬁcant. However, simulation studies show this test
has low power in meta-analyses typically seen in practice [44, 57] and therefore its use
has been discouraged [8, 51]. A stronger argument against this test for heterogeneity
is that meta-analyses are likely to contain heterogeneous studies even if there is no
evidence from their results [40, 112].
The random-eﬀects model is advocated when studies are potentially heterogeneous.
The model reduces to the ﬁxed-eﬀect model when the heterogeneity variance is es-
timated to be zero, which occurs frequently using the DerSimonian-Laird method
in practice [64]. The random-eﬀects model is commonly used in meta-analysis and
leads to more conservative results than the ﬁxed-eﬀect model when the heterogen-
eity variance parameter is positive by producing wider conﬁdence intervals of the
summary eﬀect [8].
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The random-eﬀects model is not without criticisms. True study eﬀect sizes are as-
sumed to be normally distributed, which is unlikely given that bias (e.g. publication
bias) is often present but undetectable [109]. Second, small studies are sometimes
given a disproportionately high weight when studies are pooled using the inverse
variance method [46]; small and large studies can have almost equal weight if the
heterogeneity variance is comparatively high. Finally, estimating the heterogeneity
variance parameter in a random-eﬀects model presents many additional problems,
as I will detail in the next section and address in the rest of this thesis.
1.10 An overview of the thesis
1.10.1 An overview of problems associated with heterogeneity
variance estimation
Estimates of the heterogeneity variance in a random eﬀects meta-analysis are usually
imprecise [48, 120]. This is mainly because there are rarely suﬃcient numbers of
studies contained in meta-analyses of health interventions [21]. Additional problems
are apparent in meta-analyses with binary outcome measures such as the log odds
ratio [78]. Binary outcome eﬀect measures are correlated with their variance but the
random-eﬀects model assumes they are independent. Also, studies with rare events
have large within-study variances, may require a continuity correction and contribute
less to the summary eﬀect [3].
Aside from the general problems of estimating the heterogeneity variance, the Der-
Simonian and Laird method in particular has been criticised. Simulation studies
show the method underestimates heterogeneity variance when the underlying level
of heterogeneity is high [78, 79, 124]. The method's bias is thought to be attributed
to a failure of the methods only assumption: within-study variances used to calculate
study weights are assumed to be known. The method has been proven theoretically
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unbiased when this assumption holds [7, 124], but within-study variances can usually
only be estimated in practice.
An estimate of the heterogeneity variance is required to calculate many other com-
monly reported statistics in meta-analysis, such as the summary eﬀect and its con-
ﬁdence interval. The Wald-type method for producing these conﬁdence intervals has
been shown in simulation studies to be artiﬁcially narrow [61, 96]. The two main
reasons for this are: (1) As already mentioned, DerSimonian-Laird on average un-
derestimates the heterogeneity variance and (2) the Wald-type method assumes the
heterogeneity variance is known, but is usually estimated and imprecise [96].
Alternative methods have since been proposed to estimate the heterogeneity variance
and conﬁdence interval of the summary eﬀect. Some of these methods show more
promising results in simulated data [16, 37, 40, 74, 93, 100, 102]. However, most of
these studies are not comprehensive and recommend conﬂicting alternative methods.
Therefore, there is currently no overall consensus as to which methods should be used
in frequentist random-eﬀects meta-analysis.
1.10.2 Focus of the thesis
My thesis reviews and compares methods to estimate the heterogeneity variance
as deﬁned in the standard random-eﬀects model in section 1.5.2. This model in
particular contains no covariates and assumes all observed between-study variance
is random and cannot be explained. However, heterogeneity estimation methods
can readily be applied to a random-eﬀects model with covariates, so I discuss in the
conclusion chapter whether my ﬁndings can be applied in this context. I focus almost
solely on heterogeneity estimation in the frequentist framework, but allow exceptions
for Bayesian methods that do not require complex integration and inexplicit prior
distributions.
I focus speciﬁcally on methods for two-stage meta-analysis. A two-stage meta-
analysis refers to the methods outlined in this chapter. It is deﬁned as 'two-stage' be-
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cause study summary data must ﬁrst be extracted/derived before the meta-analysis is
conducted. An alternative to a two-stage meta-analysis is a one-stage meta-analysis
of individual participant data (IPD) [90, 104]. Many IPD meta-analyses combine
each study dataset and perform a meta-analysis in one step, which allows for a full
exploration of the study data [8]. However, the approach is usually more time-
consuming and therefore not as common as the two-stage approach [119].
1.10.3 Aims
Expanding on the last section, the aims are to:
1. Conduct a comprehensive review of heterogeneity variance estimation methods
currently available in the literature.
2. Assess the level of agreement between diﬀerent heterogeneity variance methods
in practice.
3. Compare the relative performance of methods in simulated data to establish
which method(s) have the best properties.
4. Investigate the absolute performance of methods in simulated data to establish
if and when all methods perform poorly.
5. Investigate whether any characteristics of meta-analyses can explain the prop-
erties of methods.
6. Recommend methods for random-eﬀects meta-analysis and propose alternative
strategies when all methods perform poorly.
In all chapters of this thesis where heterogeneity variance estimators are compared,
I compare not only their estimates but their impact on the summary eﬀect estimate
and its conﬁdence interval. As a consequence, the properties of methods to calculate
these statistics are investigated as a secondary aim.
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1.10.4 Structure of the thesis
The introductory chapters continue with a review of methods in two-stage random-
eﬀects meta-analysis. Chapter 2 contains a comprehensive review of heterogeneity
variance estimation methods. Conﬁdence interval methods for the summary eﬀect
follow in chapter 3. The latter is not intended to be a complete review, but an
introduction to the conﬁdence interval methods I have selected to use throughout
the rest of the thesis.
To address the second aim of the thesis, chapter 4 compares methods in 12,894 em-
pirical meta-analyses extracted from the Cochrane Database of Systematic Reviews
(CSDR). Chapter 5 then reports a systematic review of previous studies that com-
pare the properties of heterogeneity variance estimators in simulated meta-analysis
data. Findings from this systematic review show that aims 3-5 have not been suf-
ﬁciently addressed in the literature and so a further simulation study was required.
Chapter 6 details the protocol of a further simulation study, designed in light of the
limitations of current evidence identiﬁed in the systematic review. Chapters 7 and
8 then present the results from this simulation study.
Finally, chapter 9 concludes the thesis by summarising the main ﬁndings and dis-
cusses their implications for methods in random-eﬀects meta-analysis. I make re-
commendations informed by ﬁndings from this thesis and from a review of the wider
evidence base. Limitations of the heterogeneity variance methods and any limita-
tions caused by scope of the thesis are discussed along with opportunities for further
research.
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Chapter 2
Methods for estimating the
heterogeneity variance
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2.1 Introduction
An estimate of the heterogeneity variance is often used to gauge inconsistency between
study eﬀects and is required to conduct a random-eﬀects meta-analysis. I described in
chapter 1 the DerSimonian-Laird method, commonly used to estimate the heterogen-
eity variance. This method has been widely criticised in the literature for producing
negatively biased estimates [78, 101, 124] and therefore, many other methods have
since been proposed. I present a comprehensive review of heterogeneity estimation
methods in this chapter, highlight any methodological similarities and ﬁnish with an
example to show these similarities in the context or a real meta-analysis.
This chapter was written concurrently with a systematic review of methods for es-
timating the heterogeneity variance that I co-authored [122]. I provided amendments
after it was initially drafted by the ﬁrst author. Methods in this paper were identiﬁed
in a formal search of the PubMed database by the ﬁrst author (Areti Angeliki Ver-
oniki); the details of this search are given in appendix 9.5. All articles identiﬁed in
this search are referenced in this chapter, which otherwise represents my own work.
The heterogeneity variance estimators in this chapter fall within a number of distinct
approaches. I ﬁrst introduce the method of moments approach in section 2.2, which
consists of the DerSimonian-Laird estimator and a number of others. The maximum
likelihood approach is introduced in section 2.5 and the Bayesian approach in section
2.6.
A number of estimators are proposed that only allow for positive heterogeneity
variance estimates. These are proposed with the ethos described by Hartung and
Makambi [40]: ...it may sometimes be diﬃcult, in many applications, to accept
zero as an estimate of the between-study variance when it is well known that there
is some variation (albeit small) between groups/studies under consideration. This
makes it desirable to derive a positive estimator for between-study variance. These
positive estimators include Hartung-Makambi (section 2.3.1), those belonging to the
Sidik-Jonkman approach (section 2.3.2) and all Bayesian estimators (section 2.6).
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I introduce acronyms for each estimator in this chapter, which are used in the rest of
the thesis. Table 2.1 on page 43 details all acronyms for reference. Also note, I use
the general notation wˆi for estimated study weights but these vary from estimator-
to-estimator; I specify their functional form in each section.
Methods in this chapter were programmed in R (3.2.3) for use in all analyses in the
rest of this thesis. I coded all methods that were not already available in the R
package metafor [126].
2.2 Method of moments approach
This uniﬁed approach to heterogeneity estimation was initially proposed by Kacker
[59], then DerSimonian and Kacker [24] explained the approach within a meta-
analysis context. DerSimonian-Laird, Cochran's ANOVA and Paule-Mandel are
estimators that pre-date this approach but have since been recognised within this
uniﬁed identity [24]. I explain the commonality between these estimators before
introducing them individually in sections 2.2.1 - 2.2.5.
The approach is based on the generalised Q-statistic:
QMM =
k∑
i=1
wi
(
θˆi − θˆ
)2
θˆ =
k∑
i=1
(
wiθˆi
)
/
k∑
i=1
wi (2.1)
where k denotes the number of studies in the meta-analysis and study weights are
denoted by wi
We assume wi takes no speciﬁc form for the general method of moments approach
and may be known or estimated from the study data. Therefore, θˆ is a generic
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weighted average of study eﬀects θˆi. QMM becomes the Q-statistic introduced in
chapter 1 when wˆi = 1/σˆ
2
i is substituted for wi.
The aim of this section is to derive a general method of moments formula for the
heterogeneity variance. First, recall that V ar
(
θˆi
)
is made of the two variance com-
ponents σ2i + τ
2 in a random-eﬀects model and θˆ is calculated as in equation 2.1. If
we take the expected value of the unweighted squared error for a given study i [59]:
E
[(
θˆi − θˆ
)
2
]
= V ar
(
θˆi − θˆ
)
= V ar
(
θˆi
)
+ V ar
(
θˆ
)
− 2Cov
(
θˆi, θˆ
)
=
(
σ2i + τ
2
)
+
∑k
i=1w
2
i (σ
2
i + τ
2)(∑k
i=1wi
)
2
− 2wi (σ
2
i + τ
2)∑k
i=1wi
Therefore, the expected value of QMM is:
E
[
k∑
i=1
wi
(
θˆi − θˆ
)
2
]
=
∑
k
i=1E
[
wi
(
θˆi − θˆ
)
2
]
=
k∑
i=1
w2i
(
σ2i + τ
2
)
+
∑k
i=1w
2
i (σ
2
i + τ
2)∑
wi
− 2
∑k
i=1w
2
i (σ
2
i + τ
2)∑
wi
=
k∑
i=1
w2i
(
σ2i + τ
2
)− ∑ki=1w2i (σ2i + τ 2)∑
wi
To derive a formula for the estimated heterogeneity variance (τˆ 2), equate the expec-
ted value to its observed value:
k∑
i=1
wi
(
θˆi − θˆ
)
2 =
k∑
i=1
wiσ
2
i + τˆ
2
k∑
i=1
wi −
∑k
i=1w
2
i σ
2
i∑k
i=1wi
− τˆ 2
∑k
i=1w
2
i∑k
i=1wi
= τˆ 2
(
k∑
i=1
wi −
∑k
i=1w
2
i∑k
i=1wi
)
+
k∑
i=1
wiσ
2
i −
∑k
i=1w
2
i σ
2
i∑k
i=1wi
⇐⇒
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τˆ 2 =
∑k
i=1wi
(
θˆi − θˆ
)
2 −
(∑k
i=1wiσ
2
i −
∑k
i=1 w
2
i σ
2
i∑k
i=1 wi
)
∑k
i=1wi −
∑k
i=1 w
2
i∑k
i=1 wi
(2.2)
The approach assumes that σ2i are known and these are usually replaced by estimates
σˆ2i in the above formula [6]. All method of moments estimators can be derived from
the formula 2.2, but with wi taking diﬀerent functional forms.
None of the proposed study weights ensure τˆ 2 > 0 in formula 2.2. Therefore, for
all method of moments estimators, τˆ 2 is truncated to zero whenever it would oth-
erwise be negative. Method of moments estimators make no assumption about the
distribution of θi, unlike most other methods introduced in this chapter [62, 93, 94].
2.2.1 DerSimonian-Laird (DL)
The DerSimonian-Laird (DL) estimator [25] was introduced in the introduction
chapter. I showed that DL is derived from the Q-statistic, which is the same as
QMM with study weights wˆi = 1/σˆ2i . With these weights, the method of moments
formula 2.2 derived earlier for τˆ 2 becomes:
τˆ 2DL = max
0,
∑k
i=1 (1/σˆ
2
i )
(
θˆi − θˆDL
)
2 − (k − 1)∑k
i=1 (1/σˆ
2
i )−
∑k
i=1(1/σˆ2i )
2∑k
i=1(1/σˆ2i )

where θˆDL =
∑k
i=1
(
wˆiθˆi
)
/
∑k
i=1 wˆi
Kontopantelis et al. [64] introduced an alternative DL estimator (DLP), with a cut-oﬀ
value of 0.01 to ensure all estimates are positive.
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2.2.2 Cochran's ANOVA (CA)
Cochran's ANOVA (CA) estimator [18] was proposed in 1954 before being introduced
into the random-eﬀects meta-analysis context by Hedges and Olkin [42]. Kacker [59]
then showed CA is part of the general method of moments approach. CA assigns
equal weight to each study, most commonly wi = 1/k [24], but any positive constant
would produce identical heterogeneity variance estimates.
Weights wi = 1/k are substituted into formula 2.2:
τˆ 2CA = max
{
0,
1
k − 1
k∑
i=1
(
θˆi − θˆCA
)
2 − 1
k
k∑
i=1
σˆ2i
}
(2.3)
where θˆCA =
∑k
i=1 θˆi/k
Cochran [18] originally derived the estimator by rearranging θˆ's variance components:
τ 2 = V ar
(
θˆ
)
− σ2
σ2 denotes the typical within-study variance, estimated assuming equal variances:
σˆ2 =
∑k
i=1 σˆ
2
i /k. V ar
(
θˆ
)
is estimated using the unweighted formula for a sampling
variance. This equates to formula 2.3 above.
2.2.3 Non-parametric Bootstrap DerSimonian-Laird (DLB)
Kontopantelis et al. [64] proposed a bootstrap version of the standard DL estimator
(DLB) to reduce the number of zero τ
2 estimates. A bootstrap estimate of τ 2 is
calculated in four steps:
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1. k studies are sampled randomly with replacement (the same number as in the
meta-analysis)
2. τˆ 2DL is calculated for the sample.
3. 1-2 is repeated 10,000 times in order to derive a distribution for τˆ 2DL. Note,
fewer samples may be required if k is small.
4. The mean of this distribution is the bootstrap estimate of τ 2.
The bootstrap method could trivially be applied to other τ 2 estimators [26].
2.2.4 Paule-Mandel (PM)
The Paule-Mandel estimator (PM) [80] was originally proposed in the more general
context of combining measurements from diﬀerent experiments. The method has
since been introduced into the meta-analysis framework [9, 24].
Weights of each study take the form wˆi = 1/ (σˆ
2
i + τˆ
2
PM). A non-closed form expres-
sion for τˆ 2PM can be derived by substituting these weights wˆi into formula 2.2:
τˆ 2PM =
∑k
i=1 wˆi(θˆi − θˆPM)2 −
(∑k
i=1 wˆiσ
2
i −
(∑k
i=1 wˆ
2
i σ
2
i
)
/
(∑k
i=1 wˆi
))
∑k
i=1 wˆi −
(∑k
i=1 wˆ
2
i
)
/
(∑k
i=1 wˆi
) (2.4)
where θˆPM =
∑k
i=1
(
wˆiθˆi
)
/
∑k
i=1 wˆi
As the heterogeneity variance parameter is included in the study weights, τˆ 2PM is
found by a process of iteration until convergence. The initial estimate of τˆ 20 = 0 is
commonly used to begin the process. If at any step the estimate is negative, then
set τˆ 2PM = 0. Rukhin et al. [94] demonstrated that there is always just one solution
and the process always converges irrespective of the initial estimate.
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Alternatively, a neater expression than formula 2.4 can be derived if we substitute
wˆi into QMM . Since wˆi are random-eﬀects weights that account for the total study
variance, we constrain QMM to asymptotically follow the χ
2
k−1-distribution with ex-
pected value k − 1 on the assumption that θˆi are normally distributed around θi.
Equating QMM in this case to this expected value:
k∑
i=1
(
θˆi − θˆPM
)2
σˆ2i + τˆ
2
PM
= k − 1
However, ﬁnding τˆ 2PM using this expression involves an iterative process that is less
intuitive [24, 80].
PM is also known as the empirical Bayes estimator because they were thought to be
separate methods until Rukhin [93] noted their equivalence. Despite this alternative
name, PM is not an empirical Bayes approach to heterogeneity variance estimation.
It gets this name from Morris [77], who used the PM heterogeneity variance estimator
in an empirical Bayes approach to estimate θ.
2.2.5 Two-step versions of Paule-Mandel (PMCA & PMDL)
DerSimonian and Kacker [24] introduced two alternative versions of PM that do not
require complete iteration to convergence. They use the same random-eﬀects study
weights as PM but iteration is restricted to two-steps with initial estimates τˆ 20 = τˆ
2
CA
and τˆ 20 = τˆ
2
DL. For the former, the general method of moments formula 2.2 becomes
the following closed form expression:
τˆ 2PMCA =
∑k
i=1 wˆi(θˆi − θˆCA)2 −
(∑k
i=1 wˆiσ
2
i −
(∑k
i=1 wˆ
2
i σ
2
i
)
/
(∑k
i=1 wˆi
))
∑k
i=1 wˆi −
(∑k
i=1 wˆ
2
i
)
/
(∑k
i=1 wˆi
) (2.5)
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where wˆi = (σˆ
2
i + τˆ
2
CA)
−1 and θˆCA is deﬁned in section 2.2.2
For the latter two-step estimator, weights are wˆi = (σˆ
2
i + τˆ
2
DL)
−1 and θˆDL is deﬁned
in section 2.2.1.
The main criticism of PMCA and PMDL is that restricting PM to two iterative steps
is unnecessary and not considered statistically optimal. PM heterogeneity variance
estimates can easily be computed using reliable iterative techniques widely available
in many statistical software packages.
2.3 Non-truncated moments-based approaches
2.3.1 Hartung-Makambi (HM)
As mentioned in section 2.2, method of moments estimators allow for negative es-
timates of the heterogeneity variance and should be truncated at zero. Hartung
and Makambi [40] proposed a correction to τˆ 2DL so that τˆ
2 is always positive and
truncation is not required. Recall that:
τˆ 2DL = max
{
0,
Q− (k − 1)
c
}
where c =
∑k
i=1 wˆi −
(∑k
i=1 wˆ
2
i /
∑k
i=1 wˆi
)
, wˆi = 1/σˆ2i and Q is the statistic deﬁned
in chapter 1.
τˆ 2DL is negative and must be truncated to zero when Q < (k − 1). The estimator is
derived by taking the ﬁrst term of τˆ 2DL (Q/c), which is always positive and applying a
positive multiplicative correction factor denoted by ε. This correction factor accounts
for the bias introduced as a result of excluding the term (k − 1) /c. The estimator
takes the form τˆ 2HM = ε ·Q/c, where:
29
ε =
Q
2 (k − 1) +Q
and therefore:
τˆ 2HM = ε ·
Q
c
=
Q
2 (k − 1) +Q
(
Q
c
)
=
Q2
c (2 (k − 1) +Q)
It is not clear in the original paper [40] why ε takes this form or the extent that Q/c
is biased before a correction factor is applied.
2.3.2 Sidik-Jonkman (SJ)
This method was ﬁrst introduced by Sidik and Jonkman [101] and yields only positive
estimates. The method is derived from the standard formula for V ar
(
θˆ
)
(formula
1.3 in the introduction chapter) with study weights deﬁned as:
wˆi =
1
(σˆ2i /τˆ
2) + 1
=
τˆ 2
σˆ2i + τˆ
2
V ar
(
θˆ
)
can be re-expressed in terms of the new weights wˆi:
V ar
(
θˆ
)
=
τˆ 2∑k
i=1 wˆi
(2.6)
This method also uses an alternative weighted estimator of V ar
(
θˆ
)
proposed by
Hartung [38]:
V arHK
(
θˆ
)
=
∑k
i=1 wˆi
(
θˆi − θˆ
)2
(k − 1)∑ki=1 wˆi
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If we equate V arHK
(
θˆ
)
and V ar
(
θˆ
)
from equation 2.6, then:
τˆ 2 =
1
k − 1
k∑
i=1
1
(σˆ2i /τˆ
2) + 1
(
θˆi − θˆ
)2
The formula above is naturally iterative, so Sidik and Jonkman [101] proposed a
two-step process with initial estimate τˆ 20 =
1
k
∑k
i=1
(
θˆi − θˆCA
)2
. The SJ estimator is
deﬁned as:
τˆ 2SJ =
1
k − 1
k∑
i=1
1
(σˆ2i /τˆ
2
0 ) + 1
(
θˆi − θˆSJ
)2
(2.7)
where θˆSJ is the weighted least squares estimate of θ with weights wˆi = 1/ ((σˆ
2
i /τˆ
2
0 ) + 1)
and θˆCA is the unweighted estimate of θ from section 2.2.2.
Study weights wˆi are undeﬁned when τˆ
2
0 = 0, which occurs in the unlikely case when
all θˆi are equal. In this case, set τˆ
2
SJ = 0.
Sidik and Jonkman [101] noted that alternative τˆ 20 estimates may lead to an es-
timator with better properties. Therefore, Sidik and Jonkman [102] proposed τˆ 20 =
max (0.01, τˆ 2CA) in a follow-up paper; I denote the resulting estimator as SJCA. As
with the original estimator, τˆ 2SJCA is a two-step estimator that is simple to compute
and always results in a positive estimate of the heterogeneity variance.
These estimators have methodological similarities with PM, introduced in section
2.2.4. Their weights are equivalent to the PM random-eﬀects study weights, multi-
plied by the constant τˆ 2; this transformation ensures SJ estimators are positive.
2.4 Hunter-Schmidt (HS)
The Hunter-Schmidt estimator (HS) [53] is derived by expressing the variance com-
ponents for θˆ as V ar
(
θˆ
)
= τ 2+σ2. A 'typical' within-study variance from all studies
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i is denoted by σ2. Weighted unbiased estimators of V ar
(
θˆ
)
and σ2 are substituted
into the variance components to derive the estimator of heterogeneity:
τˆ 2HS = max
0,
∑k
i=1 wˆi
(
θˆi − θˆ
)
2∑k
i=1 wˆi
−
∑k
i=1 wˆiσ
2
i∑k
i=1 wˆi
 (2.8)
with ﬁxed-eﬀect weights wˆi = 1/σˆ2i
Using these weights, the estimator can be re-expressed as [96]:
τˆ 2HS = max
0,
∑k
i=1 wˆi
(
θˆi − θˆ
)
2 − k∑k
i=1 wˆi
 (2.9)
Other weights that have been proposed include [124]; (1) wi = 1/ (n1i + n2i) where
n1i and n2i are the sample sizes in groups one and two of study i and (2) wi = 1/k.
A method for deriving the CA estimator (see section 2.2.2) also directly involves
splitting the variance components, the only diﬀerence being that CA uses unweighted
estimates of V ar
(
θˆ
)
and σ2.
2.5 Maximum likelihood approach
Maximum likelihood and restricted maximum liklelihood (REML) estimators can
both be derived from a log-likelihood function derived from the probability density
function of θˆi ∼ N (θ, σ2i + τ 2) [37]. Hence, it is assumed that θi and θˆi are normally
distributed around the central parameter θ, unlike the estimators in the method of
moments approach.
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2.5.1 Maximum likelihood (ML)
The log likelihood function for the maximum likelihood estimator is:
lML
(
θ, τ 2
)
= −1
2
k∑
i=1
ln
(
2pi
(
σ2i + τ
2
))− 1
2
k∑
i=1
(θi − θ)
σ2i + τ
2
2
(2.10)
The maximum likelihood estimate of τ 2 is the value that maximises lML (θ, τ
2).
The maximum can be found by partially diﬀerentiating lML with respect to τ
2 and
equating this to zero. This leads to:
τˆ 2ML = max
0,
∑k
i=1 wˆ
2
i
((
θˆi − θˆML
)2
− σˆ2i
)
∑k
i=1 wˆ
2
i
 (2.11)
where wˆi = (σˆ
2
i + τˆ
2
ML)
−1 and θˆML is the maximum likelihood estimate of θ. The
formula for θˆML is derived by partially diﬀerentiating lML with respect to θ:
θˆML =
∑k
i=1 wˆiθˆi∑k
i=1 wˆi
(2.12)
Maximum likelihood estimates are calculated by solving (2.11) and (2.12) simultan-
eously and iteratively, starting with an initial estimate τˆ 20 . There are many iter-
ative methods used in maximum likelihood including the Newton-Raphson method,
Fisher's scoring algorithm and the simplex algorithm [58]. If at any step τˆ 2 < 0, then
the process of iteration stops and we evaluate τˆ 2ML = 0. For any iteration method,
convergence is not guaranteed [64]. In this thesis, I use τˆ 20 = τˆ
2
CA and use Fisher's
scoring algorithm.
The method assumes that within-study variances and θ are known, when in reality
they must be estimated from study data [102]. Cheung [14] suggested this is likely
to lead to an underestimate of τ 2.
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2.5.2 Restricted maximum likelihood (REML)
To derive the REML estimator of τ 2, the log-likelihood function (2.10) is trans-
formed so that it excludes the summary eﬀect parameter θ [41]. In doing so, REML
avoids making the assumption that θ is known and is therefore thought to be an
improvement on the ML estimator [124]. This produces the following log-likelihood
function:
lREML
(
τ 2
)
= −k
2
ln (2pi)− 1
2
k∑
i=1
ln
(
σ2i + τ
2
)− 1
2
k∑
i=1
(
θˆi − θˆ
)
σ2i + τ
2
2
− 1
2
ln
(
k∑
i=1
1
σ2i + τ
2
)
To derive a formula for τˆ 2, we partially diﬀerentiate lREML with respect to τ
2 and
setting this diﬀerential to zero. This results in the following equation:
τˆ 2REML = max
0,
∑k
i=1 wˆ
2
i
((
θˆi − θˆREML
)2
− σˆ2i
)
∑k
i=1 wˆ
2
i
+
1∑k
i=1 wˆi

where θˆREML =
∑k
i=1
(
wˆiθˆi
)
/
∑k
i=1 wˆi and wˆi = (σˆ
2
i + τˆ
2
REML)
−1
τˆ 2REML is found by the same iterative process as τˆ
2
ML from section 2.5.1 and conver-
gence is also not guaranteed.
2.5.3 Approximate restricted maximum likelihood (ARML)
The approximate restricted maximum likelihood (ARML) estimator, is thought to
give similar estimates as REML [2, 77, 124]. Heterogeneity variance estimates are
calculated by iteration and the following formula:
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τˆ 2ARML = max
0,
∑k
i=1 wˆ
2
i
k
k−1
((
θˆi − θˆARML
)2
− σˆ2i
)
∑k
i=1 wˆ
2
i

where the weights are deﬁned as wˆi = (σˆ
2
i + τˆ
2
ARML)
−1.
ARML is a simpliﬁed version of REML, with the additional assumption that sampling
variances σ2i for all studies are equal. Regardless, the process of ﬁnding τˆ
2
ARML
involves iteration and has no obvious beneﬁt over REML. When all σ2i are equal, both
give identical estimates and only diﬀer slightly otherwise although this is diﬃcult to
prove algebraically [124].
2.6 The Bayesian approach
I described the general framework for Bayesian meta-analysis in the introduction
chapter (section 1.5.4). Bayesian heterogeneity variance estimators are based on this
model and allow for prior beliefs of model parameters to be combined with meta-
analysis data. This is the deﬁning diﬀerence from the frequentist estimators outlined
in the rest of this chapter. I introduce the full Bayesian approach in section 2.6.1.
Following this, I introduce a series of semi-Bayesian τ 2 estimators that are more
simple to compute including approximate Bayes (AB), empirical Bayes (EB), Bayes
modal (BM) and estimators proposed by Rukhin [93].
2.6.1 Full Bayesian
The full Bayesian approach estimates the heterogeneity variance simultaneously with
all other parameters of interest in the model. In doing so, it can account for un-
certainty of these parameters [106]. In a Bayesian random-eﬀect model with no
covariates, we can deﬁne prior distributions for τ 2 and θ:
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τ 2 ∼ p1(ϕ1)
θ ∼ p2(ϕ2)
where p1 and p2 are the chosen probability distributions with ﬁxed parameter vectors
ϕ1 and ϕ2.
Prior distributions and their ﬁxed parameters vary between meta-analyses in practice
and are chosen based on external evidence, expert opinion or they are vague to reﬂect
a lack of prior knowledge [111]. Therefore, it is not possible to deﬁne a distinct full
Bayesian method. Possible assumed distributions for τ 2 include the inverse gamma,
uniform or normal [66, 88]. A normal distribution for θi is often assumed and is
therefore the chosen prior distribution for θ [111].
The aim of this approach is to calculate a joint posterior distribution for τ 2 and θ by
combining prior distributions with meta-analysis data. The posterior distribution is
derived by Markov Chain Monte Carlo (MCMC) methods such as Gibb's sampler
[106]. This requires specialist software such as WinBUGS [72]. From the joint
posterior distribution, expected values and credibility intervals for τ 2 and θ can be
extracted.
2.6.2 Approximate Bayes Estimator (AB)
The approximate Bayes estimator (AB) was originally proposed within the context
of sequential meta-analysis [50]. It does not require any form of Gibbs sampling or
process of iteration and is therefore more simple to compute than full Bayes.
The prior for τ 2 follows the inverse-gamma distribution Γ−1 (η, λ), with parameters
η and λ deﬁning the shape and spread of the distribution respectively and zero
probability of τ 2 < 0. The inverse-gamma distribution has the following p.d.f:
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p
(
τ 2; η, λ
)
=
λη
Γ (η)
(
τ 2
) −η−1exp(− λ
τ 2
)
where Γ represents the gamma function.
The underlying eﬀects of each study i are assumed known, i.e. σ2i = 0. Higgins
et al. [50] suggest this has minimal impact on τˆ 2. By making this assumption, it
follows that the posterior distribution will also be an inverse-gamma distribution with
parameters η = η0 + (k/2) and λ = λ0 + (kτ
2/2) [35] . τ 2 in this case represents the
heterogeneity variance from the data, for which Higgins et al. [50] suggests using the
DL estimate (section 2.2.1). A posterior estimate of τ 2 can be derived by substituting
the formulas for the posterior parameters η and λ into the formula for the mean of
an inverse-gamma distribution:
τˆ 2AB =
λ
η − 1 =
2λ0 + kτˆ
2
DL
2 (η0 − 1) + k
The prior distribution for τ 2 has mean λ0/ (η0 − 1), implying the expected value of
λ0 is τˆ
2
0 (η0 − 1). This can be substituted into the formula for τˆ 2AB above:
τˆ 2AB =
2τ 20 (η0 − 1) + kτˆ 2DL
2 (η0 − 1) + k
This last step is carried out because it is often easier to deﬁne a prior value for
τ 20 than the spread parameter λ0. To calculate τˆ
2
AB, we must provide two of three
prior values for τ 20 , η0 and λ0. In the context of sequential meta-analysis in the
original publication [50], τ 20 is the estimate of τ
2 from the previous update to the
meta-analysis. Outside of this context, τ 20 can represent our best estimate from prior
beliefs.
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2.6.3 Bayes modal (BM)
Bayes Modal (BM) can estimate τ 2 numerically without the need for MCMC meth-
ods. It imposes a gamma prior distribution for τ [16, 17]:
p (τ ; η, λ) =
1
Γ (α)
τα−1e−λτ
α and λ are the shape and scale parameters deﬁned from prior information. Chung
et al. [16] suggest using α = 2 and λ ≈ 0 for a vague prior. The gamma distribution
is chosen because it has the property p (τ = 0; η, λ) = 0 for any α or λ, thus avoid-
ing zero estimates of τ 2 from the posterior. The density function of the posterior
distribution can be derived if we assume an improper uniform prior for θ:
p (τ, θ) = lML
(
θ, τ 2
)
+ (α− 1) logτ − λτ + c
where c is an undeﬁned constant and lML (θ, τ
2) is the log-likelihood function (2.10).
Software packages are available to ﬁnding estimates of (τ, θ) that maximise the above
equation such as lmer in R and gllamm in Stata [17]. The BM estimator can al-
ternatively be considered a maximum likelihood approach with a penalty imposed to
avoid zero estimates; the above log-likelihood is that of lML (θ, τ
2) with added terms
[17].
2.6.4 Rukhin's approach
Rukhin [93] proposed two semi-Bayesian heterogeneity variance estimators. These
diﬀer from estimators derived from a more typical Bayesian approach, which involves
specifying prior distributions for the unknown parameters and requires MCMCmeth-
ods ﬁt observed data to the model. Rukhin's estimators are more simple to compute
and only require a ﬁxed prior estimate of τ 2, denoted τˆ 20 .
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Rukhin's estimators are derived from a generalised version of method of moments
from section 2.2. He ﬁrst explicitly derives the formula for V ar (τˆ 2) under this uniﬁed
approach. Then, his general formula ﬁnds τˆ 2 such that V ar (τˆ 2) is locally minimised
around the prior estimate of τ 2. I refer the reader to the original paper for a detailed
derivation of this approach [93]. The general formula for Rukhin's heterogeneity
variance estimators is:
τˆ 2RB =
∑k
i=1
(
θˆi − θˆ
)2
k + 1
+
(∑k
i=1 (n1i + n2i)− k
)(
2kτˆ 20 − (k − 1)
∑k
i=1 σˆ
2
i
)
(∑k
i=1 (n1i + n2i)− k + 2
)
k (k + 1)
(2.13)
where n1i and n2i are the sample sizes in intervention groups one and two, θˆ =∑k
i=1
(
θˆiwˆi
)
/
∑k
i=1 wˆi and wˆi = (σˆ
2
i + τˆ
2
0 )
−1
.
Rukhin [93] proposed two formulae for τˆ 20 :
1. τˆ 20 = 0, which leads to following heterogeneity variance estimator (B0):
τˆ 2B0 =
∑k
i=1
(
θˆi − θˆ
)2
k + 1
+
(∑k
i=1 (n1i + n2i)− k
)
(k − 1)
(∑k
i=1 σˆ
2
i
)
(∑k
i=1 (n1i + n2i)− k + 2
)
k (k + 1)
2. τˆ 20 = 0.5 (k − 1)
∑k
i=1 (σˆ
2
i ) /k, which leads to (BP):
τˆ 2BP =
∑k
i=1
(
θˆi − θˆ
)2
k + 1
For a given k, τˆ 2BP is a ﬁxed proportion of the total sample variance V ar
(
θˆ
)
=
(k − 1)−1∑ki=1 (θˆi − θˆ)2. There is little logic for this relationship, so BP is unlikely
to have good properties. Rukhin [93] suggested this prior for τ 2 only to simplify the
general formula 2.13.
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Another estimator, which forms a part of the same approach, assumes σ2i to be
known. This estimator is given by the formula:
τˆ 2SB =
∑k
i=1
(
θˆi − θˆ
)2
k + 1
+
2τˆ 20 k − (k − 1)
∑k
i=1 σˆ
2
i
k (k + 1)
Prior estimates τˆ 20 must be speciﬁed to calculate τˆ
2
SB, but Rukhin [93] made no
speciﬁc suggestions.
2.7 Malzahn, Böhning and Holling (MBH)
Malzahn et al. [74] proposed a τ 2 estimator that makes no assumption on how θi are
distributed. The estimator can only be applied to SMD meta-analyses, the outcome
measure I introduced in section 1.3.1. First, formulae for the typical variance of θi
are derived under both ﬁxed-eﬀect and random-eﬀects assumptions. An estimate of
τ 2 is then derived by taking the diﬀerence between the two variances, this results in:
τ 2MBH =
(
1
k − 1
) k∑
i=1
(1−Ki)
(
θˆi − θˆCA
)2
− 1
k
k∑
i=1
(
n1i + n2i
n1in2i
)
− 1
k
k∑
i=1
(
Kiθˆ
2
i
)
where Ki = 1 − ((Ni − 2) /NiJ2i ), Ni = n1i + n2i − 2, θˆCA =
∑k
i=1 θˆi/k and Ji =
1−3/ (4Ni − 1). Ji is the bias correction factor proposed by Hedges [43] and already
introduced in section 1.3.1.
2.8 Alternative within-study variance estimates
All heterogeneity variance estimators in this chapter are dependent on within-study
variances. So far in this chapter, I assumed within-study variances have been calcu-
lated by conventional means as introduced in chapter 1. Two other methods have
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been proposed to improve within-study variance estimates, which then in theory lead
to improved heterogeneity variance estimates. All alternative methods identiﬁed and
presented in this section can only be applied to binary outcome meta-analyses.
2.8.1 Bhaumik et al (2012)
Bhaumik et al. [3] proposed an alternative method of calculating within-study vari-
ances in meta-analyses with an odds ratio outcome measure and rare events. The
method works by allowing studies to borrow strength from the other studies in a
meta-analysis and in doing so assumes within-study variances are equal. Within-
study variances are estimated by the following:
σˆ2i =
1
n1i + 1
[
exp
(
−odds2 − θˆCA + τˆ
2
2
)
+ 2 + exp
(
odds2 + θˆCA +
τˆ 2
2
)]
+
1
n2i + 1
[exp (−odds2) + 2 + exp (odds2)]
where odds2 are the observed odds of an event in the group 2 of study i, θˆCA is
the equally-weighted combined eﬀect estimate as in section 2.2.2 with a continuity
correction to deal with zero events 2.2.2.
In the original paper [3], τˆ 2 is calculated using the PM estimator from section 2.2.4.
However, these alternate estimates of σ2i could be applied to any other τ
2 estimator.
2.8.2 Berkey et al (1995) and Knapp & Hartung (2003)
Berkey et al. [2] proposed a smoothed estimator of the within-study variances in
meta-analyses with a relative risk outcome measure. The idea was introduced to
reduce correlation between the relative risk estimate and the within-study variances:
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σˆ2i =
1
k · n1i
k∑
i=1
(
n1i − ai
ai
)
+
1
k · n2i
k∑
i=1
(
n2i − ci
ci
)
where ai and ci are the number of events in treatment groups 1 and 2 respectively.
Knapp and Hartung [61] proposed an adapted version that includes a continuity
correction:
σˆ2i =
1
k · n1i
k∑
i=1
(
n1i − ai + 0.5
ai + 0.5
)
+
1
k · n2i
k∑
i=1
(
n2i − ci + 0.5
ci + 0.5
)
These estimators cannot be applied to other binary outcome meta-analyses, where
the outcome is for example an odds ratio [86].
2.9 A summary of methods
In this chapter, I reviewed methods for estimating the heterogeneity variance in a
random-eﬀects meta-analysis. A complete list of methods is given in table 2.1.
The estimators share many methodological aspects in common and can be grouped
into the following categories. Method of moments estimators are derived from a
generalised Q-statistic with weights that depend on the speciﬁc estimator being
used. Other moments based estimators include HM, SJ and SJCA, which were de-
veloped so that the heterogeneity variance is positive in all meta-analyses. Max-
imum likelihood estimators are derived from maximising the log-likelihood function
of a random-eﬀects model assuming normality; these estimators include ML, REML
and its approximate version (ARML). Bayesian estimators are derived from Bayes
rule of conditional probabilities and take into account prior beliefs about the model
parameters. Alternative methods for estimating the within-study variances in sec-
tion 2.8 are not strictly heterogeneity variance estimators, but have been proposed
to improve its estimates indirectly.
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Estimator Acronym Section
Method of moments approach (section 2.2)
DerSimonian-Laird DL 2.2.1
Positive DerSimonian-Laird DLP 2.2.1
Cochran's ANOVA CA 2.2.2
Paule-Mandel PM 2.2.4
Two-step Cochran's ANOVA PMCA 2.2.5
Two-step DerSimonian-Laird PMDL 2.2.5
Other non-truncated moments-based approaches (section 2.3 and 2.4)
Hartung-Makambi HM 2.3.1
Sidik-Jonkman SJ 2.4
Sidik-Jonkman (CA initial estimate) SJCA 2.3.2
Hunter-Schmidt HS 2.4
Maximum likelihood approach (section 2.5)
Maximum Likelihood ML 2.5.1
Restricted Maximum Likelihood REML 2.5.2
Approximate Restricted Maximum Likelihood ARML 2.5.3
Bayesian approach (section 2.6)
Full Bayes FB 2.6.1
Approximate Bayes AB 2.6.2
Bayes modal BM 2.6.3
Rukhin (zero prior) B0 2.6.4
Rukhin (simple) BP 2.6.4
Rukhin (alternate) SB 2.6.4
Bootstrap approach
Bootstrap DerSimonian-Laird DLB 2.2.1
SMD outcome only
Malzahn, Böhning and Holling MBH 2.7
Table 2.1: Summary of heterogeneity variance estimators
Some heterogeneity variance estimates are easier to compute than others. Many
can be expressed explicitly, such as DL, and are therefore simple to compute. PM
and estimators derived from the maximum likelihood approach require a process
of iteration to converge to a solution; this is because they deﬁne random-eﬀects
study weights that include the heterogeneity variance parameter. Alternatives to
PM have been proposed that that restrict the process of iteration to two-steps; those
proposed under the method of moments approach in section 2.2.5 and Sidik and
Jonkman estimators in section 2.3.2. The full Bayesian method requires MCMC
43
simulation methods to converge to a solution. Researchers have often favoured the
more simple methods [64, 95, 101]. However, I believe reliable iterative methods
should not be considered inferior to simple methods on this basis alone, particularly
when software packages exist that automate the process and always converge to the
optimal estimate for the given method.
Heterogeneity variance estimators introduced in this chapter require statistical as-
sumptions, of which many are unlikely to hold. A frequent assumption is that within-
study variances are known, when in practice they can only be estimated from the
study data. When estimated within-study variances account for more than the ob-
served total variance (i.e. when they are overestimated), methods such as DL produce
a heterogeneity variance estimate truncated to zero as it would otherwise be negative.
Only the full Bayesian method in section 2.6.1 does not require this assumption.
The maximum likelihood estimators assume that true study eﬀects are normally
distributed. The validity of this assumption has been questioned in medical meta-
analyses [11, 28, 48]. The assumption is particularly questionable in the presence
of publication or reporting bias [92] or in binary outcome meta-analyses with small
study sample sizes [116]. A typical check for normality, such as that proposed by
Egger et al. [27], often lacks suﬃcient power [11]. We also typically make the as-
sumption of normally distributed eﬀects in the Bayesian approach, but other more
ﬂexible distributions can be assumed.
2.10 Example meta-analysis
I present a meta-analysis of studies comparing hawthorn extract with placebo for
treatment of chronic heart failure [82] to put the methods outlined in this chapter
into context. The primary outcome is 'maximum work load' measured in METS
(metabolic equivalents), which captures the amount of oxygen consumed and groups
are compared by a mean diﬀerence (the outcome measure introduced in section 1.3.1).
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The results of each study are presented graphically in the form of a forest plot in
ﬁgure 2.1. All studies had positive eﬀect estimates in favour of hawthorn extract but
only Zapfe [129] was statistically signiﬁcant at the 5% level.
Figure 2.1: Forest plot with ﬁve studies in a meta-analysis evaluating
hawthorn extract for chronic heart failure
Table 2.2 shows estimates of the heterogeneity variance according to most methods
introduced in this chapter along with the associated estimate of I2 (calculated using
formula 1.6 in the last chapter). Estimates of the heterogeneity variance ranged from
0 (using Cochran's ANOVA method) up to 24.56 (using Rukhin's simple estimator,
BP). Corresponding I2 estimates range from 0% to 53.1%. All other estimators
derived from the method of moments approach, except Cochran's ANOVA, have
relatively similar τ 2 estimates (DL, DLP, PM, PMCA, PMDL). Sidik and Jonkman
estimators (SJ and SJCA) has wildly diﬀerent estimates despite being methodolo-
gically similar; this is perhaps because SJCA uses the small initial estimate derived
from Cochran's ANOVA, which results in a ﬁnal estimate of CA's truncated value.
HM is also a non-truncated estimator and has a relatively large heterogeneity vari-
ance estimate (τ 2 = 11.14). There is a large diﬀerence between ML and REML
heterogeneity variance estimates, despite their methodological similarity.
I use the same meta-analysis as an example in the next chapter, to show how dif-
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ferences in heterogeneity estimates impact on the summary eﬀect and its conﬁdence
interval.
Estimator τˆ 2 Iˆ2 Estimator τˆ 2 Iˆ2
DL 6.56 23.2 ML 1.27 5.5
DLP 6.56 23.2 REML 9.31 30.0
CA 0 0.0 ARML 7.16 24.8
PM 5.88 21.3 AB ** 6.56 23.2
PMCA 6.56 23.2 BM 5.48 20.2
PMDL 5.78 21.1 B0 2.47 10.2
HM 11.14 33.9 BP 24.56 53.1
SJ 13.93 39.1 DLB 4.39 16.8
SJCA 0.01 0.1 MBH * - -
HS 0.80 3.6
Table 2.2: Heterogeneity variance estimates derived from diﬀerent methods
and associated I2 estimates
*Malzahn, Böhning and Holling's estimator (MBH) could not be calculated as
study eﬀects are not on the standardised scale
**Approximate Bayes estimate based on τ 2 = 0 and η = 1 priors.
2.11 Conclusions
In this chapter, I reviewed methods for estimating the heterogeneity variance in
a random-eﬀects meta-analysis. I described how they are derived, their formulae,
methodological similarities and weaknesses. I identiﬁed 20 distinct methods for het-
erogeneity variance estimation. Some of these methods have only recently been
proposed, such as those by Rukhin [93]; these are unlikely to have been compared
extensively with pre-existing methods in simulated or empirical data.
I have previously mentioned the weaknesses of the commonly used DerSimonian-
Laird method that have been brought to light in the literature [78, 79, 124]. The
numerous alternatives as outlined in this chapter suggests there may exist one or
more methods with better properties. It is imperative that the properties of these
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estimators are better understood so that informed recommendations can be made
for frequentist random-eﬀects meta-analysis.
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Chapter 3
Methods for conﬁdence intervals of
the summary eﬀect
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3.1 Introduction
The impact of using a heterogeneity variance estimator in random-eﬀects meta-
analysis extends beyond its point estimate. In order to perform a comprehensive
comparison of heterogeneity variance estimators in this thesis, I also compare these
estimators in terms of their impact on the summary eﬀect and its conﬁdence interval.
I focus only on the inverse variance method for calculating estimates of the summary
eﬀect, as described in section 1.6 of the introduction chapter.
Selected conﬁdence interval methods are introduced in this chapter that will be used
throughout the rest of this thesis; a comprehensive review is not required because
these methods are not the main focus. Conﬁdence interval methods introduced in this
chapter include Wald-type (section 3.2), t-distribution (section 3.3) and Hartung-
Knapp conﬁdence intervals (section 3.4). The Wald-type conﬁdence interval is cur-
rently reported as standard in meta-analyses in Cochrane reviews [51]. The other
two methods are included because they have shown promising results in simulation
studies [61, 93, 96] and are methodologically diverse. None of the chosen methods
are theoretically related to a speciﬁc heterogeneity variance estimator, meaning any
heterogeneity variance estimate can be used to derive a conﬁdence interval. This is
a key characteristic given the aims of this thesis. Other methods can be found in the
literature [11, 12, 37, 45, 83, 96]. For example, the proﬁle likelihood method [37] is
based on the same log-likelihood function as the maximum likelihood heterogeneity
variance estimator.
All conﬁdence interval methods included in this chapter can be adapted for both
random and ﬁxed-eﬀect meta-analysis. Given the focus of this thesis, I present
these methods assuming random-eﬀects. The methods can also be adapted for any
conﬁdence level; I present their generalised form in this chapter but I focus on the
95% conﬁdence level in the rest of this thesis.
Many conﬁdence interval methods are also available to express uncertainty around
the heterogeneity variance estimate [60, 125]. These methods will not be considered
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as the scope of this thesis is limited to the impact on point estimates of the hetero-
geneity variance, subsequent summary estimates and their conﬁdence intervals.
3.2 Wald-type conﬁdence interval
The Wald-type conﬁdence interval is most commonly used in meta-analysis, and is
previously described in the introduction chapter (section 1.6). Recall [25, 100]:
[
θˆ − Φ−1
(
1− α
2
)
·
√
V arW
(
θˆ
)
, θˆ + Φ−1
(
1− α
2
)
·
√
V arW
(
θˆ
)]
Φ−1
(
1− α
2
)
is the
(
1− α
2
)
th percentile of the normal distribution and, for a 95%
conﬁdence interval, set α = 0.05. V arW
(
θˆ
)
is the variance of the summary eﬀect
and is calculated by the formula:
V arW
(
θˆ
)
=
1∑k
i=1 (wˆi)
(3.1)
where wˆi = 1/ (σˆ
2
i + τˆ
2) and k is the number of studies in the meta-analysis.
This conﬁdence interval method assumes that study eﬀect estimates (θˆi) follow a nor-
mal distribution [12]. Also, the method assumes τ 2 and σˆ2i are known, but estimates
of these parameters are used in practice [11, 96].
3.3 t-distribution conﬁdence interval
The t-distribution conﬁdence interval for the summary eﬀect addresses the small
sampling bias of the Wald-type conﬁdence interval, and is therefore thought to im-
prove coverage [28]:
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[
θˆ − tk−1
(
1− α
2
)
·
√
V arW
(
θˆ
)
, θˆ + tk−1
(
1− α
2
)
·
√
V arW
(
θˆ
)]
(3.2)
tk−1
(
1− α
2
)
is the
(
1− α
2
)
th percentile of the t-distribution with k − 1 degrees of
freedom. V arW
(
θˆ
)
is the same variance estimate as for the Wald-type conﬁdence
interval and makes all the same assumptions.
3.4 Hartung-Knapp conﬁdence interval
The Hartung-Knapp method [3840] also relies on a t-distribution with k−1 degrees
of freedom and uses an alternative weighted variance of θ. I stated the formula for
this weighted variance in the last chapter, as it was used to derived SJ estimators of
the heterogeneity variance (section 2.3.2). Its formula can be derived as follows.
If we make the assumption that random-eﬀects weights wˆi = 1/ (σˆ
2
i + τˆ
2) are known,
then:
θˆ − θ√
1/
∑k
i=1 wˆi
∼ N (0, 1)
and
k∑
i=1
wˆi
(
θˆi − θˆ
)2
∼ χ2k−1
Since these two variables are independent (as proven by Hartung [38] and Sidik and
Jonkman [100]), and by deﬁnition of the t-distribution, we can derive:
N (0, 1)√
χ2k−1/ (k − 1)
=
(
θˆ − θ
)/√
1/
∑k
i=1 wˆi√∑k
i=1 wˆi
(
θˆi − θˆ
)2/
(k − 1)
∼ tk−1 (3.3)
52
Given that
(
θˆ − θ
)/√
V ar
(
θˆ
)
∼ tk−1, we can equate this to equation 3.3 above
and derive the following formula for the weighted variance:
V arHK
(
θˆ
)
=
∑k
i=1 wˆi
(
θˆi − θˆ
)2
(k − 1)∑ki=1 wˆi
and thus the Hartung-Knapp conﬁdence interval is:
[
θˆ − tk−1
(
1− α
2
)
·
√
V arHK
(
θˆ
)
, θˆ + tk−1
(
1− α
2
)
·
√
V arHK
(
θˆ
)]
(3.4)
This method is the equivalent to the t-distribution method in the last section, but
the variance is multiplied by a scaling factor as explained by Sidik and Jonkman
[100]. In many cases, the scaling factor can be < 1, which leads to a narrower
conﬁdence interval that the Wald-type method. A variation on this method have
been proposed to deal with this problem by constraining the scaling factor to be ≥ 1
[61]. Throughout this thesis, the original Hartung-Knapp method without constraint
will be used.
As with the other two conﬁdence intervals in this chapter, the variance components
are assumed to be known and study eﬀects normally distributed.
3.5 Example meta-analysis
I now revisit the example meta-analysis from section 2.10 comparing hawthorn ex-
tract with placebo for increasing maximum workload in patients with chronic heart
failure. I present its summary eﬀect and 95% conﬁdence interval according to all com-
binations of heterogeneity variance and summary eﬀect conﬁdence interval estimation
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methods (16 heterogeneity variance methods and 3 conﬁdence interval methods). All
results of this meta-analysis are plotted in ﬁgure 3.1.
The heterogeneity variance estimate was zero according to Cochran's ANOVAmethod
and more than zero for all other methods (see section 2.10). A narrower conﬁdence
interval is observed when Cochran ANOVA's zero estimate is used as shown in ﬁgure
3.1. Similarly, Rukhin's simple estimator (BP) estimated the highest heterogeneity
variance (τˆ 2 = 24.56) and lead to the widest conﬁdence intervals. Summary eﬀects
are fairly consistent between methods, but conﬁdence interval widths diﬀer more
signiﬁcantly when Wald-type and t-distribution methods are used. Hartung-Knapp
conﬁdence intervals appear more robust to changes in the heterogeneity variance
estimate. Only Wald-type conﬁdence intervals produced a statistically signiﬁcant
result at the 5% level.
3.6 Concluding remarks
In this chapter, I described three conﬁdence intervals proposed for the summary
eﬀect in random-eﬀects meta-analysis; namely Wald-type [25], t-distribution [28]
and Hartung-Knapp conﬁdence intervals [38].
The Wald-type conﬁdence interval for the summary eﬀect is most commonly used
in meta-analysis. This method, coupled with the DerSimonian-Laird estimator of
the heterogeneity variance, is often referred to as the DerSimonian-Laird approach
to random-eﬀects meta-analysis [25]. However, I associate DerSimonian-Laird solely
with the heterogeneity variance estimator in this thesis. Wald-type conﬁdence inter-
vals, and the other two methods introduced in this chapter, can be calculated with
any heterogeneity variance estimator.
In this chapter, I also presented these methods in the context of a real meta-analysis
to show the choice of methods can lead to diﬀerent conﬁdence interval estimates. I
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Figure 3.1: The summary eﬀect and 95% conﬁdence interval for all
combinations of heterogeneity variance and conﬁdence interval methods
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compare heterogeneity variance estimators in more empirical meta-analysis data in
the next chapter.
56
Chapter 4
An empirical comparison of
heterogeneity variance estimators
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4.1 Introduction
In this chapter, I assess the impact of using diﬀerent heterogeneity variance es-
timators on published meta-analyses, using empirical data derived from a complete
snapshot of the Cochrane Database of Systematic Reviews (CDSR) up to 2008 [107].
Because the Cochrane Collaboration's Review Manager software [87] is used to write
all Cochrane reviews, the data are formatted in a highly consistent way. Results
from each study of each meta-analysis could therefore be extracted, including type
of outcome, sample size, 2Ö2 tables for dichotomous outcomes, and means with
standard deviations for continuous outcomes. Extraction of the data is described
in more detail elsewhere [21]. Permission to use the dataset for this analysis was
granted by Rebecca Turner, who is acknowledged in the front matter of this thesis.
These data allowed me to look at (1) the magnitude of diﬀerences in heterogeneity
variance estimates in practice, (2) the impact of the choice of heterogeneity variance
estimator on conclusions and (3) the extent to which recommendations of the best
heterogeneity variance estimator are required. I also examine two selected examples
from the dataset, where diﬀerences between estimation methods are particularly
prominent.
This chapter expands on a previous empirical study to compare statistical inference
between heterogeneity variance estimators [117]. Limitations of the previously pub-
lished study were as follows. First, estimates were compared from only ﬁve methods
(DL, CA, HM, SJ and REML) so I compare many more (as detailed in section 4.2.1).
Second, estimates were transformed to the scale of the D2 statistic [127] and com-
pared on this scale as a measure of agreement. The D2 statistic is a measure of the
degree of heterogeneity and, much like the I2 statistic, takes values between 0% and
100%. The issue is the D2 statistic is rarely used in practice, so I compare estim-
ates on the scale of the I2 statistic (more details and reasoning are given in section
4.2.4). Furthermore, the previous study is based on 920 meta-analyses; I conduct
my analysis on 12,894 empirical meta-analyses to gain more precise estimates of
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agreement.
4.2 Methods
4.2.1 Included methods for estimating the heterogeneity vari-
ance
I present a comparison of seven methods for estimating the heterogeneity variance
in a meta-analysis: DerSimonian-Laird (DL) [25], Cochran's ANOVA (CA) [59],
Paule-Mandel (PM) [80], Hartung-Makambi (HM) [40], Sidik-Jonkman (SJ) [101],
maximum likelihood (ML) [37] and restricted maximum-likelihood (REML) [41].
These seven estimators were selected from the comprehensive list in chapter 2 because
of their popularity and availability in statistical software. DL is derived from the
method of moments approach to heterogeneity variance estimation and is the most
frequently used heterogeneity variance estimator in practice. It is the default method
in the Stata command metan and is currently the only method implemented in
RevMan software [22]. CA assigns equal weightings to studies and represents a
simple alternative to DL. PM assigns random-eﬀects weights to studies, which are
considered the statistically optimal weights in the method of moments approach [24].
REML is the default method in the R package metafor [126]. ML is a widely-used
approach to statistical parameter estimation and is therefore also included in this
analysis. In contrast to these estimators, HM and SJ were selected as non-truncated
estimators that always estimate a positive heterogeneity variance.
I stated in chapter 2 that the PM estimator can theoretically be interpreted as a
simple approximation of the REML approach in speciﬁc situations [94]. The extent
of agreement between PM and REML estimates has not been investigated in other
empirical studies [117] so both estimators are included and compared here.
Results in this chapter are representative of a comparison of all heterogeneity variance
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estimators. To demonstrate this, many of the estimators not included in the main
text are given in ﬁgure B.1 in the appendix. This ﬁgure shows a comparison between
two included methods (DL and REML) and many that are excluded (PMCA, PMDL,
HS, SJCA and ARML). I also exclude Bayesian methods that rely on a subjective
choice of prior distribution because of diﬃculties deﬁning these distributions out of
context. Rukhin's estimators [93] are excluded because simulations results later in
this thesis show they have poor properties. The estimator proposed by Malzahn,
Böhning and Holling [74] is excluded because it can only be used in meta-analyses
with a standardised mean diﬀerence outcome measure. I exclude bootstrapping
because the approach could theoretically be applied to any heterogeneity variance
estimator.
4.2.2 Empirical study dataset
A complete re-analysis of all meta-analyses in the CDSR dataset was possible from
the study-level data available. I re-conducted all meta-analyses of dichotomous or
continuous outcomes containing at least three studies. Those containing two stud-
ies were excluded from the results because it is arguably inappropriate to estimate
heterogeneity in such cases. Eﬀect estimates and standard errors were calculated
for all studies from basic summary statistics. I calculated the log odds ratios for
all dichotomous outcome meta-analyses and standardised mean diﬀerences for all
continuous outcome meta-analyses. Hedges' g method was used to estimate stand-
ardised mean diﬀerence eﬀects, which corrects for bias caused by small sample sizes
[8] and is detailed in section 1.3.1.
4.2.3 Summary statistics
I used four summary statistics to compare the seven estimation methods: (i) the
estimated heterogeneity variance, (ii) the estimated summary eﬀect from a random-
eﬀects meta-analysis, (iii) the estimated standard error of the summary eﬀect, and
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(iv) the p-value for this result. These statistics were chosen because they are the
key statistics used to draw inference from a meta-analysis and may be aﬀected by
the estimated heterogeneity variance. Furthermore, by comparing standard errors,
I can also compare the widths of conﬁdence intervals of the summary eﬀect because
conﬁdence interval formulae for all included methods are otherwise independent of
τˆ 2.
I calculated standard errors and hence p-values for the overall summary eﬀect (i.e.
summary statistics (iii) and (iv) above) using both Wald and Hartung-Knapp meth-
ods (i.e. two of the three methods outlined in chapter 3). The Wald method is the
currently used as standard in Cochrane meta-analyses [51] and was introduced in
section 1.6. The Hartung-Knapp method uses an alternative weighted standard er-
ror of the summary eﬀect and derives a p-value from the t-distribution. This method
was introduced in section 3.4 and derived from the same approach as the Hartung-
Knapp conﬁdence interval for the summary eﬀect. I omitted p-values based on the
t-distribution method outlined in section 3.3 because they are based on the same
formula for the variance as the Wald-type method and therefore results would be be
similar.
4.2.4 Data analysis
I illustrate pair-wise agreement between results from diﬀerent estimation methods
using Bland-Altman plots [5], thereby illustrating how the discrepancy between two
methods depends on the underlying value of the parameter (estimated as the average
result across the two methods). Pair-wise plots are arranged in a matrix to facilitate
simultaneous comparison of each method with all others. Bland-Altman plots are
used to examine the ﬁrst three of our four summary statistics (heterogeneity variance,
summary eﬀect and precision of summary eﬀect). I superimpose non-parametric 80%
reference ranges on the same plots to illustrate the spread of agreement. To calculate
the 80% reference ranges, I split meta-analyses into groups of 200 according to their
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order on the x-axis and calculated the 10th and 90th percentiles of the discrepancies.
The plotted reference range is a smoothed line between the calculated percentiles.
Bland-Altman plots traditionally present raw diﬀerences between parameter estim-
ates on the y-axis, but precisions of the summary eﬀect are compared as a ratio for
two reasons: (1) They naturally conform to a log-normal distribution. (2) By includ-
ing precision of the summary eﬀect in this analysis, I can also compare the widths of
summary eﬀect conﬁdence intervals and these comparisons are more meaningful on
the ratio scale. For example, a conﬁdence interval that is half the width of another
is half as likely to include the null value with all else being equal. Heterogeneity
variance estimates also have a skewed distribution in practice [21], but I apply a
transformation as detailed below and present raw diﬀerences.
I sought to measure discrepancies between heterogeneity variance (τ 2) estimates on
an appropriate scale that would maximise the generalisability of the results and be
intuitively interpretable. The most obvious option is to present the raw diﬀerences
of τ 2 estimates, but the scale of these diﬀerences is too dependent on the average
τ 2 estimate (as shown in appendix A.1). Therefore, I transformed τ 2 estimates to
the scale of the I2 statistic and present their raw diﬀerences (see equation 1.6 for I2
in the introduction chapter). I consider this a transformation because all parameter
estimates other than the heterogeneity variance estimate τ 2 remain ﬁxed between
methods. Diﬀerences in I2 statistics reﬂect only diﬀerences in values of τ 2.
The summary eﬀect and its standard error depend on the scale of measurement.
Therefore, I multiplied standardised mean diﬀerences and standard errors from each
continuous meta-analysis by a value of 1.81 to obtain a result that is approximately
comparable to a log odds ratio [15]. The I2 statistic and p-values for the sum-
mary eﬀect are independent of the scale of measurement and so do not require a
transformation. I carried out separate analyses on continuous and binary outcome
meta-analyses, but since I found no diﬀerence between the results I present results
with all meta-analyses combined.
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I compared p-values of the summary eﬀect by tabulating categories of levels of statist-
ical signiﬁcance. First, p-values were dichotomised at the 5% level to explore agree-
ment for the threshold most commonly applied in practice. Second, p-values were
categorised to represent a wider range of levels of statistical signiﬁcance: p ≤ 0.01,
0.01 < p ≤ 0.05, 0.05 < p ≤ 0.1 and p > 0.1. I considered p-values that diﬀer by at
least 2 categories on this ﬁner scale to be suﬃciently diﬀerent to change inference. I
recognise the limitations of using statistical signiﬁcance to draw inferences [110, 117],
but also appreciate their widespread use.
In a secondary analysis, I explored whether the level of agreement between hetero-
geneity variance estimates can be explained by two meta-analysis characteristics;
the number of studies (k) and the total information (V ). Hardy and Thompson [37]
deﬁnes the total information as V =
∑k
i=1 wˆi , which takes into account the number
and sizes of studies. Hardy and Thompson [37] found using simulations that the
power to detect heterogeneity (using the Q-statistic from section 1.7.1) depends on
these characteristics, so I explored whether they also aﬀect the level of agreement
between heterogeneity variance estimators. I illustrate their eﬀects using the same
plots of pair-wise agreement as for the main analysis, but with the the number of
studies and total information on the x-axes.
4.3 Results
A summary of the characteristics of meta-analyses in the CDSR is presented in
section 4.3.1. Heterogeneity variance estimators are compared in sections 4.3.2 to
4.3.5 for each of the four summary statistics. In section 4.3.6, I show whether the
level of agreement between heterogeneity variance estimates is aﬀected by two meta-
analysis characteristics.
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4.3.1 A summary of CDSR meta-analyses
The 2008 version of the CDSR contains 22,453 meta-analyses, of which I excluded
9559 (42.6%). 8641 meta-analyses were excluded because they contain fewer than
three studies and the remaining 918 meta-analyses were excluded because the type of
outcome measure is missing or something other than binary or continuous. A total
of 12,894 meta-analyses from 1817 systematic reviews are included in these analyses.
Type of outcome Outcome measure N (%)
binary odds ratio 3295 (26%)
relative risk 5568 (43%)
risk diﬀerence 116 (1%)
continuous standardised mean diﬀerence 948 (7%)
mean diﬀerence 2967 (23%)
Total 12,894
Table 4.1: The original outcome measures of included meta-analyses from the
CDSR
8979 (70%) included meta-analyses have a dichotomous outcome and 3915 (30%)
have a continuous outcome (as shown in table 4.1). I calculated odds ratio outcome
measures for all binary outcome meta-analyses in this analysis, of which 3295 (37%)
use this measure in the original publication. For continuous meta-analyses, I calcu-
lated a standardised mean diﬀerence outcome measure, of which 948 (24%) originally
used this measure.
Figure 4.1 shows the numbers of studies contained in included meta-analyses from
the CDSR dataset. Having excluded those that contain fewer than three studies,
the median number of studies is 4 (inter-quartile range 3-7) and 11,009 (85.4%)
meta-analyses contain fewer than 10 studies.
Figure 4.2 shows the distribution of DL estimates of the heterogeneity variance and
I2 statistics for both dichotomous outcomes (based on odds ratios) and continuous
outcomes (based on standardised mean diﬀerences). The DL method estimated τˆ 2 =
0 for 4395 (49%) dichotomous outcome meta-analyses and 1315 (33.6%) continuous-
outcome meta-analyses.
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Figure 4.1: The numbers of studies included in all 2,894 meta-analyses
4.3.2 Agreement between heterogeneity variance estimates
I present in ﬁgure 4.3 Bland-Altman plots of pair-wise agreement between heterogen-
eity variance estimates, expressed on the I2 scale, for the seven estimation methods:
Cochran's ANOVA (CA), DerSimonian-Laird (DL), Paule-Mandel (PM), Hartung-
Makambi (HM), Sidik-Jonkman (SJ), ML and REML. The plots show the diﬀerence
between two I2 statistics for a particular pair of methods on the y-axes as a measure
of agreement. 80% reference ranges are shown by the thick red lines. Because I2
values depend both on between-study variance and within-study variance, the ho-
rizontal positioning of the meta-analyses on this scale is aﬀected by both of these:
meta-analyses to the left have either low heterogeneity or high within-study vari-
ance (or both), and those to the right have high heterogeneity or low within-study
variance.
There is a relatively high level of agreement between DL and PM estimates of I2, with
perfect agreement when estimates of the heterogeneity variance are zero. In few cases
do DL and PM estimates of I2 diﬀer by more than 25% in absolute value. There is
also relatively high agreement between SJ and HM estimates when I2 < 25% because
neither method produces zero heterogeneity variance estimates. SJ estimates of I2
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Figure 4.2: The distribution of τ2 and I2 estimates for OR and standardised
mean diﬀerence meta-analyses calculated from the DL method.
Frequencies expressed as a percentage.
are generally larger than other estimates. REML has low agreement with both DL
and PM estimators when I2 < 75%. ML generally produces lower I2 estimates than
other methods in all comparisons. Apart from the reasonable agreement observed
between DL and PM, all other comparisons show a low level of agreement where in
many cases one method estimates I2 = 0% and the other estimates I2 > 50%. In
particular, CA I2 estimates have low agreement with all other I2 estimates. Points
which make up straight diagonal lines seen in most plots show where one estimate
is I2 = 0% and the other is positive; extreme diﬀerences in I2 estimates occur more
frequently in these cases. There appears to be less agreement between estimates
when the average I2 (x-axis) is around 50% and a high level of agreement close to
0% or 100%; this however is largely because absolute diﬀerences in I2 estimates have
a limited range when the average is close to the upper and lower limits of I2.
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Figure 4.3: Bland-Altman scatter plots comparing I2 estimates from diﬀerent
heterogeneity variance methods.
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Figure 4.4: Bland-Altman scatter plots comparing summary eﬀect estimates
using diﬀerent heterogeneity variance estimation methods.
θ estimates represent log odds ratios, including standardised mean diﬀerences in
continuous outcome meta-analyses converted to the same scale
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4.3.3 Agreement between summary eﬀects
Figure 4.4 shows Bland-Altman plots of the pair-wise agreement between summary
eﬀects. These are expressed as log odds ratios, calculated either from a dichotom-
ous outcome meta-analysis or from a continuous outcome meta-analysis after being
transformed to the log odds ratio scale as detailed in the methods section. Summary
eﬀects agree most between DL, PM and REML heterogeneity variance estimators.
However, the level of agreement is high for all pair-wise comparisons, in most cases
diﬀering by a negligible amount. Some 80% reference ranges appear to show poor
agreement far from the null value; this is most likely because extreme summary
eﬀects are few in number and as such have considerable impact on the reference
range. The agreement of summary eﬀects between REML and all other heterogen-
eity variance estimators appear to depend on whether the summary eﬀect is positive
or negative. None of the methods depend on the direction of eﬀect, so such eﬀects
are due to chance alone or due to diﬀerences in characteristics of meta-analyses with
positive and negative eﬀects.
4.3.4 Agreement between precision of the summary eﬀect
Figure 4.5 shows Bland-Altman plots of the level of agreement between standard
errors of the summary eﬀect. The upper-right panel displays agreement of Wald
standard errors and the lower-left displays agreement of Hartung-Knapp weighted
standard errors. Agreement is measured as a ratio of standard errors (equivalently
a ratio of conﬁdence interval widths), and plotted on the log-scale.
Results suggest that changing the heterogeneity variance estimator can possibly halve
or double the size of Wald standard errors. These standard errors agree most for
the pair-wise comparisons DL v PM and DL v HM. The SJ estimator in most meta-
analyses produced higher standard error than other heterogeneity variance estim-
ators; this is expected given that the SJ estimate of I2 was higher than other I2
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Figure 4.5: Bland-Altman scatter plots comparing summary eﬀect estimates
and standard errors using diﬀerent heterogeneity variance estimation methods.
(1) Lower-left panel: Comparing Hartung-Knapp weighted standard errors (2)
Upper-right panel: Comparing the Wald standard errors (diﬀerences presented on
the log scale in all plots)
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estimates in almost all meta-analyses. The ML estimator in most meta-analyses
produces a lower standard error than other heterogeneity variance estimators; this
is expected given than results in section 4.3.2 show that ML tends to produce lower
I2 estimates than other estimators. All comparisons show poor agreement.
Hartung-Knapp standard errors have much higher agreement than Wald standard
errors, a change in the heterogeneity variance estimator can lead to a 25% reduction
or 50% increase in the standard error. Agreement of these standard errors is highest
between DL, PM and REML estimators. Also, SJ and HM estimators have high
agreement, even though agreement between their Wald standard errors is relatively
low. ML and SJ estimators typically produce low and high Hartung-Knapp standard
errors respectively (as they do for Wald standard errors).
4.3.5 Agreement between p-values
Tables 4.2 and 4.3 show pair-wise agreement between p-values of the summary eﬀect
when diﬀerent heterogeneity variance estimators are used. The p-values in table 4.2
are derived from the Wald-statistic and p-values in table 4.3 are derived from the t-
statistic; methods for deriving these p-values are given in section 4.2.2. The lower-left
panels of both tables present agreement between p-values split into two categories:
p ≤ 0.05 and p > 0.05. The upper-right panels present agreement between p-values
split into ﬁner categories: p ≤ 0.01, 0.01 < p ≤ 0.05, 0.05 < p ≤ 0.1 and p > 0.1.
Results in table 4.2 suggest that choice of heterogeneity variance estimation method
can have an eﬀect on inference when p-values are derived from the Wald-statistic.
Statistical signiﬁcance of these p-values at the 5% level is discordant between at
least two heterogeneity variance estimators in 10.3% of meta-analyses. The lowest
agreement in statistical signiﬁcance at the 5% level is observed between SJ and ML
with 8.6% of meta-analyses having discordant p-values. The highest agreement is
observed between DL and REML and between PM and REML methods; 2% of
meta-analyses were discordant.
71
D
isco
rd
an
t
C
o
n
co
rd
an
tC
A
2
4
.
3
1
.
1
0
.
1
0
.
2
2
4
.
7
0
.
8
0
.
1
0
.
1
2
2
.
9
2
.
3
0
.
2
0
.
3
2
1
.
6
3
.
2
0
.
4
0
.
5
2
5
.
1
0
.
5
0
.
1
0
.
1
2
4
.
1
1
.
2
0
.
2
0
.
2
𝒑
≤
𝟎
.𝟎
𝟏
2
.
1
7
.
8
0
.
8
0
.
3
1
.
1
9
0
.
6
0
.
2
1
.
9
6
.
3
2
0
.
7
0
.
2
7
.
1
2
.
5
1
.
2
3
.
2
7
.
4
0
.
2
0
.
1
1
.
8
7
.
9
0
.
9
0
.
4
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
0
.
4
1
.
4
4
.
3
0
.
9
0
.
1
1
5
.
3
0
.
7
0
.
3
1
.
3
3
.
2
2
.
2
0
0
.
3
3
.
8
3
0
.
7
2
4
0
.
3
0
.
4
1
.
1
4
.
5
1
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
.
3
0
.
9
1
.
7
5
3
.
3
0
.
1
0
.
3
1
5
4
.
9
0
.
3
0
.
8
1
.
5
5
3
.
7
0
0
0
.
3
5
6
0
.
7
1
.
3
2
.
8
5
1
.
5
0
.
4
0
.
7
1
.
4
5
3
.
8
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
7
.
7
3
.
2
D
L
2
5
.
5
1
.
3
0
.
1
0
.
1
2
5
1
.
8
0
.
1
0
2
1
.
5
4
.
6
0
.
5
0
.
5
2
6
.
6
0
.
3
0
.
1
0
.
1
2
5
.
8
1
.
1
0
0
.
1
𝒑
≤
𝟎
.𝟎
𝟏
0
.
5
9
.
4
1
0
.
4
0
.
4
8
.
5
2
0
.
4
0
.
3
5
.
7
3
.
4
1
.
9
2
.
6
8
.
3
0
.
3
0
.
1
0
.
8
9
.
3
0
.
9
0
.
3
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
0
5
9
0
0
.
4
5
.
4
1
.
1
0
0
.
4
4
.
5
2
.
1
0
0
.
2
2
.
8
3
.
9
0
.
2
2
4
.
4
0
.
3
0
0
.
5
5
.
5
0
.
9
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
0
.
3
5
4
.
3
0
0
0
.
4
5
4
.
3
0
0
0
.
2
5
4
.
4
0
.
2
0
.
7
2
.
3
5
1
.
5
0
0
.
2
0
.
5
5
4
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
2
.
2
0
.
2
3
2
.
4
0
P
M
2
3
.
8
2
0
.
1
0
2
1
.
8
3
.
6
0
.
3
0
.
3
2
5
.
9
0
.
1
0
0
2
5
.
4
0
.
7
0
0
𝒑
≤
𝟎
.𝟎
𝟏
1
.
3
7
.
2
2
.
1
0
.
5
0
6
.
9
2
.
8
1
.
3
3
8
0
.
1
0
1
.
1
9
.
3
0
.
6
0
.
1
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
5
.
5
6
2
.
1
8
.
6
5
9
0
.
1
1
3
.
7
2
.
1
0
0
3
.
7
3
.
1
0
.
4
2
.
2
4
.
3
0
.
1
0
.
2
0
.
7
5
.
5
0
.
5
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
.
1
0
.
4
1
.
2
5
4
.
2
0
0
0
.
1
5
5
.
9
0
.
4
0
.
9
2
.
7
5
1
.
9
0
.
1
0
.
3
0
.
8
5
4
.
7
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
4
.
9
1
.
2
3
5
.
6
0
.
6
3
2
.
2
3
.
9
H
M
2
1
.
6
3
.
3
0
.
3
0
.
2
2
5
0
.
3
0
.
1
0
.
1
2
4
.
4
0
.
9
0
0
.
1
𝒑
≤
𝟎
.𝟎
𝟏
0
.
2
7
.
2
2
.
5
0
.
9
4
6
.
3
0
.
3
0
.
2
2
.
1
7
.
6
0
.
8
0
.
3
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
2
.
8
6
1
.
1
5
.
4
5
8
.
5
0
.
2
6
3
.
7
0
0
.
1
4
2
.
9
0
.
4
3
.
4
2
.
9
0
.
3
0
.
2
2
4
0
.
9
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
0
.
2
5
6
.
6
0
.
3
1
.
3
3
.
8
5
1
.
4
0
.
1
0
.
6
2
.
1
5
4
.
1
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
6
.
5
0
.
7
3
7
0
.
1
3
2
.
4
4
.
8
3
4
.
4
2
.
7
1
.7
SJ
2
1
.
8
0
0
0
2
1
.
7
0
.
2
0
0
𝒑
≤
𝟎
.𝟎
𝟏
5
.
8
4
.
7
0
0
3
.
9
6
.
5
0
.
2
0
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
1
.
3
6
1
.
6
3
.
9
5
9
0
6
2
.
8
1
.
7
6
1
.
1
1
3
.
9
2
0
.
1
0
.
6
2
.
8
3
.
4
0
.
2
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
1
.
1
2
.
6
5
.
1
5
1
.
9
0
.
6
1
.
6
3
.
3
5
5
.
2
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
7
.
1
1
.
3
3
7
.
8
0
.
5
3
2
.
1
6
.
2
3
5
.
8
2
.
6
3
6
.
7
1
.
7
M
L
2
6
.
7
2
.
6
0
.
2
0
.
2
𝒑
≤
𝟎
.𝟎
𝟏
0
8
.
4
2
.
3
0
.
6
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
0
.
7
6
1
3
.
1
5
8
.
5
0
.
3
6
1
.
3
0
.
4
6
1
.
2
0
.
4
6
1
.
2
0
0
4
.
4
2
.
7
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
0
5
1
.
9
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
5
.
1
1
.
6
3
6
.
2
0
.
5
3
2
.
1
4
.
6
3
3
.
4
3
.
3
3
5
.
7
1
3
5
.
3
1
.
4
R
EM
L
p
>
𝟎
.𝟎
𝟓
2
.
6
6
0
.
7
4
.
8
5
8
.
5
0
.
3
6
3
2
.
7
6
0
.
6
1
.
5
6
1
.
8
3
6
0
.
3
T
a
b
le
4
.2
:
T
h
e
d
iﬀ
e
re
n
ce
be
tw
ee
n
h
e
te
ro
g
e
n
e
ity
v
a
ria
n
ce
e
stim
a
tio
n
m
e
th
o
d
s
in
te
rm
s
o
f
p
-v
a
lu
e
ca
teg
o
rie
s
d
e
riv
ed
fro
m
th
e
W
a
ld
-sta
tistic
.
U
pper-right
pan
el:
P
-valu
e
categories
split
in
to
4:
p
>
0.1,
0.05
<
p≤
0.1,
0.01
<
p≤
0.05
an
d
p≤
0.01.
L
ow
er-left
pan
el:
P
-valu
e
categories
split
in
to
2:
p
>
0.05
an
d
p≤
0.05.
72
D
is
co
rd
an
t
C
o
n
co
rd
an
t C
A
1
7
.
5
0
.
2
0
0
1
7
.
6
0
.
1
0
0
1
6
.
9
0
.
7
0
0
1
6
.
7
0
.
9
0
.
1
0
.
1
1
7
.
6
0
.
1
0
0
1
7
.
5
0
.
2
0
0
𝒑
≤
𝟎
.𝟎
𝟏
0
.
5
1
3
.
6
0
.
3
0
.
1
0
.
4
1
3
.
9
0
.
2
0
.
1
0
.
4
1
3
0
.
9
0
.
2
0
.
2
1
2
.
9
1
0
.
3
0
.
8
1
3
.
4
0
.
2
0
0
.
6
1
3
.
5
0
.
3
0
.
1
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
0
.
1
0
.
9
8
.
4
0
.
3
0
0
.
5
8
.
8
0
.
2
0
0
.
8
7
.
7
1
0
0
.
5
7
.
8
1
.
3
0
.
1
1
8
.
2
0
.
3
0
.
1
1
8
.
2
0
.
4
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
.
1
0
.
8
5
7
.
3
0
0
.
1
0
.
6
5
7
.
5
0
0
.
1
0
.
9
5
7
.
2
0
0
.
1
0
.
7
5
7
.
4
0
0
.
3
1
.
1
5
6
.
7
0
0
.
2
1
5
6
.
9
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
1
.
8
0
.
4
D
L
1
7
.
5
0
.
2
0
0
1
7
.
6
0
.
1
0
0
1
6
.
9
0
.
7
0
0
1
6
.
7
0
.
9
0
.
1
0
.
1
1
7
.
6
0
.
1
0
0
𝒑
≤
𝟎
.𝟎
𝟏
0
.
5
1
3
.
6
0
.
3
0
.
1
0
.
4
1
3
.
9
0
.
2
0
.
1
0
.
4
1
3
0
.
9
0
.
2
0
.
2
1
2
.
9
1
0
.
3
0
.
8
1
3
.
4
0
.
2
0
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
1
.
1
6
6
.
7
0
.
1
0
.
9
8
.
4
0
.
3
0
0
.
5
8
.
8
0
.
2
0
0
.
8
7
.
7
1
0
0
.
5
7
.
8
1
.
3
0
.
1
1
8
.
2
0
.
3
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
.
1
0
.
8
5
7
.
3
0
0
.
1
0
.
6
5
7
.
5
0
0
.
1
0
.
9
5
7
.
2
0
0
.
1
0
.
7
5
7
.
4
0
0
.
3
1
.
1
5
6
.
7
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
2
0
.
2
3
2
.
5
0
.
4
P
M
2
3
.
8
2
0
.
1
0
2
1
.
8
3
.
6
0
.
3
0
.
3
2
5
.
9
0
.
1
0
0
2
5
.
4
0
.
7
0
0
𝒑
≤
𝟎
.𝟎
𝟏
1
.
3
7
.
2
2
.
1
0
.
5
0
6
.
9
2
.
8
1
.
3
3
8
0
.
1
0
1
.
1
9
.
3
0
.
6
0
.
1
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
0
.
7
6
7
.
1
0
.
2
6
7
0
.
1
1
3
.
7
2
.
1
0
0
3
.
7
3
.
1
0
.
4
2
.
2
4
.
3
0
.
1
0
.
2
0
.
7
5
.
5
0
.
5
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
.
1
0
.
4
1
.
2
5
4
.
2
0
0
0
.
1
5
5
.
9
0
.
4
0
.
9
2
.
7
5
1
.
9
0
.
1
0
.
3
0
.
8
5
4
.
7
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
1
.
1
1
.
1
3
1
.
9
1
3
1
.
5
1
.
1
H
M
1
7
.
2
0
.
8
0
0
1
6
.
8
1
.
1
0
.
1
0
.
1
1
8
0
.
1
0
0
𝒑
≤
𝟎
.𝟎
𝟏
0
.
2
1
3
.
4
1
0
.
1
0
.
1
1
2
.
9
1
.
3
0
.
3
0
.
5
1
3
.
9
0
.
2
0
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
1
6
6
.
8
0
.
2
6
6
.
9
0
.
5
6
6
.
9
0
0
.
5
8
1
0
0
.
4
7
.
7
1
.
4
0
0
.
7
8
.
5
0
.
3
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
0
.
5
5
7
.
3
0
0
0
.
5
5
7
.
3
0
0
.
2
0
.
8
5
6
.
8
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
0
.
7
1
.
5
3
0
.
8
2
3
0
.
9
1
.
8
3
1
1
.
1
1
.7
SJ
1
6
.
8
0
.
2
0
0
1
6
.
8
0
.
1
0
0
𝒑
≤
𝟎
.𝟎
𝟏
1
.
5
1
2
.
3
0
.
5
0
.
1
1
.
2
1
2
.
8
0
.
3
0
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
0
.
6
6
7
.
2
0
.
5
6
6
.
7
0
.
4
6
6
.
9
0
.
3
6
7
.
6
0
.
1
1
.
8
6
.
9
0
.
7
0
.
1
1
.
5
7
.
5
0
.
4
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
.
1
0
.
6
2
.
1
5
6
.
3
0
.
1
0
.
4
1
.
7
5
6
.
9
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
1
.
9
0
.
3
3
2
.
7
0
.
2
3
2
.
4
0
.
2
3
1
.
7
0
.
4
3
0
.
7
0
.
6
M
L
1
8
.
2
0
.
3
0
0
𝒑
≤
𝟎
.𝟎
𝟏
0
.
1
1
4
.
3
0
.
5
0
.
1
𝟎
.𝟎
𝟏
<
𝒑
≤
𝟎
.𝟎
𝟓
p
>
𝟎
.𝟎
𝟓
1
.
5
6
6
.
3
0
.
8
6
6
.
3
1
6
6
.
4
1
.
7
6
6
.
2
2
.
7
6
6
0
0
.
3
8
.
7
0
.
5
𝟎
.𝟎
𝟓
<
𝒑
≤
𝟎
.𝟏
0
0
0
.
3
5
6
.
7
𝒑
>
𝟎
.𝟏
p
≤
𝟎
.𝟎
𝟓
3
1
.
8
0
.
4
3
2
.
7
0
.
1
3
2
.
4
0
.
2
3
1
.
9
0
.
2
3
1
0
.
3
3
2
.
8
0
.
6
R
EM
L
p
>
𝟎
.𝟎
𝟓
1
.
3
6
6
.
5
0
.
4
6
6
.
7
0
.
7
6
6
.
7
1
.
2
6
6
.
7
2
.
1
6
6
.
6
0
.
3
6
6
.
3
T
a
b
le
4
.3
:
T
h
e
d
iﬀ
e
re
n
ce
be
tw
ee
n
h
e
te
ro
g
e
n
e
it
y
v
a
ri
a
n
ce
e
st
im
a
ti
o
n
m
e
th
o
d
s
in
te
rm
s
o
f
p
-v
a
lu
e
ca
te
g
o
ri
e
s
d
e
ri
v
ed
fr
o
m
th
e
H
a
rt
u
n
g
-K
n
a
p
p
m
e
th
o
d
.
U
pp
er
-r
ig
ht
pa
n
el
:
P
-v
al
u
e
ca
te
go
ri
es
sp
li
t
in
to
4:
p
>
0.
1,
0.
05
<
p
≤
0.
1,
0.
01
<
p
≤
0.
05
an
d
p
≤
0.
01
.
L
ow
er
-l
ef
t
pa
n
el
:
P
-v
al
u
e
ca
te
go
ri
es
sp
li
t
in
to
2:
p
>
0.
05
an
d
p
≤
0.
05
.
73
When p-values from the Wald-statistic are split into ﬁner categories (also in table
4.2), there were diﬀerences of two or more categories between at least two hetero-
geneity variance estimators in 6.2% of meta-analyses. 1.4% of meta-analyses had
p-values diﬀering by 3 categories. P-values derived from SJ and ML heterogeneity
variance estimators had the lowest agreement; 4.7% of meta-analyses diﬀered by at
least 2 p-value categories for this comparison and all where ML gave the lowest p-
value. The highest agreement was observed between DL and HM methods; 0.6% of
meta-analyses diﬀered by at least 2 p-value categories and 0.05% of meta-analyses
diﬀered by 3 categories. There is also a high level of agreement between DL and
PM methods; this is consistent with the level of agreement observed in terms of the
other measures, including I2, the summary eﬀect and standard error.
Results from table 4.3 show p-values based on the t-statistic have much higher agree-
ment between heterogeneity variance estimators. Statistical signiﬁcance at the 5%
level is discordant between at least two heterogeneity variance estimators in 3.7%
of meta-analyses - roughly two-thirds less than the proportion of Wald-statistic p-
values. Comparisons with low and high agreement are consistent between Wald-
statistic and t-statistic p-values. The lowest agreement is observed between SJ and
ML methods; 3.3% of meta-analyses have discordant statistical signiﬁcance at the
5% level between these methods. The highest agreement is observed between DL
and REML with discordance at the 5% level in 0.5% of meta-analyses.
When p-values derived from the t-statistic are split into ﬁner categories (as shown
in the upper-left panel of table 4.3 ), only 1.1% of meta-analyses had p-values that
are discordant by two or more categories between any two estimators; almost six
times fewer meta-analyses than p-values derived from the Wald-statistic. Again, the
comparison between SJ and ML shows the lowest agreement, with p-values of 0.9%
of meta-analyses discordant by two or more categories. In many other pair-wise
comparisons, 0.1% or fewer meta-analyses are discordant by two or more categories.
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4.3.6 Factors to explain the level of agreement between het-
erogeneity variance estimates
Figure 4.6 shows pairwise agreement between I2 estimates plotted against the num-
ber of studies (in the upper-right panel) and total information (in the lower-left
panel).
Results show that the general level of agreement between I2 estimates is not cor-
related with how many studies there are in the meta-analysis. However, rare and
extreme I2 diﬀerences of close to 100% only occur in meta-analyses with fewer than
20 studies. The only exception is the comparison between ML and REML; diﬀer-
ences between ML and REML estimates of I2 are close to zero when there are 40
or more studies. For all other comparisons it appears the scatter of meta-analyses
is showing a trend, but this is because most meta-analyses contain few studies and
are situated to left hand side of the graph giving the appearance of less agreement
between I2 estimates.
When diﬀerences in I2 are plotted against the total information, results show there
is no trend in any of the comparisons. Extreme diﬀerences in I2 close to 100% occur
much less when the total information is high, but this can only be attributed to
a high power to detect heterogeneity and therefore fewer zero I2 estimates derived
from the truncated estimators CA, DL, PM, ML and REML.
4.4 Examples
I selected two examples from the CDSR dataset, speciﬁcally chosen with widely
diﬀerent estimates of the heterogeneity variance to show how such diﬀerences may
lead to diﬀerent conclusions.
Example 1. Omega-3 fatty acids for prevention and treatment of cardiovascular
disease
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Figure 4.6: Bland-Altman scatter plots comparing diﬀerences in I2 estimates
against (upper-right panel) the number of studies and (lower-left panel) the
total information
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Figure 4.7: Forest plot of a meta-analysis of seven studies, with combined
eﬀects illustrated from various methods of heterogeneity variance estimation
Wald-type conﬁdence intervals for the summary eﬀect presented.
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The forest plot in ﬁgure 4.7 shows a meta-analysis of trials comparing the eﬀect of
high and low doses of omega-3 fatty acids in relation to systolic blood pressure (SBP)
at the end of the study [52]. Seven studies were combined, originally by the random-
eﬀects inverse variance method with a DL estimate of the heterogeneity variance
and summary eﬀect conﬁdence interval calculated using the Wald-type and Hartung-
Knapp methods. The systematic review was used to inform guidance from The US
Food and Drug Administration [29], although SBP was a secondary rather than a
primary outcome. DL estimated I2 as 32.3% with I2 estimates ranging from the ML
estimate of 0% to the SJ estimate of 70.6%. Estimates of the overall mean diﬀerence
were aﬀected by diﬀerences in heterogeneity variance estimates, ranging from -1.09 to
-0.59. The Wald-type 95% conﬁdence interval around the pooled eﬀect when the SJ
estimate of the heterogeneity variance is used is 2.37 times the size of the equivalent
conﬁdence interval derived using the ML estimate. By contrast, the Hartung-Knapp
method produced conﬁdence intervals with a up to 1.6 times diﬀerence in width (SJ
vs ML also). All summary eﬀects were not statistically signiﬁcant with p-values
ranging from 0.371 to 0.590. Therefore, choice of heterogeneity variance estimator
did not aﬀect inferences despite notably diﬀerent estimates.
Example 2. Interventions used to improve control of blood pressure in patients with
hypertension
The second example is from a systematic review of interventions to improve control
of blood pressure in patients with hypertension [34]. Figure 4.8 shows the forest plot
of a meta-analysis comparing educational interventions directed at the physician
versus a control group. The outcome of the meta-analysis is whether the patient
was able to control their blood pressure, and intervention groups are compared in
the form of an odds ratio. The Cochrane systematic review containing this meta-
analysis has informed health practice: it has been used in a NICE guideline for
treating hypertension [91] and is referenced in a related Cochrane review [84]. The
original ﬁxed-eﬀect analysis suggests a statistically signiﬁcant result in favour of
active intervention (p < 0.001). The I2 statistic varied considerably between the CA
78
Figure 4.8: Forest plot of a meta-analysis of six studies, with combined eﬀects
illustrated from various methods of heterogeneity variance estimation
Wald-type conﬁdence intervals for the summary eﬀect presented.
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estimate of 0% and the DL estimate of 60.5%. When an inverse-variance random-
eﬀects approach is used to combine the studies, results vary considerably with p-
values ranging between < 0.001 and 0.148, even though there are minimal diﬀerences
between pooled eﬀect estimates. Therefore, using the Wald-type method, conclusions
of this meta-analysis might change considerably depending on whether ﬁxed- or
random-eﬀects are assumed as well as on which method of heterogeneity variance
estimation is chosen. Conclusions are more robust using the Hartung-Knapp method.
4.5 Discussion
I have shown that there is considerable inconsistency in ﬁndings of meta-analyses
when diﬀerent methods are used to estimate heterogeneity variance in a random-
eﬀects model. In some cases, I2 estimates diﬀered by more than 50% in absolute
value. In extreme cases, one method can produce an I2 statistic of 0% while a dif-
ferent method can produce an I2 close to 100%. Extreme inconsistencies mostly
occurred when one method estimated I2 = 0%. Some methods are more consistent
with each other, such as the DerSimonian-Laird (DL) and Paule-Mandel (PM) estim-
ators. These methods give perfectly consistent results where I2 = 0%, but absolute
diﬀerences in I2 may still be up to 25%. Sidik-Jonkman (SJ) and Hartung-Makambi
(HM) estimates had high agreement for low levels of heterogeneity and in few cases
diﬀerences in I2 exceeded 50%; this was likely due to both methods producing no I2
estimates of 0%.
PM has been described as a simpliﬁed version of REML. Rukhin et al. [94] there-
fore suggested these methods should produce similar estimates of the heterogeneity
variance, yet our results show low agreement between them. Rukhin et al addressed
the simpler situation of a single sample of normally distributed observations arising
in each study and estimated the within-study variance using REML methods rather
than the maximum likelihood approach usually used for two-group studies such as
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clinical trials [8, 124]. These diﬀerences may explain the low agreement between the
methods.
While estimates of heterogeneity may be very diﬀerent, this does not translate into
substantial diﬀerences in the summary eﬀect estimates. It can, however, lead to
very diﬀerent conﬁdence intervals for the summary eﬀect estimates, and hence to
diﬀerent p-values. Diﬀerences in p-values showed that conclusions of a meta-analysis
may diﬀer in a small number of cases, but frequently enough to cause concern. P-
values derived from the commonly-used Wald-statistic were discordant at the 5%
signiﬁcance level in 10.3% of meta-analyses between at least two of the seven het-
erogeneity variance estimators. If the DL random-eﬀects approach was used in all
meta-analyses, 3.1% of meta-analyses would have had diﬀerent conclusions (by at
least two p-value categories) when at least one of the other heterogeneity variance
estimates is used. If p-values were derived from the Hartung-Knapp method [38],
conclusions would have changed much less frequently; p-values were discordant at
the 5% level in 3.7% of meta-analyses between any two heterogeneity variance es-
timators. These results are consistent with an empirical study comparing DL with
other heterogeneity variance estimators [117].
In a secondary analysis, I found the number of studies and total information in
a meta-analysis has little impact on the level of agreement between heterogeneity
variance estimates. Therefore, diﬀerences between estimates are not caused by lack
of data, but perhaps by inherent diﬀerences between the heterogeneity estimation
methods. The meta-analysis examples given in section 4.4 have a high level of dis-
agreement between many summary statistics, but have no noticeable characteristics
that would explain such disagreement. These ﬁndings suggest that large diﬀerences
between heterogeneity variance estimates are possible in meta-analyses of all sizes.
My use of the CDSR dataset means that this analysis has some limitations. The
dataset contained on average seven meta-analyses per systematic review and results
within each systematic review are likely to be correlated, meaning heterogeneity
variance estimates are not independent. Also, the dataset included meta-analyses
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that were not really meta-analyses, in that the studies were presented together in
a forest plot but not synthesised in the original publication. These `meta-analyses'
may have diﬀerent characteristics from those that did combine the results and are
likely to be more heterogeneous. Therefore, there may be a diﬀerence between the
range of heterogeneity variance estimates in our analysis and the range reported in
actual Cochrane reviews. Finally, the limitation of using empirical data is that the
true heterogeneity variance is unknown and I cannot infer which method produces
the closest estimate to the true value. Simulated data is required for this purpose,
which I use predominantly in the rest of this thesis.
4.6 Conclusion
Diﬀerences across methods suggests the need for further research into the properties
of the heterogeneity variance estimators, such as whether they give biased results.
This can only be achieved through simulation rather than empirical meta-analysis
data. Therefore, in the next chapter, I conducted a systematic review of simulation
studies that compare heterogeneity variance estimators.
In summary, the choice of heterogeneity variance estimator can aﬀect the results
of a meta-analysis, including estimates of the degree of heterogeneity, the standard
error of the summary eﬀect and less frequently the statistical signiﬁcance of results.
The use of a single estimate of the heterogeneity variance may therefore lead to
inappropriate conclusions in some meta-analyses. When conducting a random-eﬀects
meta-analysis, researchers should be aware that the choice of heterogeneity variance
estimator may alter the conclusions drawn from the analysis. Sensitivity analysis
using a wide range of plausible heterogeneity variances may be advised.
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Chapter 5
A review of simulation studies to
compare heterogeneity variance
estimators
83
5.1 Introduction
In the last chapter, I presented an empirical comparison of heterogeneity variance es-
timators using meta-analysis data derived from the Cochrane Database of Systematic
Reviews. Results showed considerable disagreement between heterogeneity variance
estimates derived from many diﬀerent methods, including DerSimonian-Laird [25].
Diﬀerences between these estimates may have led to discordant conclusions in a
small, but noteworthy proportion of meta-analyses. These ﬁndings provide motiva-
tion for further investigation of the properties of heterogeneity variance estimators
in this chapter and for the rest of my thesis.
I present in this chapter a systematic review of studies that compare heterogeneity
variance estimators in simulated meta-analysis data. In studies based on simulated
data, the properties of methods can be investigated. In this review, I aim to (1)
identify whether there is consistent evidence across simulation studies, (2) under-
stand how diﬀerent heterogeneity methods impact on estimation of the heterogeneity
variance itself, the meta-analytic summary eﬀect and its conﬁdence interval, (3) po-
tentially recommend method(s) for estimating heterogeneity in practice without the
need for further simulation studies; and (4) to identify areas where further simulation
research may be required.
In section 5.2, I detail the methods I used to search and select simulation studies for
inclusion in my review. I present a summary of the identiﬁed studies in section 5.3,
including summaries of their designs in sections 5.3.1 - 5.3.4 and results from their
simulations in section 5.3.5. The discussion and conclusion are in sections 5.4 and
5.5.
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5.2 Methods
5.2.1 Search Strategy
I searched the databases MEDLINE, Web of Science Core Collection and JSTOR on
8th Nov 2014. Details of the search strategy are given in appendix C.1. For each of
the included papers I examined reference lists and performed a citation search using
Google Scholar. Search results were restricted to those written in English.
5.2.2 Eligibility criteria
I included papers if:
1. results were presented from simulated meta-analysis data;
2. simulated data were generated from a random-eﬀects model with at least one
scenario with τ 2 > 0; and
3. results compared the performance of more than one heterogeneity variance
estimator.
Papers were excluded if they contained only the following types of simulated data:
1. network meta-analyses;
2. one-stage individual participant data (IPD) meta-analyses;
3. meta-analyses of diagnostic accuracy studies; or
4. meta-regression, if covariates were responsible for all heterogeneity present.
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5.2.3 Data extraction
I extracted details of the methods used to simulate data from each study. This
included parameter values for the heterogeneity variance, summary eﬀect and cov-
ariates for simulations of meta-regression data. Other method details include the
type of outcome measure (e.g. odds ratio), the number of studies in each meta-
analysis and the distributions for generating study eﬀects and study sample sizes.
Findings from simulation results relating to the performance of each heterogeneity
variance estimator were collated and summarised. I also extracted raw study results
(where available) to attempt a formal synthesis, but this was not feasible due to
diﬀerences in the design of the included studies. Instead, I graphically present selec-
ted results from studies in which raw results were provided. Recommendations from
the concluding sections of each paper were extracted, including which heterogen-
eity variance estimator(s) the authors thought performed best and any other general
recommendations for heterogeneity variance estimation.
5.3 Results
5.3.1 Search Results
The database search returned 1,472 matches in MEDLINE, 1,918 matches in Web
of Science Core Collection and 530 matches in JSTOR with a total of 3,225 non-
duplicate matches. Ten publications met the eligibility criteria. I identiﬁed a further
two from searching reference lists and citations [79, 102], leading to a total of 12
included simulation studies, which are listed in table 5.1. Among the 12 simulation
studies, eight proposed new methods for heterogeneity estimation and then conduc-
ted a simulation study to compare the methods with existing methods. Sidik and
Jonkman conducted two simulation studies [101, 102] and proposed new methods in
each; their 2007 study was intended to supersede the earlier 2005 study. The remain-
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ing four publications were simulation studies that only compared existing methods
[78, 79, 96, 124].
5.3.2 Simulation methods and parameter values
Table 5.1 details methods that were used to simulate meta-analysis data in each
study. Six (50%) studies simulated meta-analyses containing studies with a binary
outcome, four of which used an odds ratio eﬀect measure and two used a relative risk
eﬀect measure. Four (33%) studies simulated continuous outcome meta-analyses, all
of which used a standardised mean diﬀerence eﬀect measure, and one study also
used the `unstandardised' mean diﬀerence [124]. In both binary and continuous
meta-analyses, study sample sizes were most commonly generated from a uniform
distribution [78, 79, 101, 102]. The within-study variance of each study was then
derived from these sample sizes. Only three (25%) studies simulated sample sizes or
within-study variances using more than one set of parameter values [79, 93, 124].
Three (25%) studies simulated meta-analysis data with a generic eﬀect measure
[17, 64, 93]. These studies allow investigation of the properties of the estimators
without conﬂation with estimation of speciﬁc outcome measures. Generic study ef-
fects in these three studies were simulated directly from the random-eﬀects model.
Chung et al. [16] and Kontopantelis et al. [64] used known within-study variances to
calculate heterogeneity variance estimates, while Rukhin [93] used within-study vari-
ances estimated from simulated participant-level data. These within-study variances
are rarely known in practice and therefore results from Chung et al. [16] and Kon-
topantelis et al. [64] represent the performance of heterogeneity variance estimators
under ideal conditions.
All simulation studies presented results for a range of heterogeneity variance para-
meters, including zero in all but one case [64]. All studies except Kontopantelis et al.
[64] gave no reasoning for their choice of parameter values or simply stated they
chose values to reﬂect real meta-analyses in practice. In these studies, there was
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Reference 
𝝉2 parameter 
values 
Scen-
ario 
Corresponding mean 𝑰2 (%) 
 
Knapp and Hartung 
(2003) 
0, 0.05, 0.1, 0.2, 0.3 
𝑝1𝑖 =
0.05   
𝑝1𝑖 =
0.1   
Panityakul et al (2013)  0 to 0.5 (by 0.05) 
Small 
studies  
Large 
studies  
Bhaumik et al (2012)  
0, 0.2, 0.4, 0.6, 0.8, 1, 
1.2 
𝑝1𝑖 =
0.004   
𝑝1𝑖 =
0.996   
Sidik and Jonkman 
(2005)  
0, 0.10, 0.25, 0.5, 
0.75, 1, 1.25, 1.50, 2 
- 
 
Sidik and Jonkman 
(2007) 
0 - 0.5 (by 0.1) and 
0.5 - 1.75 (by 0.25) 
- 
 
Novianti et al (2014) * 
0, 0.5, 1, 1.5 (OR) - 
 
0, 0.0122, 0.0244, 
0.0366 (SMD) 
- 
 
Malzahn et al (2000)  0, 0.09, 0.25, 1, 4 - 
 
Sanchez-Meca and 
Marin-Martinez (2008)  
0, 0.04, 0.08, 0.16, 
0.32 
- 
 
Viechtbauer (2005)  
0, 0.001, 0.025, 0.05, 
0.1 (SMD) 
Small 
studies  
Large 
studies  
0, 0.125, 0.25, 0.5, 1 
(MD) 
Small 
studies  
Large 
studies  
Chung et al (2013) * 0, 0.01, 0.05, 0.1, 0.2 - 
 
Kontopantelis et al 
(2013) * 
0.01, 0.03, 0.1 - 
 
Rukhin (2013) 0 - 2 (by 0.1) - 
 
 
Table 5.2: Underlying ranges of I2 in each publication
* Similar I2 values are also reported in the original articles. I2 values in
Kontopantelis et al. [64] diﬀer from those in the table because they used estimates of
I2 based on the formula dependent on the Q statistic (see formula 1.5). I2 values in
Chung et al. [16] diﬀer because they were calculated individually for all k.
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inconsistency between the ranges of heterogeneity variances; Viechtbauer [124] used
parameter values up to 0.1 and Malzahn et al. [74] used parameter values up to 4
to simulate SMD meta-analyses. Kontopantelis et al. [64] chose parameter values
that correspond to a range of low, moderate and high I2 (as deﬁned in the study). I
derived the range of underlying I2 values for all simulation studies and present them
in table 5.21. There was low consistency between the range of I2: seven studies
(58%) contained only meta-analyses with non-zero underlying I2 values greater than
40%. Nevertheless, I use the terms 'low', 'moderate' and 'high' heterogeneity in the
rest this review as they were used in the original publications.
Over all publications identiﬁed in this review, meta-analyses were simulated that
contain 2 - 100 studies. Six (50%) publications include simulated meta-analyses with
fewer than 10 studies and ﬁve (42%) publications include simulated meta-analyses
with 50 or more studies.
5.3.3 Performance measures
Performance measures reported from each simulation study are listed in Table 5.3.
Ten studies compared bias of heterogeneity variance estimators. Nine compared the
variance, eﬃciency or MSE; I deﬁne these three performance measures as measures
of variability of heterogeneity variance estimates, and refer to them as such in the
rest of this paper. For details on how these measures are calculated, see appendix
C.2.
Many of the studies reported performance measures to quantify the impact of hetero-
geneity variance estimators on other commonly reported statistics in meta-analysis.
Three reported the performance of estimates of the summary eﬀect [93, 96, 101]. Six
compared the coverage of 95% conﬁdence intervals for the summary eﬀect. Konto-
pantelis et al. [64] also reported performance of conﬁdence interval for the summary
1I2calculated from the formula I2 = 100 · τ2/ (τ2 + σ2), where σ2 is the typical variance and
derived from 1000 replications of each simulated scenario.
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Simulation study 
Heterogeneity variance Summary effect 
Confidence interval 
for mean effect 
B
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Knapp and Hartung (2003) ✔  ✔     ✔  
Panityakul  et al (2013) ✔ ✔        
Bhaumik et al (2012) ✔         
Sidik and Jonkman (2005) ✔ ✔    ✔ ✔ ✔  
Sidik and Jonkman (2007) ✔ ✔        
Novianti et al (2014) ✔  ✔        
Malzahn et al (2000) ✔  ✔       
Sanchez-Meca and Marin-Martinez (2008)      ✔  ✔  
Viechtbauer (2005) ✔ ✔  ✔      
Chung et al (2013) ✔ ✔   ✔   ✔  
Kontopantelis et al (2013) ✔    ✔   ✔ ✔ 
Rukhin (2013)  ✔     ✔ ✔  
Total 10 6 3 1 2 2 2 6 1 
Table 5.3: Summary of performance measures reported in the 12 included
simulation studies
eﬀect in terms of mean error interval estimates, that is, the average ratio between
observed and actual 95% conﬁdence interval widths.
Given the range of reported performance measures, I present the performance of
heterogeneity variance estimators in three sections: properties of the point estimate
of heterogeneity in section 5.3.5, properties of the point estimate of the summary
eﬀect in section 5.3.6 and properties of conﬁdence intervals for the summary eﬀect
in section 5.3.7.
5.3.4 Heterogeneity variance estimators
Table 5.4 shows which heterogeneity variance estimators were compared in each sim-
ulation study. DerSimonian-Laird was included in all 12 studies. Other estimators
frequently included were Cochran's ANOVA (CA), restricted maximum likelihood
(REML), maximum likelihood (ML), Paule-Mandel (PM) and Sidik-Jonkman (SJ).
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Rukhin's Bayesian estimators (RU, B0, BP, SB) were only included in two simulation
studies only with a generic outcome measure [64, 93]. Methods including the boot-
strap DerSimonian-Laird (DLB), positive DerSimonian-Laird (DLP), two of Rukhin's
estimators (RU, SB) and Bayes Modal (BM) have only been compared in the one
study in which they were initially proposed. For details on each heterogeneity vari-
ance estimator, see chapter 2. I frequently refer to heterogeneity variance estimators
by their acronyms in the rest of this chapter; the acronym deﬁnitions are given in
table 5.4.
5.3.5 Performance of point estimators of the heterogeneity
variance
In this section, I summarise the properties of heterogeneity variance estimators iden-
tiﬁed in this review in terms of bias, variability (e.g. mean squared error), and
the proportion of zero estimates they produce. Estimators are summarised together
when they are slight variations of the same method or have similar properties. This
section excludes the Hartung and Makambi estimator, which has only been compared
in terms of performance measures relating to the summary eﬀect and its conﬁdence
interval [96] (see sections 5.3.6 and 5.3.7 for these results).
Selected results are presented in ﬁgures 5.1 and 5.2; these were recreated from the raw
study results in the supplementary material of Novianti et al. [78] to back up some
of the ﬁndings in this section. These raw study results included the performance
measures bias and variance, but I present bias and mean squared error. The mean
squared error is a more meaningful measure of performance than the variance and
could be derived from the raw results given.
I present those compared in many simulation studies ﬁrst, beginning with the DerSimonian-
Laird estimator.
94
Es
ti
m
at
o
rs
 *
 
A
cr
o
n
ym
 
Knapp and Hartung 
(2003) 1 
Panityakul  et al 
(2013) 
Bhaumik et al (2012) 
Sidik and Jonkman 
(2005) 
Sidik and Jonkman 
(2007) 
Novianti et al (2014) 
Malzahn et al (2000) 
Sanchez-Meca and 
Marin-Martinez (2008) 
Viechtbauer (2005) 2 
Chung et al (2013) 
Kontopantelis et al 
(2013) 
Rukhin (2013) 
Total 
D
er
Si
m
o
n
ia
n
-L
ai
rd
 (
1
9
8
6
) 
D
L 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
1
2
 
P
o
si
ti
ve
 D
e
rS
im
o
n
ia
n
-L
ai
rd
 (
2
0
1
3
) 
 
D
L P
 
 
 
 
 
 
 
 
 
 
 
✅
 
 
1
 
B
o
o
ts
tr
ap
 D
er
Si
m
o
n
ia
n
-L
ai
rd
 (
2
0
1
3
) 
D
L B
 
 
 
 
 
 
 
 
 
 
 
✅
 
 
1
 
C
o
ch
ra
n
's
 A
N
O
V
A
 (
1
9
8
5
) 
C
A
 
 
✔
 
 
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
✔
 
9
 
P
au
le
-M
an
d
el
 (
1
9
8
2
) 
P
M
 
✔
 
✔
 
✔
 
 
✔
 
✔
 
 
 
 
 
 
✔
 
6
 
Tw
o
-s
te
p
 P
au
le
-M
an
d
el
 (
C
A
 a
 p
ri
o
ri
) 
(2
0
0
7
) 
P
M
C
A
 
 
 
 
 
 
 
 
 
 
 
✔
 
 
1
 
Tw
o
-s
te
p
 P
au
le
-M
an
d
el
 (
D
L 
a
 p
ri
o
ri
) 
(2
0
0
7
) 
P
M
D
L 
 
 
✔
 
 
 
✔
 
 
 
 
 
✔
 
 
3
 
H
ar
tu
n
g-
M
ak
am
b
i (
2
0
0
3
) 
H
M
 
 
 
 
 
 
 
 
✔
 
 
 
 
 
1
 
Si
d
ik
-J
o
n
km
an
 (
2
0
0
5
) 
SJ
 
 
✔
 
 
✅
 
✔
 
✔
 
 
✔
 
 
 
✔
 
 
6
 
Si
d
ik
-J
o
n
km
an
 (
C
A
 a
 p
ri
o
ri
) 
(2
0
0
7
) 
SJ
C
A
 
 
 
 
 
✅
 
✔
 
 
 
 
 
✔
 
 
3
 
H
u
n
te
r-
Sc
h
m
id
t 
(2
0
0
4
) 
H
S 
 
 
 
 
 
 
 
✔
 
✔
 
 
 
 
2
 
M
ax
im
u
m
 li
ke
lih
o
o
d
 (
1
9
9
6
) 
M
L 
 
✔
 
 
 
✔
 
 
 
✔
 
✔
 
✔
 
✔
 
 
6
 
R
es
tr
ic
te
d
 m
ax
im
u
m
 li
ke
lih
o
o
d
 (
1
9
7
7
) 
R
EM
L 
 
✔
 
 
 
✔
 
✔
 
 
✔
 
✔
 
✔
 
✔
 
 
8
 
A
p
p
ro
xi
m
at
e 
re
st
ri
ct
ed
 m
ax
im
u
m
 li
ke
lih
o
o
d
 (
1
9
8
3
) 
A
R
M
L 
✔
 
 
 
 
 
 
 
 
 
 
 
 
1
 
R
u
kh
in
 (
u
n
b
ia
se
d
) 
(2
0
1
3
) 
R
U
 
 
 
 
 
 
 
 
 
 
 
 
✅
 
1
 
R
u
kh
in
 (
ze
ro
 p
ri
o
r)
 (
2
0
1
3
) 
B
0
 
 
 
 
 
 
 
 
 
 
 
✔
 
✅
 
2
 
R
u
kh
in
 (
si
m
p
le
) 
(2
0
1
3
) 
B
P
 
 
 
 
 
 
 
 
 
 
 
✔
 
✅
 
2
 
R
u
kh
in
 (
al
te
rn
at
e)
 (
2
0
1
3
) 
SB
 
 
 
 
 
 
 
 
 
 
 
 
✅
 
1
 
B
ay
es
ia
n
 m
o
d
al
 (
2
0
1
3
) 
B
M
 
 
 
 
 
 
 
 
 
 
✅
 
 
 
1
 
M
al
za
h
n
, B
o
h
n
in
g 
an
d
 H
o
lli
n
g 
(S
M
D
 o
n
ly
) 
(2
0
0
0
) 
M
B
H
 
- 
- 
- 
- 
- 
- 
 
✅
 
✔
 
 
- 
- 
- 
2
 
 
T
a
b
le
5
.4
:
S
u
m
m
a
ry
o
f
h
e
te
ro
g
e
n
e
it
y
v
a
ri
a
n
ce
e
st
im
a
to
rs
co
m
p
a
re
d
in
th
e
1
2
in
c
lu
d
ed
si
m
u
la
ti
o
n
st
u
d
ie
s
K
ey
:

B
in
ar
y
ou
tc
om
e,

co
n
ti
n
u
ou
s
ou
tc
om
e
an
d

ge
n
er
ic
ou
tc
om
e
m
et
a-
an
al
ys
es
si
m
u
la
te
d.
S
ig
n
iﬁ
es
w
he
re
es
ti
m
at
or
s
ar
e
co
m
pa
re
d
an
d
al
so
pr
op
os
ed
in
th
e
sa
m
e
pu
bl
ic
at
io
n
.
*
F
or
re
fe
re
n
ce
s
an
d
de
ta
il
s
of
ea
ch
he
te
ro
ge
n
ei
ty
va
ri
an
ce
es
ti
m
at
or
,
se
e
ch
ap
te
r
2.
1
H
et
er
og
en
ei
ty
va
ri
an
ce
es
ti
m
at
es
ca
lc
u
la
te
d
u
si
n
g
bo
th
sm
oo
th
ed
an
d
u
su
al
w
it
h-
st
u
dy
va
ri
an
ce
es
ti
m
at
es
.
2
P
er
fo
rm
an
ce
of
es
ti
m
at
or
s
re
po
rt
ed
u
si
n
g
n
on
-t
ru
n
ca
te
d
es
ti
m
at
es
.
95
5.3.5.1 DerSimonian-Laird (DL)
Performance of the DL estimator is documented in all 12 publications, which gener-
ally suggest that DL is negatively biased when the level of heterogeneity is moderate
to high. The negative bias is more prominent when within-study variance estimates
are imprecise, such as in SMD meta-analyses with small study sample sizes [74] and
in binary outcome meta-analyses [79, 102], particularly when there are few events
occurring in each study [3]. This negative bias can be observed in ﬁgure 5.1 (top
right), where heterogeneity is high and meta-analyses have an OR outcome measure.
Minimal negative bias was observed in continuous outcome meta-analyses with mod-
erate study sample sizes [124] and binary outcome meta-analyses with large study
samples sizes [61]. When within-study variances are known, Kontopantelis et al.
[64] showed that DL becomes asymptotically unbiased as the number of studies in a
meta-analysis increase; Viechtbauer [124] previously noted this in theory. Novianti
et al. [78] showed that DL remains biased in binary outcome meta-analyses as the
number of studies increases. In terms of mean squared error (MSE), DL performs re-
latively poorly in scenarios where negative bias is also observed [102]. In continuous
and generic outcome meta-analyses, DL has a relatively low MSE and comparable
performance to REML [16, 124].
Kontopantelis et al. [64] proposed a bootstrap version of DL (DLB), with the aim
of reducing the proportion of zero heterogeneity variance estimates. DLB had the
least number of zero estimates out of all methods that allowed zero estimates. In
small meta-analyses (2-3 studies), DLB has the highest positive bias of all estimators
compared and comparable bias in meta-analyses with 5-10 studies [64].
Kontopantelis et al. [64] also proposed a positive version of DL (DLP), which trun-
cates heterogeneity variance estimates below 0.01. DLP was one of the least biased
estimators when the level of heterogeneity was low-to-moderate. However, this result
may be misleading because 0.01 is also the lowest heterogeneity variance parameter
value chosen in this study.
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5.3.5.2 Cochran's ANOVA (CA)
CA has a small positive bias under most simulated conditions and remains positively
biased even when the level of heterogeneity is high, unlike many other estimators
such as DL, PM and REML [78, 79]. This can be observed in ﬁgure 5.1. Chung
et al. [16] and Sidik and Jonkman [102] showed CA had the highest MSE out of all
estimators compared, because of its large bias. Chung et al. [16] also found that
CA had the highest percentage of zero estimates despite its positive bias in the
same simulated conditions. It was, however, the least biased estimator considered
by Panityakul et al. [79] when study sample sizes are small.
5.3.5.3 Paule-Mandel (PM), and its variants (PMCA and PMDL)
PM was compared in six simulation studies, with ﬁve reporting bias and ﬁve report-
ing some measure of variability (see table 5.3). Novianti et al. [78] showed that PM
performs well in terms of bias in SMD outcome meta-analyses, although it is com-
parable with many other estimators including CA, DL, PMDL, SJ, SJCA and REML.
PM was compared with self-proposed Bayesian estimators by Rukhin [93], in simu-
lated generic outcome meta-analyses (see section 5.3.5.9 for performance of Bayesian
estimators); results showed that PM has a lower MSE when the level of heterogeneity
is low, but has a larger MSE than all Rukhin's Bayesian estimators for moderate to
large levels of heterogeneity. In binary outcome meta-analyses [78, 79, 102], PM is
negatively biased for high levels of heterogeneity but to a lesser extent than DL and
REML, and approximately unbiased when study sample sizes are large (between 100
and 300 per group) [79]. Sidik and Jonkman [102] showed that PM is comparable
with SJCA and both perform well in terms of bias and MSE. PM performs well overall
but some of the most comprehensive simulation studies that included many estim-
ators did not include PM [64, 124]. In particular, there is relatively little evidence
for PM in continuous outcome meta-analyses.
PMCA and PMDL estimators are two-step versions of PM that use CA and DL as
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Figure 5.1: Mean bias from selected simulation results in Novianti et al. [78]
including simulated meta-analyses of type SMD and OR.
The following parameters remain constant throughout these results:
n1i, n2i ∼ U(20, 200), n1i = n2i, pi ∼ U(0.05, 0.65) and θ = 0.5
initial estimates respectively. Kontopantelis et al. [64] included both PMCA and
PMDL in their comparisons, Novianti et al. [78] and Bhaumik et al. [3] included
PMDL only. Results showed that PMCA and PMDL have a level of bias comparable
with PM (see ﬁgure 5.1). No publication reported the variability of PMCA or PMDL
estimates (although Novianti et al. [78] included the variance of estimates as raw
supplementary data).
5.3.5.4 Restricted maximum likelihood (REML) and its approximation
(ARML)
REML was included in seven simulation studies: six reported bias in heterogeneity
variance estimates and ﬁve reported some measure of variability (see Table 5.3 for
details). In meta-analyses with moderate study sample sizes, REML becomes neg-
atively biased as the level of heterogeneity increases, but to a lesser extent than DL
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Figure 5.2: Mean squared error from selected simulation results in Novianti
et al. [78] including simulated meta-analyses of type SMD and OR.
The following parameters remain constant throughout these results:
n1i, n2i ∼ U(20, 200), n1i = n2i, pi ∼ U(0.05, 0.65) and θ = 0.5
or ML [78, 79, 102] as shown in ﬁgure 5.1 (top right). For low levels of heterogen-
eity and when studies are homogeneous, REML and DL have similar levels of bias
[102]. For large study sample sizes (between 100 and 300 per group), Panityakul
et al. [79] showed REML to be approximately unbiased, performing better in terms
of bias than the other estimators compared, including CA, DL, PM, SJ and ML.
Viechtbauer [124] also showed that, when studies typically have a large sample size,
REML has a lower MSE than the other estimators compared including CA, DL, HS
and ML.
Knapp and Hartung [61] compared the approximate restricted maximum likelihood
(ARML) in terms of bias and variance in simulated OR meta-analyses. For all levels
of heterogeneity above zero, ARML had a greater negative bias than DL and PM.
ARML had the lowest variance of the three estimators compared, but this may be
as a consequence of its negative bias.
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5.3.5.5 Maximum likelihood (ML)
ML was included in six studies, of which ﬁve reported bias of heterogeneity variance
estimates and three reported some measure of variability (see Table 5.3 for details).
ML tends to underestimate the heterogeneity variance and is one of the least posit-
ively biased estimators when there is no underlying heterogeneity. ML has a negative
bias particularly when there are fewer than 10 studies in the meta-analysis [16] and
produces more zero estimates when there are fewer than ﬁve studies [16]. As a con-
sequence of the negative bias, ML performs well in terms of MSE when the level of
heterogeneity is low.
5.3.5.6 Hunter-Schmidt (HS)
HS was included in two studies [96, 124], of which only one reported bias and some
measure of variability (variance) [124]. Viechtbauer [124] stated that the performance
of HS is comparable with ML in terms of bias and MSE and grouped their results
together.
5.3.5.7 Sidik- Jonkman estimators (SJ and SJCA)
SJ is a two-step non-truncated heterogeneity variance estimator that only produces
positive estimates of heterogeneity and was included in six simulation studies. Five
publications reported bias and four reported some measure of variability. Results
from all simulation studies showed that SJ is positively biased for small to moderate
levels of heterogeneity and when study sample sizes are below 200 [78, 102]; this is
illustrated in all scenarios in ﬁgure 5.1. For meta-analyses containing studies with
larger sample sizes (between 100 and 300 per group), SJ has relatively a small amount
of positive bias [79]. SJ's positive bias has been demonstrated in OR [78, 102], SMD
[78] and generic [64] outcome meta-analyses and can be attributed to SJ being a non-
truncated estimator that only produces positive heterogeneity variance estimates.
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SJCA is derived from the same two-step approach as SJ but uses CA as an initial
heterogeneity variance estimate for the ﬁrst iterative step. Three studies compared
SJCA with SJ and found that SJCA has less positive bias when the level of hetero-
geneity is low [64, 78, 102]. SJ and SJCA have a comparable MSE in all the reported
results by Sidik and Jonkman [102].
5.3.5.8 Malzahn, Bohning and Holling (MBH)
MBH was included in two studies and can only be used in meta-analyses with a
SMD outcome measure. Malzahn et al. [74] compared MBH with DL and CA in
terms of bias and MSE. However, the results of this simulation were not given: the
paper states only that MBH has a smaller MSE than CA. Sanchez-Meca and Marín-
Martínez [96] only compared MBH in terms of performance measures relating to the
overall summary eﬀect and its conﬁdence intervals.
5.3.5.9 Bayesian estimators: Bayesian modal (BM) and Rukhin's estim-
ators (RU, B0, BP, SB)
Chung et al. [16] was the only study to include the Bayesian modal estimator (BM),
and did so in simulated generic outcome meta-analyses. BM is a non-truncated
estimator that only produces positive estimates. Therefore results showed that BM
is more positively biased than CA, DL, ML and REML for low levels of heterogeneity
and a larger MSE. For moderate to high levels of heterogeneity, BM has low bias
comparable with DL and REML and performs better in terms of MSE.
Rukhin proposed a series of Bayesian heterogeneity variance estimators that only
produce positive estimates, and compared them with CA, DL and PM in terms of
MSE. All Rukhin's estimators have comparable MSE when the level of heterogeneity
is moderate to high, which is lower than CA, DL and PM. When the level of het-
erogeneity is low, PM performs better than Rukhin's estimators in terms of MSE.
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Kontopantelis et al. [64] also compared the bias of B0 and BP with many other es-
timators and found that BP had the highest positive bias of all estimators compared.
B0 and BP remained positively biased in large meta-analyses containing 20 studies.
5.3.6 Performance of estimators of the summary eﬀect
Three studies included performance measures relating to point estimates of the sum-
mary eﬀect [93, 96, 101]. All of these calculated summary eﬀects by the standard
inverse variance method, where study weights are dependent on heterogeneity vari-
ance estimates calculated by a number of methods. Sidik and Jonkman [101] and
Rukhin [93] found that estimates of the summary eﬀect were unbiased, had small
MSE and had a high level of agreement across all heterogeneity estimation methods.
Sanchez-Meca and Marín-Martínez [96] showed θˆ has a negligible amount of bias for
all heterogeneity variance estimators compared.
5.3.7 Performance of conﬁdence intervals for the summary
eﬀect
Six studies reported performance measures relating to 95% conﬁdence intervals for
the summary eﬀect [16, 61, 64, 93, 96]. All of these used coverage as a performance
measure. Three of these studies calculated Wald-type conﬁdence intervals and re-
ported that these are sensitive to which heterogeneity variance estimators are used
and to the level of heterogeneity. For low levels of heterogeneity, coverages are above
the nominal level of 95% and fall to 85-90% for moderate to high levels of hetero-
geneity. Coverage probabilities for t-distribution conﬁdence intervals were reported
in two studies and are also sensitive to level of heterogeneity but to a lesser extent
than Wald-type conﬁdence intervals [96]. Coverage of t-distribution conﬁdence in-
tervals with Hartung-Knapp variance estimates was reported in three studies; results
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showed this conﬁdence interval method is not sensitive to which method of hetero-
geneity estimation is used and maintains coverages close to the nominal 95% for all
simulated scenarios [61, 93, 96].
5.3.8 Performance of heterogeneity variance estimators using
other methods to estimate the within-study variance
Two studies investigated whether using alternatives to the usual study variance es-
timation methods help improve estimation of heterogeneity [3, 61]. I deﬁne the usual
study variances as those calculated by methods described in chapter 1.
Knapp and Hartung [61] proposed a method for calculating within-study variances
that reduces the correlation with study eﬀects and found that using this method
reduces the negative bias of DL and REML estimators. Results showed that using
this method makes little diﬀerence to the coverage of conﬁdence intervals for the
summary eﬀect.
Bhaumik et al. [3] proposed an alternative Paule-Mandel estimator, which calculates
estimates of the heterogeneity variance using PM with other within-study variance
estimates. Precision of these variance estimates in improved by borrowing strength
from other studies in the meta-analysis. Results showed that PM heterogeneity vari-
ance estimates using this alternative method have less negative bias than DL, PMDL
and PM that use usual within-study variance estimates. The method can easily be
applied with any heterogeneity variance estimator, but only PM was considered in
this paper. The method can be applied only to odds ratio eﬀects.
5.3.9 A summary of recommendations
Table 5.5 summarises recommendations made in the 12 publications. Ten make clear
recommendations about which heterogeneity variance estimator(s) should be used in
103
practice. DL was included in all 12 simulation studies and was recommended twice:
by Sidik and Jonkman [102] and Malzahn et al. [74]. However, in these studies,
DL is compared only with SJ [74, 102] and CA [74], and in both publications is
recommended only when the level of heterogeneity is low.
Three independent studies made recommendations from a comparison of only pre-
existing estimators; two of these studies recommended PM [78, 79] over all other
estimators compared. The other independent study, Viechtbauer [124], recommen-
ded REML in continuous outcome meta-analyses but did not include PM in the
study. Novianti et al. [78] also stated that REML is a good alternative to PM in
simulated SMD meta-analyses, but is not recommended in OR meta-analyses due to
negative bias comparable with DL. Other estimators were recommended in the same
publication where the estimator was initially proposed, including SJCA [102], BM
[16], MBH [74], DLB [64], B0 and BP [93]. Sidik and Jonkman [101] recommended
their own SJ estimator, but a later (2007) recommendation of SJCA supersedes this.
SJ is included in three other simulation studies [64, 78, 79] and is not recommended
in any. There may have been a conﬂict of interest in these non-independent studies.
Furthermore, many of these compared a small subset of methods, in few simulated
scenarios with a limited range of heterogeneity levels (see table 5.2).
5.4 Discussion
Many papers have reported that the DerSimonian-Laird estimator of heterogeneity
is negatively biased for moderate to large levels of heterogeneity, and suggest that
better-performing heterogeneity variance estimators are available. In this review of
comparative simulation studies, I found that the Paule-Mandel estimator generally
performs well, is easy to compute and was speciﬁcally recommended in three pub-
lications from results based on both continuous and binary outcome meta-analyses
[3, 78, 79]. REML was also recommended on the basis of two simulation studies
of continuous outcome meta-analyses [78, 124]. However, computing REML estim-
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Reference 
Effect 
meas-
ure  1 
Heterogeneity var-
iance estimators 2 
Recommendations / conclusions 3 
Knapp and 
Hartung (2003) 
RR 
DL, ARML, PM* (with 
and without using a 
smoothed within-study 
variance estimates) 
No heterogeneity estimator recommended. Neither the 
smoothed or usual within-study variances are 
recommended. Smoothed are no better than 'usual' for 
calculating CIs of the summary effect. 
Panityakul et al 
(2013)  
RR 
CA, DL, PM, SJ, ML, 
REML 
PM recommended. Avoid CA and SJ because of positive 
bias. 
Bhaumik et al 
(2012)  
OR 
DL, PMDL, PM (PM 
with an without using 
alternative within-study 
variance estimates) 
PM with alternative within-study variance estimates 
recommended for meta-analyses with OR effect 
measure. 
Sidik and 
Jonkman (2005)  
OR 
DL, SJ SJ recommended. DL preferred over SJ for low levels of 
heterogeneity. SJ recommended for Wald-type 
confidence intervals of the summary effect 
Sidik and 
Jonkman (2007) 
OR 
CA, DL, SJ, SJCA, ML, 
REML, PM* 
SJ where 'high levels of heterogeneity, SJCA or PM when 
low or moderate. SJCA preferred over PM because SJCA 
is easier to compute. Avoid DL, ML and REML (to a 
lesser extent) due to negative bias. 
Novianti et al 
(2014) 
OR & 
SMD 
CA, DL, PMDL, PM, SJ, 
SJCA, REML 
PM and PMDL recommended in meta-analyses with OR 
and SMD outcome measures. REML recommended as a 
valid alternative only in SMD meta-analyses. 
Malzahn et al 
(2000)  
SMD 
CA, DL, MBH MBH recommended. DL recommended only for low 
levels of heterogeneity and sample sizes are 'large'. 
Sanchez-Meca 
and Marin-
Martinez (2008)  
SMD 
CA, DL, HM, HS, SJ, 
ML, REML, MBH. 
No heterogeneity estimator recommended. Simulation 
study focuses on confidence intervals for the summary 
effect 
Viechtbauer 
(2005)  
SMD 
& MD 
CA, DL, HS, ML, 
REML (no estimator 
was truncated) 
REML recommended. Avoid HS and ML due to 
negative bias and avoid FE meta-analysis. 
Chung et al 
(2013)  
G 
CA, DL, ML, REML, 
BM  
BM recommended. Avoid FE meta-analysis. 
Kontopantelis et 
al (2013)  
G 
CA, DL, DLP, DLB, 
PMCA, PMDL, SJ, SJCA, 
ML, REML, B0, BP 
DLB recommended (to decrease the number of zero 
heterogeneity estimates). Avoid FE meta-analysis. 
Sensitivity analysis advised, particularly when a meta-
analysis contains few studies. 
Rukhin (2013) G 
CA, DL, PM, RU, B0, 
BP, SB  
B0 or SB recommended for t-distribution CIs for the 
summary effect. BP recommended as a point estimate of 
the heterogeneity variance. 
Table 5.5: A summary of recommendations from the 12 included publications
1 RR=relative risk; OR=odds ratio; SMD=standardised mean diﬀerence;
MD=mean diﬀerence; G=generic. 2 Full names of estimators are given in table
5.4. 3 CI=conﬁdence interval. *Publication refers to the empirical Bayes estimator,
but this is equivalent to the Paule and Mandel estimator (PM) [93].
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ates involves a process of iteration that does not converge in a small proportion of
meta-analyses [64]. Other recommended estimators included SJCA, DLb, MBH, BM,
B0, SB and BP, but recommendations came from the same publication where the
method was originally proposed and therefore may be unduly inﬂuenced by conﬂict-
ing interests; these estimators have been compared in few other simulation studies.
Studies show summary eﬀect estimates are unbiased with low MSE, irrespective of
which heterogeneity variance estimate is used. Wald-type conﬁdence intervals of the
summary eﬀect are currently reported as standard in meta-analyses in Cochrane re-
views, yet studies indicate that coverage depends highly on the heterogeneity variance
estimate, and coverage can be as low as 85-90%. Sanchez-Meca and Marín-Martínez
[96] recommended t-distribution conﬁdence intervals with Hartung-Knapp variance
estimates; this method has coverage closer to the nominal 95% and is not sensitive
to the heterogeneity variance estimate used. A simulation study not included in this
review (because only conﬁdence interval methods were compared) has also called for
wide-spread use of the Hartung-Knapp method [55].
There is still no overall consensus on which heterogeneity variance estimator to use
in meta-analysis, in part because recommendations are based on subjective inter-
pretation of the results and a trade-oﬀ between many performance measures. For
example, ML and HS generally have low MSE, but only as a consequence of their
negative bias. Viechtbauer [124] recommended REML as a compromise between
bias and MSE and Novianti et al. [78] recommended PM based on bias alone. I sum-
marised author's recommendations in section 5.3.9 in an attempt to make practical
and collaborative conclusions, but my ﬁndings suggest that further research is still
required.
This review has identiﬁed a number of limitations of the design of the simulation
studies. All studies compared only a subset of all heterogeneity variance estimators
available. This limits the conclusions of this review because, for example, PM and
BM are not directly compared in any study and both have been recommended by
diﬀerent authors. Results described in section 5.3.8 suggest that using alternative
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estimates of within-study variances improves estimation. However, evidence is based
on meta-analyses with study eﬀects generated from equal event probabilities, which
represents optimal conditions for performance of these methods. Finally, most sim-
ulation studies generated study sample sizes from only one distribution. Those that
simulated from a range of distributions [79, 93, 124] suggest the range of sample
sizes in a meta-analysis aﬀects the performance of these methods. More research is
needed to investigate this eﬀect.
Although the main limitations of this review stem from limitations in the evidence
base, methods for this review could be improved in a number of ways. Relevant
articles could have been missed from the online search by only including articles
containing the word 'meta-analysis'. For example, simulation studies could have
been carried out in the context of 'multiple laboratory experiments', given this is
the context in which some of the estimators in chapter 2 are derived (CA and PM).
Relevant articles may have been missed by restricted the search to English language
only. Furthermore, the process of selecting of articles for inclusion could have been
double checked by an independent reviewer to minimise the chance of human error.
In general, I found that simulations did not reﬂect the observed characteristics of
meta-analyses in practice. 86% of meta-analyses from Cochrane reviews contain
fewer than 10 studies [21], yet half of the reviewed simulation studies contained only
meta-analyses with at least 10 studies [16, 61, 93, 96, 124]. Also, heterogeneity vari-
ance parameter values did not reﬂect the full range of levels of heterogeneity. For
instance, seven studies contained only meta-analyses with non-zero underlying I2
values greater than 40% [16, 61, 64, 74, 78, 101, 102]. Findings from this review
suggest that properties of methods depend more strongly on I2 than the heterogen-
eity variance parameter. I2 depends on both the heterogeneity variance and the
within-study variances.
Given that Cochrane meta-analyses typically contain few studies [21], heterogen-
eity variance estimates are imprecise regardless of the estimation method. As such,
Kontopantelis et al. [64] suggested that a sensitivity analysis is required to test how
107
robust meta-analysis ﬁndings are to changes in this estimate. Other included simu-
lation studies focused only on comparing the relative performance of estimators. In
meta-analyses with few studies, there is little power to detect heterogeneity [16, 64]
so truncated heterogeneity variance estimators produce a high number of zero estim-
ates. Therefore, Chung et al. [16] recommended the non-truncated estimator, BM,
and Kontopantelis et al. [64] recommended DLB, which produces a lower number of
zero estimates in comparison with DL. Meta-analyses containing a truly homogen-
eous group of studies and therefore zero heterogeneity is thought to be untenable in
practice [48].
5.5 Conclusion
This review suggests there are better-performing heterogeneity variance estimators
than the commonly used DerSimonian and Laird method. On the basis of the current
evidence, the Paule-Mandel estimator may be the best alternative to calculate point
estimates of heterogeneity and for calculating conﬁdence intervals for the summary
eﬀect. Many recently proposed estimators including BM, DLb, B0, SB and BP show
promise, however, more research is required to compare them with a wider range of
heterogeneity variance estimators before they can be recommended.
There are four main reasons why my recommendations based on this review are not
conclusive: (1) many recommendations have been based on simulation studies pro-
posing a new estimator, and so may have conﬂicts of interest, (2) they are based
only on comparisons of a small subset of all heterogeneity estimation methods avail-
able, (3) they are based on simulated meta-analyses that do not reﬂect those found
in typical systematic reviews and (4) they do not address suﬃciently the practical
situation that in many meta-analyses all heterogeneity variance estimates are very
imprecise. Further independent simulation studies are needed to address these lim-
itations. In the following chapters, I detail the design and present results of such
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as simulation study. The study is designed in light of the identiﬁed limitations of
existing simulation studies from this review.
109
110
Chapter 6
Methods for a new simulation study
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6.1 Introduction
In the last chapter, I conducted a systematic review of previous studies that com-
pared heterogeneity variance estimators in simulated meta-analysis data. Studies
were in agreement that the DerSimonian-Laird estimator [25] of the heterogeneity
variance is negatively biased in certain scenarios. Most studies advocated an altern-
ative estimator, most commonly the Paule-Mandel estimator [80]. However, studies
gave many other conﬂicting recommendations and therefore my systematic review
was inconclusive overall. I suggested many reasons why studies came to conﬂicting
conclusions, two of these reasons are: (1) most studies compared a small number of
existing methods with those newly proposed and (2) recommendations were based on
subjective trade-oﬀ between many performance measures. To address these issues,
I propose to conduct a new simulation study that is collaborative and compares a
comprehensive list of pre-existing heterogeneity variance estimators.
A study protocol was produced prior to simulating any meta-analysis data. This pro-
tocol was sent to a number of collaborators, who commented edited and approved
the ﬁnal protocol. These collaborators are: Mark Simmonds1, Julian Higgins2, Dan
Jackson3, Jack Bowden3, Areti Angeliki Veroniki4, Evangelos Kontopantelis5 and
Wolfgang Viechtbauer6. The protocol includes simulation methods for both binary
and continuous outcome meta-analyses, the heterogeneity variance estimators com-
pared and performance measures used to compare them. A summary of the design
1Centre for Reviews and Dissemination, University of York, York, YO10 5DD, UK
2School of Social and Community Medicine, University of Bristol, Bristol, UK
3School of Social and Community Medicine, University of Bristol, Bristol, UK
4Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, East Building.
Toronto, Ontario, M5B 1T8, Canada
5Centre for Health Informatics, Institute of Population Health, University of Manchester,
Manchester, UK
6Department of Psychiatry and Psychology, Maastricht University, The Netherlands
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of this new simulation study is presented here in this chapter, the original agreed
document is in appendix D.3.
6.2 Aims
The aims of is simulation study are a subset of the main aims of this thesis (declared
on page 19), namely:
1. Compare the relative performance of heterogeneity variance estimators in sim-
ulated data to establish which method(s) have the best properties.
2. Investigate the absolute performance of estimators in simulated data to estab-
lish if and when all methods perform poorly.
3. Investigate whether any characteristics of meta-analyses can explain the prop-
erties of estimators.
4. Recommend methods for random-eﬀects meta-analysis and propose alternative
strategies when all estimators perform poorly.
6.3 Heterogeneity variance estimators
Methods for estimating the heterogeneity variance in a random-eﬀects model have
been identiﬁed in chapter 2. For each simulated meta-analysis, heterogeneity variance
estimates are calculated from the following 14 methods:
1. Cochran's ANOVA (CA) [18]
2. DerSimonian-Laird (DL) [25]
3. Paule-Mandel (PM) [80]
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4. Two-step DerSimonian-Laird (PMDL) [24]
5. Two-step Cochran's ANOVA (PMCA) [24]
6. Hartung-Makambi (HM) [40]
7. Hunter-Schmidt (HS) [53]
8. Sidik-Jonkman (SJ) [101]
9. Sidik-Jonkman with Cochran's ANOVA initial estimate (SJCA) [102]
10. Maximum likelihood (ML) [37]
11. Restricted maximum likelihood (REML) [124]
12. Rukhin's estimator with zero prior (B0) [93]
13. Rukhin's simple estimator (BP) [93]
14. Malzahn, Böhning and Holling (MBH) [74]
Some of the estimators available (as detailed in chapter 2) are excluded from this
study. Rukhin's optimal unbiased estimator (RU) [93], Rukhin's estimator with al-
ternative prior (SB) [93] and positive-DerSimonian-Laird (DLp) [64] have been shown
to be inferior to other estimators in the systematic review of simulation studies in the
previous chapter. Bayesian methods that rely on a subjective choice of prior distribu-
tion are excluded because of diﬃculty in objectively comparing them to frequentist
methods. Methods that use alternative methods to estimate the within-study vari-
ances are excluded; these methods are beyond the scope of the thesis. Bootstrapping
could be theoretically applied to any heterogeneity variance estimator so any vari-
ation of this approach is excluded.
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6.4 Performance measures
Heterogeneity variance estimators are compared in terms of the following three
primary performance measures:
1. Mean and median bias of the heterogeneity variance estimate
2. Mean and median squared error of the heterogeneity variance estimate
3. Proportion of zero estimates of the heterogeneity variance estimate
Furthermore, heterogeneity variance estimators are compared in terms of the fol-
lowing secondary performance measures relating to estimation of the mean of the
random-eﬀects distribution and its conﬁdence interval. These are required to per-
form a comprehensive comparison of heterogeneity variance estimators, evaluating
them not only as a point estimate of heterogeneity, but also on other meta-analysis
statistics.
1. Mean absolute bias in estimate of the summary eﬀect *
2. Mean squared error of estimate of the summary eﬀect *
3. Coverage of 95% conﬁdence intervals for the summary eﬀect for the three con-
ﬁdence interval methods (i.e. the proportion of times the underlying summary
eﬀect falls inside the 95% conﬁdence interval) *
4. Power to detect a signiﬁcant summary eﬀect using the three conﬁdence interval
methods **
5. Mean of the error-interval estimation of eﬀect using the three conﬁdence inter-
val methods **
6. Variance of the error-interval estimation of eﬀect using the three conﬁdence
interval methods **
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* The mean eﬀect is calculated by the weighted inverse variance method (on page
1.6 in the introduction).
** Conﬁdence intervals are estimated using the three methods detailed in chapter
3. Namely, Wald-type [25], t-distribution [28] and Hartun-Knapp [38] conﬁdence
intervals. These methods are only a subset of all the conﬁdence interval methods
available, but since they relate only to the secondary performance measures, these
three methods are suﬃcient for this simulation study. All these methods are in-
dependent of the choice of heterogeneity variance estimator so any combination of
methods can be applied. All combinations are considered in this simulation study.
Bias and error are summarised using both the mean and median in performance
measures 1 and 2, all previous simulation studies only used the mean. The median
may be more appropriate because errors of heterogeneity variance estimates do not
conform to the normal distribution. Sidik and Jonkman [102] noted that mean
negative bias causes an artiﬁcially low mean squared error so we investigate whether
the median has this same issue. Error-interval estimation (performance measures
8 and 9) is a ratio between the width of the estimated conﬁdence interval and the
true conﬁdence interval, as deﬁned by a previous simulation study [64]. The range of
performance measures is comprehensive and includes measures of bias and variability
of estimates of τ 2, the summary eﬀect and conﬁdence intervals of the summary eﬀect.
Measures of performance relating to conﬁdence intervals for τ 2 are excluded as it is
beyond the scope of the thesis. Details of how to calculate each included performance
measure are in appendix C.2.
6.5 Simulation methods
We simulate meta-analysis data by the following main steps:
 A meta-analysis dataset is generated for speciﬁed parameter values using the
methods outlined in this section.
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 Heterogeneity variance estimates are calculated for the given meta-analysis
using methods listed in section 6.3.
 Steps 1 and 2 are repeated 5,000 times and performance measures are calculated
(see section 6.4)
 Steps 1-3 are repeated for all combinations of parameter values. The parameter
values are given in table 6.1 on page 121.
All steps are carried out in R [85]. Bespoke code is used to calculate estimates of the
heterogeneity variance and given in appendix D.2. Estimates from this code were
compared with estimates produced by the metafor package in R for all methods
included in this package (CA, DL, HS, SJ, ML and REML). For all other methods,
checks were made against estimates from example meta-analyses in published meth-
odology papers [3, 24, 73, 96, 101, 102]. Bespoke code was also written for Wald-type
and Hartung-Knapp conﬁdence interval methods for the summary eﬀect and checked
against the metafor package (see appendix D.3). Heterogeneity variance estimators
are compared using the same simulated datasets to eliminate some of the sampling
error.
ML and REML are iterative and fail to converge to a solution in a small number
of cases [64], but this is primarily due the chosen iteration algorithm rather than
the estimator [126]. In this study the default iteration algorithm in metafor is used,
namely, Fishers scoring method with Cochran's ANOVA the initial estimate [126].
Simulated meta-analyses that cause such failures are not replaced and instances
recorded and presented in the results. Heterogeneity variance estimates for each
meta-analysis and performance measures for each combination of parameter values
are stored for the analysis.
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6.5.1 Simulating true study eﬀects
For studies i = 1, ..., k in each meta-analysis, ﬁrst simulate true study eﬀects (θi)
such as a log odds ratio or standardised mean diﬀerence from some distribution D:
θi ∼ D
(
θ, τ 2
)
where θ is the true summary eﬀect parameter and τ 2 the heterogeneity variance
parameter of D.
The standard random-eﬀects model (on page 12 in chapter 1) assumes a normal
distribution for D, but θi are also simulated from skew-normal distributions with
moderate and high skew to test if the methods are robust when this assumption is
violated. Distributions for D and parameter values for θ and τ 2 are listed in sec-
tion 6.6. For each study i, study eﬀect estimates θˆi are then generated to simulate
within-study sampling error. The process for doing so depends on the type of out-
come of studies in each meta-analysis. In this study, two types of meta-analyses are
simulated: (1) continuous outcome meta-analyses with a standardised mean diﬀer-
ence eﬀect measure; and (2) dichotomous outcome meta-analyses with an odds ratio
eﬀect measure, as detailed in sections 6.5.2 to 6.5.3.
6.5.2 Standardised mean diﬀerence (SMD) meta-analyses
To simulate observed standardised mean diﬀerence study eﬀects, we use the following
steps for each study i:
 Generate sample sizes for each group, denoted by n1i and n2i from one of a
number of distributions as detailed in section 6.6.
 Generate n1i observations from N (0, σ21) and n2i observations from N (θi, σ
2
2),
to represent participant-level data. Without loss of generality, variances are
assumed equal by setting σ21 = σ
2
2 = 1.
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 Calculate the sample means (Z1i and Z2i) and standard deviations (sˆd1i and
sˆd2i) of these observations.
 Calculate the standardised mean diﬀerence θˆi and variance σˆ2i using Hedge's g
method (described on page 4 in chapter 1).
I chose to simulate meta-analyses with this outcome measure because study eﬀects
are standardised and can be compared between meta-analyses.
6.5.3 Odds ratio meta-analyses
To simulate odds ratio study eﬀects for each study i, I used the following steps:
 Generate the true average probability of an event across the two study groups,
denoted by pi. p1i and p2i are found from solutions to the simultaneous equa-
tions:
pi =
p2i + p1i
2
θi = log
(
p2i (1− p1i)
p1i (1− p2i)
)
pi are generated from one of a number of distributions as detailed in
section 6.6, which represent where events are common and rare.
 Generate sample sizes for each intervention group, denoted by n1i and n2i, from
one of a number of distributions in section 6.6.
 The numbers of events in the study groups are generated from the binomial
distributions B (n1i, p1i) and B (n2i, p2i). Cell counts in a 2x2 contingency table
can then be derived.
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 Add 0.5 to all cell counts if there is any zero in the table. If there are zero
events in both arms then exclude this study from the synthesis. When fewer
than 2 studies remain after exclusions, the meta-analysis is withdrawn from
the simulations without replacement. This is the current standard method
for dealing with zero cell counts, but we recognise there may be other, better
performing methods [10, 30].
 Calculate the sample log odds ratio, θˆi and its variance σˆ2i using formulae on
page 6 in chapter 1.
Meta-analyses with this outcome measure wer simulated for two reasons: (1) The
systematic review of previous simulation studies (chapter 5) suggested heterogeneity
variance estimators perform worse in this setting compared with standardised mean
diﬀerence meta-analyses and (2) the odds ratio is one of the more common outcome
measures in binary outcome meta-analyses [120].
6.6 Parameter values
Performance of the heterogeneity variance estimators are assessed for all combina-
tions of parameter values and distributions given in table 6.1, for standardised mean
diﬀerence and for odds ratio meta-analyses. There are a total of 960 standardised
mean diﬀerence meta-analyses and 15,360 simulated scenarios for odds ratio meta-
analyses. Parameter values were chosen to represent the range of values observed in
published meta-analyses. Further details and a justiﬁcation for these values are in
sections 6.6.1 to 6.6.6 that follow.
6.6.1 Number of studies
Figure 4.1 on page 57 shows the number of studies typically included in CDSR
meta-analyses and is used to inform parameter values for k. The number of studies
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Parameter Value/distribution
k Number of
studies in
the meta-
analysis
2, 3, 5, 10, 20, 30, 50, 100
I2 Mean I2 for
each
scenario
0%, 15%, 30%, 45%, 60%, 75%, 90%, 95%
θ Summary
eﬀect
0.5 for SMD meta-analyses; 0, 0.5, 1.1 and
2.3 for log odds ratio meta-analyses
(corresponding to ORs of 1, 1.65, 3 and 10)
θi Distribution
of true
study eﬀects
(a) θi ∼ N (θ, τ 2)(standard random-eﬀects
model)
(b) Normal distribution with moderate
skew: θi ∼ SN (θ, τ 2, γ = 0.7)
(c) Normal distribution with high skew:
θi ∼ SN (θ, τ 2, γ = 0.95)
τ 2 takes parameter values that satisfy the
I2 values above
n1i,
n2i
Study
sample sizes
(a) Small studies: n1i = 20
(b) Small to medium sized studies:
n1i ∼ U (20, 200)
(c) Medium sized studies: n1i = 200
(d) Small and large studies:
n11, ..., n1m = 20 and
n1m, ..., n1k ∼ U (1000, 2000) where m is the
integer half way between 1 and k (when k is
odd, one study is be generated from one of
the two distributions at random)
(e) Large studies: n1i ∼ U (1000, 2000)
In all scenarios, sample sizes are equal
between groups (n1i = n2i)
Parameters only applying to odds ratio meta-analyses
pi Average
probability
of event
across study
groups
(a) pi = 0.5
(b) pi ∼ U (0.1, 0.5)
(c) pi = 0.05
(d) pi = 0.01
Table 6.1: Set of parameter values and distributions to simulate meta-analyses
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per meta-analysis in this simulation study range between 2 and 100. Meta-analyses
with two studies are excluded from the analysis of CDSR in chapter 57, but these
are included in the simulations. For completeness, meta-analyses with up to 100
studies are included, although Cochrane meta-analyses typically containing much
fewer studies [21].
6.6.2 Heterogeneity variance parameter values
6.6.2.1 Method to derive heterogeneity variance parameter values
To ensure that heterogeneity variance (τ 2) parameter values represent the full range
of inconsistency, τ 2 are deﬁned so that they correspond to true I2 between 0% and
95% (see table 6.1 for the full range of I2). It is necessary for τ 2 values to vary
between scenarios so that I2 remain roughly constant. Also, there is diﬃculty in
deﬁning τ 2 using this method because I2 are likely to vary to some extent due to
sampling error in a given scenario. Therefore, we deﬁne τ 2 such that it produces
meta-analyses with the desired true I2 on average over 5,000 repetitions. We use
trial and error to ﬁnd the τ 2 that satisfy this deﬁnition.
The following formula is used to calculate the underlying I2 of each repetition (similar
to that introduced in chapter 1):
I2 =
τ 2
τ 2 + σ2
· 100%
where σ2 is the 'true' typical study variance:
σ2 =
(k − 1)∑ki=1 1/σ2i(∑k
i=1 1/σ
2
i
)2
−∑ki=1 (1/σ2i )2
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Preliminary analysis found that I2 is insensitive to changes in k and the distribution
of study eﬀects, so τ 2 values are consistent between these scenarios. τ 2 values diﬀer
between all other parameters.
Threshold values are deﬁned for I2 to help interpret the results: 15% and 30%
represent low inconsistency; 45% and 60% represent moderate inconsistency; and
75%, 90% and 95% represent considerable inconsistency. These threshold values
roughly correspond to the guidelines in the Cochrane handbook [51], but modiﬁed
merely so they correspond to simulated I2 values. Recall that I2 is a measure of
heterogeneity relative to typical within study variances and so loosely represents the
degree of overlap between study eﬀect conﬁdence intervals.
6.6.2.2 A summary of heterogeneity variance parameter values
Having applied this method, the derived τ 2 parameter values are given in table D.1
in the appendix. As expected, heterogeneity parameters are smallest in scenarios
where within-study variances are also small. That is, in the scenarios containing
standardised mean diﬀerence meta-analyses with large studies, where a heterogeneity
parameter of 0.0256 produces meta-analyses with a mean I2 of 95%. Conversely,
heterogeneity parameters are largest in the scenarios with odds ratio meta-analyses
containing small studies, in which a heterogeneity parameter of 15.6 produces a mean
I2 of 95%.
Underlying I2 vary in any given scenario because they depend on the sampled true
study eﬀects and within-study variances. In meta-analyses with small and large
study sizes, there are large diﬀerences in underlying I2 within the same scenario; the
5th and 95th percentiles of I2 have absolute diﬀerences of up to 50%. The diﬀerences
are smaller in all other distributions of study sizes, in which 5th and 95th percentiles
of I2 have diﬀerences of up to 20%. Variation in I2 within a given scenario is not
considered a major issue for this analysis, since this method is used only to deﬁne
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heterogeneity parameter values. The ranges of I2 values in each scenario is shown in
table D.2 in the appendix.
6.6.3 Summary eﬀect
To reduce the number of scenarios, standardised mean diﬀerence meta-analyses are
only simulated where θ = 0.5. Three previous simulation studies simulated meta-
analyses with multiple true SMD eﬀects and all suggested that the value of θ has
little bearing on any performance measure [78, 96, 124]. Odds ratio meta-analyses
are simulated with a range of summary eﬀects; 0, 0.5, 1.1 and 2.3 (corresponding
to odds ratios of 1, 1.65, 3 and 10). Results may be aﬀected by the underlying
odds ratio, particularly when the odds ratio is extremely large or small, as shown
previously in the simulation study by Bhaumik et al. [3]. An extreme underlying
odds ratio causes imbalance in the event probabilities between groups, which can
lead to one or both groups having rare events and this could aﬀect results.
6.6.4 Distribution of true study eﬀects
True study eﬀects (θi) are generated from three distributions. In all scenarios, θi are
sampled from distributions with mean θ and variance τ 2. First, θi are generated from
the normal distribution which is assumed in the standard random-eﬀects model and
represents optimal conditions where estimators may perform best (scenario a). Some
heterogeneity estimation methods such as Paule-Mandel do not assume normality of
true eﬀects and therefore it is hypothesised such estimators are more robust under
non-normal conditions [24]. Second, θi are sampled from two skew-normal distribu-
tions (scenarios b and c) with 0.7 and 0.95 skew parameter values; this represents
moderate and high negative skew as illustrated in ﬁgure 6.1. Kontopantelis et al. [64]
previously looked at performance of heterogeneity variance estimators under skew-
normal conditions, and deﬁned this similar level of skew as `moderate' and 'high'.
This distribution is deﬁned elsewhere [68].
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Figure 6.1: Probability density function of skew-normal distribution
Note that the variance diﬀers depending on the simulation scenario, but this is only
the scaling parameter.
6.6.5 Study sample sizes
Study sample sizes are generated in ﬁve ways to represent small-to-medium study
sizes (scenario a), small equally-sized studies (scenario b), medium equally-sized
studies (scenario c), small and large studies (scenario d) and large studies only
(scenario e). These scenarios are chosen to represent meta-analyses with a range of
study sizes and also a range of diﬀerences between study size. The systematic review
of simulation studies in chapter 5 suggests that performance of heterogeneity variance
estimators may be dependent on study sample sizes, but evidence is currently limited
[55].
6.6.6 Average probability of event across study groups
Binary outcome meta-analyses are generated from a range of underlying event rates.
In scenario a, the underlying average event rate is 0.5 to represent the ideal scenario
with event rates sampled as far from the asymmetric tails of the binomial distribution
as possible. Scenario b represents a situation where event rates are variable between
studies but not so rare as to be considered a big contributing factor to poor estimates
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of summary eﬀects and standard errors. Scenarios c and d represent situations where
the average underlying event rate is homogeneous and rare. It is not necessary to
simulate meta-analyses where the event of interest is extremely common (e.g. 0.95) as
the resulting odds ratios are the inverse of those obtained with extremely uncommon
event rates.
6.7 An overview of the simulation study
The systematic review of previous simulation studies in the last chapter found con-
ﬂicting recommendations. Four reasons for this were suggested, which we address
in this new study. (1) There was conﬂict of interest in most studies because they
compared existing methods with those newly proposed. To address this, we only
compare pre-existing methods in our study. (2) Most studies only compared a small
subset of the methods available, so we include a comprehensive list. (3) Simulations
were often not representative of real meta-analyses, so we deﬁne parameter values
for simulations based on meta-analyses seen in practice. (4) Studies don not address
that all methods are very imprecise in typical meta-analyses. They failed to address
this issue because their results were focused on the relative performance of methods.
We consider both relative and absolute performance in this simulation study.
Meta-analyses are simulated with odds ratio and standardised mean diﬀerence study
eﬀects to capture properties of heterogeneity variance estimators for a represent-
ative range of outcome measures. Novianti et al. [78] was the only study identi-
ﬁed in my systematic review that simulated both binary and continuous outcomes.
participant-level data is simulated to ensure simulated data is representative of real
meta-analyses. Generating participant-level data will also ensure the issues with het-
erogeneity estimation speciﬁc to certain types of outcome measures is captured. One
issue is that estimated odds ratio and standardised mean diﬀerence study eﬀects are
correlated with their variances [3, 8]. This is a particularly large issue in all binary
outcome meta-analyses with rare events [3].
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Our methods for simulating meta-analysis data diﬀer from most other previous sim-
ulation studies in two key ways. First, we deﬁne underlying τ 2 parameter values
that correspond to a consistent range of underlying I2 values. We deﬁne a range
of I2 between 0% and 95% to ensure the corresponding range of τ 2 represents zero,
low, moderate and high inconsistency in study eﬀects for all scenarios. Only Konto-
pantelis et al. [64] has previously taken a similar approach. No guidelines exist for
interpreting τ 2 estimates because the measure cannot be compared between meta-
analyses, but the Cochrane Collaboration have issued rough guidelines on interpret-
ing I2 values [51]. Second, all previous studies deﬁned the event probability of the
control group for simulating binary outcome meta-analyses. Conversely, we deﬁne
the average event probability between both study groups. In doing so, the rarity of
the event is more independent of the study eﬀect sizes.
Results are presented from these simulated meta-analyses in the following two chapters.
In the next chapter, we explore comprehensively the performance of all included het-
erogeneity variance estimators. Scenarios are identiﬁed where all estimators perform
poorly, when they perform well and in such cases which estimators perform better
than others. I then investigate how the ﬁndings from this analysis apply to real
meta-analyses in chapter 8 by combining with empirical data. Methods for analysis
of this simulated meta-analyses data are detailed in the two chapters that follow.
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Chapter 7
Main simulation study results
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7.1 Introduction
The last chapter detailed the design of a new simulation study to compare hetero-
geneity variance estimators in random-eﬀects meta-analysis. Details included the
methods for simulating meta-analysis data, which heterogeneity variance estimators
are compared and the performance measures used for comparisons. The study is
designed based on ﬁndings from a systematic review of previous simulation studies
in chapter 5 and input from other collaborators. In this chapter, the results of this
study are presented.
A number of heterogeneity variance estimators are excluded from the main results
because they are clearly inferior to other estimators; section 7.2 explains the reasons
for these exclusions. Also, given the scale of this study, it was only possible to
present a subset of all simulated scenarios and performance measures. Reasons for
choosing this subset are given in sections 7.3 and 7.4. These exclusions of estimators
and results were based on a preliminary exploration of all study results, which are
presented more fully in volume II of this thesis.
The main results are given in section 7.5 and split into three parts. First, results that
compare estimators in terms of performance measures relating to point estimates of
the heterogeneity parameter are presented in section 7.5.1. Mean bias and mean
squared error performance measures in this section are plotted on the proportional
scale to the heterogeneity variance parameter whenever τ 2 > 0. In other words,
mean bias is plotted as a proportion of the true parameter value rather than abso-
lute diﬀerence from the truth. Similarly, for a proportional mean squared error of
(for example) 100%, the average squared error is equal to τ 2. This is so that results
can be compared more easily between scenarios of diﬀerent τ 2 and to help inter-
pretation. Raw mean bias and mean squared error is presented whenever τ 2 = 0.
After results from the primary performance measures, those relating to estimation
of the summary eﬀect are presented in section 7.5.3 and ﬁnally, those relating to the
conﬁdence interval for the summary eﬀect are in section 7.5.4. Within each section,
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selected results are presented to give a representative picture of all simulated scen-
arios and a summary explains how they can be generalised to all scenarios. Results
are interpreted from two viewpoints; (1) as a relative comparison of the performance
of heterogeneity variance estimators reveal those that perform best and (2) as a gen-
eral comparison of performance between scenarios to summarise where all estimators
perform well/poorly.
7.2 Heterogeneity variance estimators excluded from
the main analysis
We excluded Rukhin's estimator with zero prior (B0), Rukhin's simple estimator
(BP) [93] and that proposed by Malzahn, Böhning and Holling (MBH) [74] in a
preliminary analysis. These estimators are not compared in the main results because
they clearly have inferior properties and would distract the reader away from those
with more reasonable properties.
To justify these exclusions, ﬁgure 7.1 presents two selected graphs from the simu-
lation results including all heterogeneity variance estimators. The y-axes present
proportional mean bias (left) and proportional mean squared error (right). These
results are from scenarios of standardised mean diﬀerence meta-analyses with small-
to-medium study sizes and heterogeneity variance of 0.0299 (which represents a mean
I2 of 60%). The ﬁgure shows B0 has considerable negative bias and BP has consid-
erable positive bias when there are more than 5 studies. MBH has a higher mean
squared error than all other estimators included in the main results, particularly
when the number of studies is low.
The 12 remaining heterogeneity variance estimators are compared extensively in the
main results in section 7.5 using graphs similar to those in ﬁgure 7.1.
131
Figure 7.1: Proportional mean bias (left-hand-side) and proportional mean
squared error (right-hand-side) in selected scenarios with B0, BP and MBH
heterogeneity variance estimators included.
Scenarios containing standardised mean diﬀerence meta-analyses (θ = 0.5) with
small-to-medium study sizes and a mean I2 of 60%.
7.3 Simulated scenarios not presented in full
Standardised mean diﬀerence and odds ratio meta-analyses data were generated for
all combinations of parameter values as detailed in the last chapter. Results were
produced from a total of 16,320 meta-analysis scenarios, of which only a represent-
ative subset could be presented in full in this chapter. The scenarios chosen are
diﬀerent for each performance measure; reasons for selection are detailed in each
section of the results. Only scenarios with normally distributed study eﬀects are
presented in this chapter because results from skew-normal distributions were not
meaningfully diﬀerent indicating that heterogeneity variance estimators and conﬁd-
ence interval methods are robust to skew-normal eﬀects. Scenarios with an eﬀect
size of 0.5 (standardised mean diﬀerence/log-odds ratio) are presented in most of
this chapter given that results for the most part were representative of other eﬀect
sizes. In section 7.5.2, results from other eﬀect sizes are presented to show where
diﬀerences were observed.
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7.4 Selected performance measures
Only a subset of the performance measures originally considered (as listed in the last
chapter) are included in the main results. Preliminary analysis showed some failed
to capture anything of interest and some showed comparable results. Therefore, ﬁve
performance measures of those originally speciﬁed are included in this chapter. The
mean bias, mean squared error and proportion of zero estimates are included that
all relate directly to point estimates of the heterogeneity variance. Also included are
bias of the summary eﬀect estimate and coverage of 95% conﬁdence intervals of the
summary eﬀect. Conﬁdence intervals are calculated by Wald-type [25], t-distribution
[28] and Hartung-Kanpp [38] methods.
Performance measures not reported are listed in table F.1 of the appendix along with
the reasons for exclusion. Selected results to show why these performance measures
are excluded are given in ﬁgures F.1 to F.6 in the same appendix.
7.5 Results
7.5.1 Properties of heterogeneity variance parameter estim-
ates
In this section of the results, heterogeneity variance estimators are compared in
terms of performance measures that relate directly to estimation of the heterogeneity
parameter (τ 2). These performance measures are mean bias, mean squared error and
the proportion of zero heterogeneity variance estimates.
A subset of results are presented from standardised mean diﬀerence and odds ratio
meta-analyses containing small studies, small-to-medium sized studies and small and
large studies. This subset of results were chosen as they represent both a range of
study sizes and also a range of diﬀerences in study size. For odds ratio meta-analyses,
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we present those containing studies with event probability simulated from a uniform
distribution between 0.1 to 0.5. These scenarios represent meta-analyses where rare
events impact the results but not so considerably that all estimators perform poorly.
Scenarios of meta-analyses with mean I2 values of 0%, 30%, 60% and 90%, which
represent the full range of inconsistency between studies.
Figures 7.2 - 7.7 (pages 136 - 141) show the mean bias, mean squared error and pro-
portion of zero heterogeneity variance estimates in standardised mean diﬀerence and
odds ratio meta-analyses separately. The properties of each estimator are described
in separate the sections that follow, based on these ﬁgures.
7.5.1.1 DerSimonian-Laird (DL)
In scenarios of standardised mean diﬀerence meta-analyses, DL is negatively biased
when study eﬀects have high I2 and study sample sizes are small (as shown in ﬁgure
7.2, plot A4). This negative bias increases as the number of studies increases and
reaches up to -20%. These scenarios have a τ 2 parameter of 0.991, so in absolute
terms the mean bias is up to -0.19. In all the other standardised mean diﬀerence
scenarios in this ﬁgure, DL is positively biased in meta-analyses containing fewer
than 10-20 studies and roughly unbiased for those with more studies. DL has similar
bias to many estimators including PMCA, PMDL and REML in scenarios with small
studies and small-to-medium studies. In meta-analyses with small and large studies
(plots C1-C4), DL is one of the least biased estimators and distinctly lower than PM
and PMCA.
Mean bias in scenarios of odds ratio meta-analyses with event probabilities between
0.1 and 0.5 is shown in ﬁgure 7.3. In these scenarios, DL's negative bias is observed
to a greater extent than in standardised mean diﬀerence scenarios and includes those
with small-to-medium sized studies and high I2. Results suggest that in odds ratio
meta-analyses, larger sample sizes are required than in standardised mean diﬀer-
ence meta-analyses to avoid DL's negatively biased estimates. Alternatively, study
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event probabilities closer to the ideal 0.5. As with standardised mean diﬀerence
meta-analyses, DL is one of the least biased estimators in odds ratio meta-analyses
containing small and large studies (plots C1-C4).
DL is compared in terms of mean squared error in ﬁgures 7.4 and 7.5. DL has a
relatively low mean squared error in the same scenarios as when the estimator is
negatively biased. However, this is a consequence of how mean squared error is
measured and so this isn't necessarily a good property. Also, DL also has relatively
low mean squared error in scenarios containing small-to medium and small and large
studies. In scenarios with small equally-sized studies, DL has mean squared error
comparable with many other estimators including CA, PM, PMCA, PMDL, SJCA and
REML.
DL consistently has one of the lowest proportions of zero heterogeneity variance
estimates of all estimators that require truncation. However, this is a similar pro-
portion as other weighted method of moments estimators including PM, PMCA and
PMDL.
7.5.1.2 Cochran's ANOVA (CA)
CA tends to produce higher estimates of the heterogeneity variance than most other
estimators in scenarios of both standardised mean diﬀerence and odds ratio meta-
analyses. As such, CA is roughly unbiased in scenarios with typically high I2 when
most other estimators are negatively biased. However, CA is one of the most pos-
itively biased estimators for up to moderate I2. CA's positive bias is particularly
prominent in scenarios with small and large studies (ﬁgures 7.2 and 7.3, plots C1-
C4). It is to be expected that CA performs poorly when there are large diﬀerences
in study size, given that the estimator assigns equal study weights. CA's positive
bias is slightly greater in odds ratio meta-analyses with event probability 0.1 to 0.5
than in standardised mean diﬀerence meta-analyses.
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Figure 7.2: Mean bias of heterogeneity variance estimates in standardised
mean diﬀerence outcome meta-analyses
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
Bias is presented on the proportional scale when τ 2 > 0.
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Figure 7.3: Mean bias of heterogeneity variance estimates in odds ratio
meta-analyses with event probability 0.1 to 0.5
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
Bias is presented on the proportional scale only when τ 2 > 0.
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Figure 7.4: Mean squared error of heterogeneity variance estimates in
standardised mean diﬀerence meta-analyses
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
Mean squared error is presented on the proportional scale only when τ 2 > 0.
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Figure 7.5: Mean squared error of heterogeneity variance estimates in odds
ratio meta-analyses with event probability 0.1 to 0.5
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
Mean squared error is presented on the proportional scale only when τ 2 > 0.
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Figure 7.6: Proportion of zero heterogeneity variance estimates in
standardised mean diﬀerence meta-analyses
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
HM, SJ, SJCA are not included as they only produce positive τ
2 estimates.
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Figure 7.7: Proportion of zero heterogeneity variance estimates in odds ratio
meta-analyses with event probability 0.1 to 0.5
Scenarios containing small studies (A1-A4), small-to-medium studies (B1-B4) and
small and large studies (C1-C4). Eﬀect size θ = 0.5.
HM, SJ and SJCAare not included as they only produce positive τ
2 estimates.
141
CA also has a higher mean squared error than most other estimators when there
are large diﬀerences in study sizes (7.4, plots C1-C4). Its mean squared error is
comparable with most other estimators when study sizes are the same (7.4, plots
A1-A4). These ﬁndings apply to both standardised mean diﬀerence and odds ratio
meta-analyses (ﬁgure 7.5).
CA produces a comparatively high proportion of zero estimates in meta-analyses
containing small and large studies. Only HS and ML have a higher proportion and
only in meta-analyses with up to 5 studies.
7.5.1.3 Paule-Mandel (PM)
PM has a mean bias similar to PMCA, PMDL and REML in scenarios of standardised
mean diﬀerence meta-analyses that contain small or small-to-medium sized studies
(ﬁgure 7.2, plots A1-A4 and B1-B4). In these scenarios, PM is roughly unbiased
when I2 is high or the meta-analysis has more than 20 studies and positively biased
otherwise. In scenarios with small and large studies (ﬁgure 7.2, plots C1-C4), PM's
mean bias is distinct from all other estimators and has a higher positive bias than ML,
HS, DL, PMDL, HM and REML. PM's relatively high positive bias in these scenarios
is particularly prominent where meta-analyses contain ﬁve or fewer studies.
PM has a similar mean bias relative to other estimators in odds ratio meta-analyses
with study event probabilities between 0.1 to 0.5 (ﬁgure 7.3). The key diﬀerences
are that PM has small levels of negative bias in scenarios containing small studies.
For example, in plot A3 for moderate I2 and τ 2 = 0.858, PM has bias of up to -20%
compared with DL's bias of up to -40%.
PM's mean squared error is comparable with PMCA, PMDL and REML in both
standardised mean diﬀerence and odds ratio meta-analyses with small equally-sized
studies (ﬁgures 7.4 and 7.5). In scenarios with small-to-medium and small and large
studies, PM has a higher mean squared error than more than half of all estimators
compared, namely ML, HS, DL, PMDL, HM and REML.
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PM produces an almost identical proportion of zero estimates as DL, PMCA, PMDL
and REML (ﬁgures 7.6 and 7.7). When I2 is low PM produces zero estimates of
heterogeneity for meta-analyses containing up to 100 studies when I2 is low. For
meta-analyses with high I2, PM produces no zero estimates when there are 10 or
more studies.
7.5.1.4 Two-step Cochran's ANOVA (PMCA)
PMCA is a two-step version of PM that uses CA as an initial estimate of heterogeneity.
As such, PMCA's mean bias and mean squared error are equal to, or somewhere
between, CA and PM in all scenarios.
PMCA has similar bias to CA and PM (and also REML) in scenarios of standardised
mean diﬀerence and odds ratio meta-analyses that contain small or small-to-medium
sized studies (ﬁgure 7.2 and 7.3, plots A1-A4 and B1-B4). For standardised mean
diﬀerence and odds ratio meta-analyses with small and large studies (plots C1-C4),
PMCAhas a more distinct mean bias, slightly lower than CA and much higher than
PM. Only CA, SJ and SJCA have more positive bias in these scenarios. PMCA also
has a distinct mean squared error in scenarios with small and large studies; slightly
higher than PM and considerably less than CA.
PMCA produces an almost identical proportion of zero estimates as DL, PMDL and
REML.
7.5.1.5 Two-step DerSimonian-Laird (PMDL)
In most scenarios, properties of PMDL are similar to both DL and PM. Results diﬀer
in standardised mean diﬀerence and odds ratio meta-analyses with small studies and
high I2 in which PMDL and PM are roughly unbiased and DL is negatively biased.
Also, PMDLand DL have relatively low positive bias and low mean squared error
in scenarios containing small and large studies, where PM's positive bias and mean
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squared error are higher. Thus, results overall show PMDL has the best properties
of DL and PM.
PMDL produces an almost identical proportion of zero estimates as DL, PMCA and
REML.
7.5.1.6 Maximum likelihood (ML) and Hunter-Schmidt (HS)
ML has similar properties to HS in terms of all performance measures. ML and
HS produce the lowest estimates of all the estimators compared, particularly when
there are ﬁve or fewer studies in the meta-analysis. As such they are the least
positively biased estimators for zero to low I2 values and have the highest negative
bias for moderate and high I2. For example, in standardised mean diﬀerence meta-
analyses with small-to-medium study sizes and a τ 2 range of 0 to 0.194 (ﬁgure 7.2,
plots B1-B4), ML and HS have minimal positive bias for zero and low I2 and a
mean bias as low as -60% for moderate to high I2. ML and HS have the lowest
mean squared errors in all meta-analyses as a consequence of their comparatively
low heterogeneity variance estimates (ﬁgures 7.4 and 7.5) and the highest proportion
of zero heterogeneity variance estimates (ﬁgures 7.6 and 7.7). These ﬁndings apply
to both standardised mean diﬀerence meta-analyses and odds ratio meta-analyses
with study event probabilities 0.1 to 0.5.
7.5.1.7 REML
REML has similar properties to DL in most scenarios. In a small number of scenarios
where DL is negatively biased, REML is also negatively biased but often to a much
lesser extent. Recall, these scenarios include standardised mean diﬀerence meta-
analyses with small studies and high I2 (ﬁgure 7.2, plot A4) and to a greater extent in
odds ratio meta-analyses containing up to medium-sized studies and from moderate
I2 (ﬁgure 7.3, plots A3, A4 and B4). REML has relatively low bias and low mean
squared error, as does DL, in scenarios containing small and large studies.
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REML has similar properties to DL and PMDL in most scenarios. The main diﬀerence
is in odds ratio meta-analyses where estimates are negatively biased, DL often has
the highest negative bias, followed by REML and PMDL has the least; this can be
observed most prominently in ﬁgure 7.3 (plot A3). Diﬀerences in bias between REML
and DL are also observed in standardised mean diﬀerence meta-analyses with small
studies and high I2 (ﬁgure 7.2, plot A4). REML has relatively low bias and low
mean squared error, as does DL and PMDL, in scenarios containing small and large
studies (ﬁgures 7.2 and 7.3, plots C1-C4).
7.5.1.8 Hartung-Makambi (HM)
Recall that HM is a transformation of the DL estimator that only produces positive
estimates of the heterogeneity. In meta-analyses with small or small-to-medium
study sizes and zero or low I2, HM tends to produce relatively high estimates of
heterogeneity and therefore has relatively high positive bias. HM tends to produce
comparatively low estimates when I2 is moderate or high and has more negative bias
DL in these scenarios. For example, in scenarios of standardised mean diﬀerence
meta-analyses with small studies, high I2 and a τ 2 parameter value of 0.991 (ﬁgure
7.2, plot A4), HM's negative mean bias is up to -25% and DL's negative mean bias
reaches -20%. In contrast, HM is one of the least biased estimators in meta-analyses
containing small and large studies, with similar bias as DL.
HM has a lower mean squared error than all estimators except HS and ML estimators,
but these estimators have much more considerable negative bias. Surprisingly, HM
has low mean squared error in scenarios with meta-analyses that have zero to low
I2, where HM has a relatively high positive bias. HM has a particularly low mean
squared error, similar to DL, in meta-analyses with small and large studies because
HM in these scenarios has relatively low bias.
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7.5.1.9 Sidik-Jonkman (SJ)
SJ typically produces one of the highest estimates of the heterogeneity variance in
both standardised mean diﬀerence and odds ratio meta-analyses. As such, SJ has
considerable positive bias for meta-analyses with up to typically moderate I2. For
example, in standardised mean diﬀerence meta-analyses containing small-to-medium
sized studies and low I2 (ﬁgure 7.2, plot B2), SJ has mean bias of more than 100%
when almost all other estimators are roughly unbiased. It is to be expected that
SJ has positive bias for low I2, given that it only produces positive heterogeneity
variance estimates. However, SJ's positive bias is much higher than other positive
estimators including SJCA and HM. In meta-analyses with high I
2 values, SJ has a
relatively low bias similar to CA, SJCA, PMCA, PMDL and REML. SJ's bias remains
constant as the number of studies in meta-analyses increase, while the bias of most
other estimators converge to zero.
SJ also has a relatively high mean squared error in meta-analyses with up to moderate
I2 values and a mean squared error similar to most other estimators when I2 is high.
7.5.1.10 Sidik-Jonkman (CA initial estimate) (SJCA)
Recall that SJCA is a two-step heterogeneity variance estimator based on the same
approach as SJ and as such only produces positive estimates. In standardised mean
diﬀerence and odds ratio meta-analyses with up to moderate I2, SJCA becomes more
positively biased as typical study sizes increase. In meta-analyses with small studies
(as shown in ﬁgures 7.2 and 7.3, plots A1-A4), SJCA is one of the least biased
estimators, with bias similar to many of the truncated methods including DL, PM
and REML. In meta-analyses with medium-sized studies, its bias is comparable with
SJ and for meta-analyses with large studies SJCA has the highest positive bias of
all estimators compared (the results of these scenarios are shown in the results in
volume II of this thesis). SJCA is roughly unbiased in meta-analyses with high I
2
similar to CA, SJ, PMCA, PMDL and REML.
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In scenarios where SJCA has positive bias, it also have relatively high mean squared
error (i.e. in meta-analyses with large studies).
7.5.1.11 A summary of all simulated scenarios
Table 7.1 summarises the simulation results across all scenarios of standardised mean
diﬀerence and odds ratio meta-analyses. The table is colour-coded to show scenarios
where the properties of all estimators are similar in terms of all three perform-
ance measures reported thus far; (1) proportional mean bias, (2) proportional mean
squared error and (3) proportion of zero heterogeneity variance estimates.
All estimators have substantial negative mean bias in odds ratio meta-analyses with
an event probability of up to 0.05, except when all studies are large (i.e. those with
sample sizes of 2000 per study group). All estimators also have considerable negative
bias in odds ratio meta-analyses with common events and small studies (i.e. those
with sample sizes of 20 per study group). In all other scenarios when there is a
suﬃcient number of studies, many of the estimators have reasonable properties.
We derived two other key observations from table 7.1. First, heterogeneity variance
estimators generally have worse properties in scenarios containing small study sizes
and in odds ratio meta-analyses with low event probabilities. Second, the properties
of heterogeneity variance estimators are similar between standardised mean diﬀerence
meta-analyses and the equivalent odds ratio meta-analyses when events are common.
The exception is in meta-analyses containing small studies; all heterogeneity variance
estimators are considerably biased in odds ratio meta-analyses with high I2 where
many are unbiased in the equivalent standardised mean diﬀerence scenario (as shown
in ﬁgures 7.2 and 7.3, plot A4).
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Table 7.1: A summary of the properties of heterogeneity variance estimators
for all scenarios of standardised mean diﬀerence and odds ratio meta-analyses
with eﬀect size 0.5.
are scenarios where all estimators have considerable negative bias. Some
estimators are reasonably unbiased in all other scenarios (if there are enough
studies).
* Mean bias presented in ﬁgure 7.2, mean squared error in ﬁgure 7.4 and
proportion of zero estimates in 7.6
** Mean bias presented in ﬁgure 7.3, mean squared error in ﬁgure 7.5 and
proportion of zero estimates in 7.7
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7.5.2 Properties of heterogeneity variance estimates for vary-
ing eﬀect sizes
The results presented thus far come from simulated scenarios with a log odds ratio
and standardised mean diﬀerence of θ = 0.5 (this corresponds to an odds ratio
of 1.65). Meta-analyses were also simulated with other log odds ratio eﬀect sizes;
θ = 0, 1.1, 2.3 (i.e. odds ratios of 1, 3 and 10). Results were generally consistent
between eﬀect sizes except in scenarios with meta-analyses containing only small
studies (a selection of these results are presented in ﬁgure 7.8). In scenarios with
rare events and small sample sizes, all methods have high negative bias regardless of
the odds ratio eﬀect size (therefore, the summary in table 7.1 can be generalised to
all eﬀect sizes in these scenarios).
In ﬁgure 7.8, mean bias is presented in meta-analyses with small studies and various
underlying log odds ratios (θ = 0.5, 1.1, 2.3). Odds ratio meta-analyses with θ = 0
are not presented in this chapter because results are roughly consistent to θ = 0.5
in all scenarios. All methods have more negative bias in the scenarios with a large
eﬀect size (C1-C3) than for low (A1-A4) and moderate (B1-B4) eﬀect sizes. This
may be partly due to a diﬀerence in τ 2 parameter values between these scenarios,
given that results are consistent when τ 2 = 0. REML is more negatively biased
relative to other estimators in meta-analyses with a small eﬀect size than with a
large eﬀect size. However, the diﬀerence in REML between eﬀect sizes is marginal.
HM is generally more robust to changes in eﬀect size than other estimators, but still
has considerable positive bias in scenarios of up to low heterogeneity.
Mean bias is the only performance measure presented in this section. However, this
measure gives an understanding of the properties of methods according to other
performance measures. Generally, results diﬀer between eﬀect sizes only in meta-
analyses with small studies and where the event is not rare across both study groups
(but could become rare in one of more study groups if the eﬀect size is extreme
enough). Appendix F.7 shows mean squared error of heterogeneity variance estimates
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Figure 7.8: Mean bias of heterogeneity variance estimates in odds ratio
meta-analyses containing small studies and with event probability 0.1 to 0.5
Scenarios with an underlying summary odds ratio of 1.65 (A1-A4), 3 (B1-B4) and
10 (C1-C3).
Bias is presented on the proportional scale only when τ 2 > 0.
There was no such τ 2 that produced a mean I2 of 90% when θ = 2.3, so these
scenarios are not presented.
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Figure 7.9: Mean bias of the summary eﬀect estimates in odds ratio
meta-analyses with rare events.
Scenarios presented are all with moderate I2 (a mean of 60%) and (A1)
Small-to-medium study sizes with an average event probability of 0.05; (B1) Small
and large study sizes with an average event probability of 0.05; (A2)
Small-to-medium studies with an average event probability of 0.01; (B2) Small and
large studies with an average event probability of 0.01.
θ = 0.5 and represents the underlying log odds ratio.
for the equivalent scenarios as in ﬁgure 7.8.
7.5.3 Properties of estimates of the summary eﬀect
This section presents a comparison of heterogeneity variance estimators in terms of
mean bias of the summary eﬀect estimates. All meta-analyses were simulated with
a true summary eﬀect of 0.5, which represents either a standardised mean diﬀerence
or a log odds ratio.
Results show that summary eﬀect estimates of θ = 0.5 are almost unbiased in all scen-
arios of standardised mean diﬀerence meta-analyses and odds ratio meta-analyses
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with common events. However, summary eﬀect estimates are negatively biased to-
wards the null value of zero in odds ratio meta-analyses with rare events. In these
scenarios, heterogeneity variance estimators also have considerable negative bias (see
table 7.1). This indicates that the problem is not solely related to heterogeneity vari-
ance estimation, but problems with two-stage meta-analysis and perhaps the choice
of continuity correction that aﬀects all methods. Results from selected scenarios are
presented in ﬁgure 7.9 of odds ratio meta-analyses with a rare event probability (0.01
and 0.05) and a mean I2 of 60%. These scenarios were selected to show negative
bias of summary eﬀect estimates to varying degrees.
Estimators that produce larger estimates of the heterogeneity variance such as SJ,
typically with positive bias, produce summary eﬀect estimates with the lowest bias in
scenarios with small-to-medium study sizes (plots A1 and A2). The opposite result is
shown in plots B1 and B2 where studies are small and large; ML and HS produce the
lowest estimates of heterogeneity and the least biased summary eﬀect estimates. This
is perhaps because larger heterogeneity variance estimates give studies more equal
weight and this can reduce bias caused imprecise within-study variance estimates (as
observed in plots A1 and A2). However, when there are large diﬀerences between
study sizes, giving studies more equal weight can increase bias of the summary eﬀect
estimates (as observed in plots B1 and B2).
For scenarios with event probability 0.05, considerable negative bias in summary
eﬀect estimates is observed only when study sizes are small (as shown in plot A2).
When the event probability is 0.01, considerable negative bias is observed in all odds
ratio meta-analyses except when all studies are large. This can be observed in the
full results in volume II of this thesis.
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7.5.4 Coverage of 95% conﬁdence intervals for the summary
eﬀect
Conﬁdence intervals of the summary eﬀect in this section are compared in terms of
coverage. Conﬁdence interval methods include Wald-type [25], t-distribution [28] and
that proposed by Knapp and Hartung [38].
A representative subset of scenarios are presented before generalising the results to all
scenarios. Results presented are from (1) standardised mean diﬀerence meta-analyses
with small-to-medium studies (ﬁgure 7.10), (2) odds ratio meta-analyses with small-
to-medium studies and 0.05 event probability (ﬁgure 7.11) and (3) odds ratio meta-
analyses with small and large studies and event probability 0.1 to 0.5 (ﬁgure 7.12).
The ﬁrst scenarios represent ideal conditions and the ﬁnal two scenarios represent
conditions where methods generally perform more poorly. Scenarios of odds ratio
meta-analyses with common events are excluded because results were consistent with
the equivalent standardised mean diﬀerence meta-analyses. Results are plotted for
τ 2 parameters that produce mean I2 values of 0%, 30%, 60% and 90%. However, a
mean I2 of 90% was unattainable in some scenarios so these results are not included.
Results are given separately for each conﬁdence interval method in sections 7.5.4.1 -
7.5.4.3 that follow, based on ﬁgures 7.10 to 7.12.
7.5.4.1 Wald-type conﬁdence interval
The Wald-type 95% conﬁdence interval is not robust to various simulated scen-
arios. Figure 7.10 shows coverage for scenarios of standardised mean diﬀerence
meta-analyses with small-to-medium studies. In these scenarios, coverage can diﬀer
by up to 5% between heterogeneity variance estimators, up to 30% between numbers
of studies and up to 20% between heterogeneity values. Coverage varies between 96-
100% when studies are homogeneous and can be as low as 65% when the mean I2 is
90% (τ 2 = 0.187) and meta-analyses have two or three studies. When heterogeneity
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is present, its coverage tends towards the nominal value of 95% as the number of
studies increases.
In scenarios of odds ratio meta-analyses and an event probability of 0.05 (ﬁgure 7.11),
coverage is above 90% when there are 20-30 studies. For meta-analyses with lower
or higher numbers of studies, coverage is as low as 85%. In ﬁgure 7.12, derived from
odds ratio meta-analyses with small and large studies, diﬀerences in coverage between
heterogeneity variance estimators is up to 25%. For example, when τ 2 = 0.038 (mean
I2 is 90%) and there are two or three studies in the meta-analysis, HS and ML has
coverage as low as 60% while SJ and HM produce a conﬁdence interval with coverage
85%.
In all scenarios, heterogeneity variance estimators that produce high estimates with
positive bias (i.e. SJ, HM) tend to produce Wald-type conﬁdence intervals with a
higher coverage. Therefore these estimators work best with this conﬁdence interval
method when I2 is high, given that coverage is typically low in these scenarios. By
similar logic, HS and ML produce the lowest estimates of heterogeneity and generally
work best with this method when I2 is low. However, in meta-analyses with small
and large studies (ﬁgure 7.12), CA produces the lowest coverage despite having
positively biased heterogeneity variance estimates in these same scenarios. Perhaps
this is because CA is the only estimator that assigns equal study weight and had
high mean squared error in these scenarios.
7.5.4.2 t-distribution conﬁdence interval
Coverage of the t-distribution 95% conﬁdence interval is generally more robust to
changes in the mean I2, as shown in ﬁgure 7.10 in standardised mean diﬀerence meta-
analyses. In these scenarios, however, coverage can diﬀer by up to 5% depending on
the heterogeneity variance estimator used and the number of studies. When there
are 20 studies or more, 95% t-distribution conﬁdence intervals have coverage 94-
97%, but perform poorly with coverages close to 100% when there are fewer than 20
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Figure 7.10: Coverage of 95% conﬁdence intervals of the summary eﬀect in
standardised mean diﬀerence meta-analyses with small-to-medium studies
Coverage of Wald-type (plots A1-A4), t-distribution (plots B1-B4) and
Hartung-Knapp (plots C1-C4) conﬁdence intervals presented. Eﬀect size θ = 0.5.
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Figure 7.11: Coverage of 95% conﬁdence intervals of the summary eﬀect in
odds ratio meta-analyses with small-to-medium studies and an average event
probability of 0.05.
Coverage of Wald-type (plots A1-A3), t-distribution (plots B1-B3) and
Hartung-Knapp (plots C1-C3) conﬁdence intervals presented.
There was no such τ 2 that produced a mean I2 of 90% so these scenarios are not
presented. Eﬀect size θ = 0.5.
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Figure 7.12: Coverage of 95% conﬁdence intervals of the summary eﬀect in
odds ratio meta-analyses with small and large studies and an average event
probability of 0.1 to 0.5.
Coverage of Wald-type (plots A1-A3), t-distribution (plots B1-B3) and
Hartung-Knapp (plots C1-C3) conﬁdence intervals presented.
There was no such τ 2 that produced a mean I2 of 90% so these scenarios are not
presented. Eﬀect size θ = 0.5.
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studies.
In odds ratio meta-analyses with event probability 0.05 (ﬁgure 7.12), the key diﬀer-
ence is that coverage does not converge to 95% as the number of studies increases.
Instead coverage remains close to 100% for meta-analyses with up to 10 studies and
becomes as low as 85% in meta-analyses with 100 studies. In meta-analyses with
small and large studies (ﬁgure 7.12), there is a greater diﬀerence between heterogen-
eity variance estimators; SJ has coverage close to 100% in all these scenarios and CA
produce a conﬁdence interval with coverage as low as 80%.
The heterogeneity variance estimator that works best with this conﬁdence interval
method varies considerably between scenarios, so it is diﬃcult to select one overall.
7.5.4.3 Hartung-Knapp conﬁdence interval
The Hartung-Knapp conﬁdence interval for the summary eﬀect has better coverage
that the other two methods in all scenarios. This method has coverage 94-96% in
standardised mean diﬀerence meta-analyses presented in ﬁgure 7.10 and insensitive
to the choice of heterogeneity variance estimator. However, the Hartung-Knapp
method's coverage can be far from optimal in other scenarios. In odds ratio meta-
analyses with event probability 0.05 (ﬁgure 7.12), coverage decreases as the number
of studies in the meta-analysis increases and can reach as low as 86%. In odds ratio
meta-analyses with small and large studies, coverage is variable between estimators;
HS and ML can produce coverage of 86% while SJ has coverage close to 95%.
The choice of heterogeneity has little impact on coverage in standardised mean dif-
ference meta-analyses with small-to-medium studies (ﬁgure 7.10), so all are equally
good candidates to be used with this conﬁdence interval method. In the other scen-
arios presented, coverage is too variable to select the best estimator overall.
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For all confidence interval methods 
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and dark grey(see figure).
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All estimators and all confidence interval methods have
poor coverage.
Z-type and t-distribution: Both methods have similar 
coverage. All estimators have close to 100% coverage 
when k=2 and falls to below 70% for k=100. 
Knapp-Hartung: Close to 95% coverage for all estimators 
and k=10, but <85% for low and high k.
Table 7.2: A summary of coverage for all scenarios of standardised mean
diﬀerence and odds ratio meta-analyses with eﬀect size 0.5
Scenarios with the same background shading show where coverage results are
consistent for each conﬁdence interval method
* Coverage presented in ﬁgure 7.10. ** Coverage presented in ﬁgure 7.11. ***
Coverage presented in ﬁgure 7.12
Recall, k denotes the number of studies in the meta-analysis
7.5.4.4 A summary of coverage in all simulated scenarios
Table 7.2 summarises coverage of all three conﬁdence interval methods in all scenarios
of standardised mean diﬀerence and odds ratio meta-analyses. The table is colour-
coded to show where results are similar for each conﬁdence interval method. All
conﬁdence interval methods could be summarised in one table because scenarios
that can be grouped are consistent between methods.
All methods performed at their worst in scenarios of odds ratio meta-analyses with
rare events (probability 0.05 or 0.01) and smaller study sizes. Methods also have poor
coverage, but to a lesser extent, in meta-analyses with small and large studies. The
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cause of poor coverage in these scenarios is that heterogeneity variance estimators
have much greater variation in mean bias and therefore coverage also varies more
between heterogeneity variance estimators. Coverage in standardised mean diﬀerence
meta-analyses is consistent with the equivalent odds ratio meta-analyses if the event
is common.
In all scenarios the Hartung-Knapp method has substantially better coverage and
consistently produces conﬁdence intervals with coverage close to 95% in standardised
mean diﬀerence meta-analyses and most odds ratio meta-analyses with common
events.
7.5.5 Convergence of ML and REML estimates of heterogen-
eity
ML and REML rarely failed to converge to a heterogeneity variance estimate. Fewer
than 0.02% of meta-analyses failed to converge and only in meta-analyses with few
studies and large diﬀerences in study sizes. A summary of these results are given in
appendix D.3 (tables F.2 and F.3).
7.5.6 An overview of the results
Results showed that properties of estimates of the heterogeneity variance are depend-
ent on the level of heterogeneity, number of studies in the meta-analysis, distribution
of sample sizes, the probability of the event outcome and to a lesser extent the size
of the eﬀect in binary outcome meta-analyses. Estimates of the summary eﬀect,
and to a lesser extent, conﬁdence intervals of the summary eﬀect are more robust to
changes in the heterogeneity variance estimate.
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7.5.6.1 Properties of estimates of the heterogeneity variance
Three performance measures that related to estimation of the heterogeneity variance
are presented in this chapter; mean bias, mean squared error and proportion of zero
estimates.
B0, BP and MBH generally have the worst properties and as such were not presented
in the main results of this chapter. B0 and BP have the highest positive bias of all
estimators compared and MBH has the highest mean squared error. The main
results also show that estimates calculated from SJ, SJCA, HS and ML generally
have poor properties and should not be used in any meta-analysis. SJ also has
considerable positive bias in meta-analyses for up to moderate levels of heterogeneity.
SJCA has relatively low bias and mean squared error in meta-analyses with small
studies but has considerable positive bias in meta-analyses with large studies. This
is perhaps because SJCA is a non-truncated two-step estimator with a minimum
initial τ 2 estimate of 0.01; this value represents high inconsistency in meta-analyses
with large studies and is therefore not an appropriate cut-oﬀ. HS and ML have
similar performance and are negatively biased in all meta-analyses when there are
few studies in a meta-analysis, particularly when the mean I2 is high.
CA, PMCA, HM can also be excluded from consideration as there are alternative
methods that have equal or better properties. CA and PMCA have a bias and mean
squared error comparable with many other estimators when study sizes are equal-
sized but they have increasing positive bias and mean squared error as the diﬀerence
between study sizes increase. HM is shown to have similar properties as DL but has
more positive and negative bias when the I2 is low and high respectively.
The remaining four methods with reasonable properties are DL, PMDL, PM and
REML. These are estimators that are shortlisted for possible recommendation in
the conclusions of this chapter. DL is one of the best performing estimators in
meta-analyses with large diﬀerences in study size. PM and PMDL in most scenarios
have similar properties and are more robust to imprecise within-study variances.
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PMDL performs better than PM with similar properties to DL when there are large
diﬀerences in study size. REML generally has low mean squared error and a relatively
low negative bias where DL has considerably more. However, in very few meta-
analyses, the iterative method failed to produce a REML estimate (see section 7.5.5).
7.5.6.2 Properties of estimates of the summary eﬀect
Mean bias and mean squared error of the inverse-variance summary eﬀect estim-
ates were presented in this chapter. In scenarios of standardised mean diﬀerence
meta-analyses and of odds ratio meta-analyses with common events, results show
summary eﬀect estimates are approximately unbiased for all heterogeneity variance
estimators. Estimates of the odds ratio summary eﬀect are biased towards the null
value when studies are simulated with a low event probability of 0.05 and 0.01, where
all heterogeneity variance estimators also have considerable negative bias.
7.5.6.3 Properties of 95% conﬁdence intervals of the summary eﬀect
In section 7.5.4, coverage is presented as the only performance measure that relates
to estimation of 95% conﬁdence intervals for the summary eﬀect. Coverage of Wald-
type [25], t-distribution [28] and Hartung-Knapp [38] conﬁdence interval methods
were presented.
The Hartung-Knapp conﬁdence interval has more optimal coverage than Z-type and
t-distribution conﬁdence intervals in nearly all scenarios. This method has coverage
close to the nominal 95% in most scenarios of standardised mean diﬀerence meta-
analyses or odds ratio meta-analyses with common events and robust to the choice
of heterogeneity variance estimator. However, in odds ratio meta-analyses with rare
events or when diﬀerences between study sizes are large, coverage probabilities of all
conﬁdence interval methods decrease to as low as 85%.
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7.6 Discussion
The DerSimonian-Laird (DL) estimator cannot be recommended for wide-spread use
in random eﬀects meta-analysis, given that it has substantial negative bias in odds
ratio meta-analyses with small studies and rare events. This ﬁnding can perhaps
be explained by DerSimonian-Laird's ﬁxed-eﬀect study weights that are based solely
on estimated within-study variances; these variances are imprecise and likely to be
biased under such conditions. This negative bias of DerSimonian-Laird estimates
has also been observed in previous simulation studies [3, 74, 78, 102] as identiﬁed in
the systematic review in chapter 5. Viechtbauer [124] and Böhning et al. [7] stated
that DerSimonian-Laird is asymptotically unbiased when within-study variances are
known. Finding from this study also show DerSimonian-Laird has good properties
in meta-analyses with large diﬀerences in study size and could be recommended,
among other estimators, in this setting.
One of the primary aims was to investigate when it is appropriate to rely on one
estimate of the heterogeneity variance. Results show all estimators are imprecise
and often fail to detect high levels of heterogeneity in meta-analyses containing fewer
than 10 studies. Chapter 4 reported that only 14% on meta-analyses in the Cochrane
Database of Systematic Reviews (CDSR) contain 10 studies or more, so it is rarely
appropriate to rely on one estimate of heterogeneity in this setting. All estimators
have poor properties even in meta-analyses containing high numbers of studies when
study sizes are small or the event of interest is rare (as shown in table 7.1). How
frequently these scenarios occur in practice is investigated in the next chapter.
Estimates of the summary eﬀect and its Hartung-Knapp conﬁdence interval are of
less cause for concern, performing well even for low numbers of studies. However,
caution must still be applied when dealing with meta-analysis datasets with rare
events, where summary eﬀects are biased and any of the included conﬁdence inter-
val methods can have coverage as low as 85%. These ﬁndings agree with a previous
simulation study [55], in which the Hartung-Knapp method (using the DL heterogen-
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eity variance estimate only) was compared with other conﬁdence interval methods
for both continuous and binary outcome measures. The results in this chapter also
show the Hartung-Knapp method is robust to changes in the heterogeneity variance
estimate, except in meta-analyses with large diﬀerences in study size.
Results are in disagreement with some previous simulation studies. In all cases,
this can be attributed to diﬀerences in parameter values and other diﬀerences in
study design. SJ, MBH, B0 and BP performed well in previous simulations and
have been recommended by their respective authors, yet this study shows they have
poor properties. SJ performed well in simulations conducted by Sidik and Jonkman
[101], yet simulations in this study shows they have considerable positive bias in
meta-analyses of up to moderate I2. This was not observed by Sidik and Jonkman
[101] because meta-analyses were only simulated with high I2. MBH has high mean
squared error in meta-analyses with few studies, but Malzahn et al. [74] only sim-
ulated meta-analyses with 15 studies. B0 and BP were recommended because they
have low mean squared error in meta-analyses with few studies. These methods are
considerably biased, but bias was not included as a performance measure in the ori-
ginal study [93]. Furthermore, PM has been recommended based on the results of
three previous simulation studies [3, 78, 79], but these studies did not simulate meta-
analyses with moderate-large diﬀerences in study size, where PM has considerable
positive bias.
Meta-analysis data were simulated from ﬁve distributions of study sample sizes.
These distributions produced small, medium and large equally-sized studies and
studies with moderate and large diﬀerences in size. DL and HM use ﬁxed-eﬀect
study weights and have the best properties in meta-analyses with large diﬀerences in
study size. PM, which uses random-eﬀects weights, has better properties when stud-
ies are equal-sized. A possible explanation of these ﬁndings is that random-eﬀects
weights can be unduly similar in small and large studies when the heterogeneity
variance estimate is large [46]. The two-step PMDL estimator can be considered a
robust compromise between DL and PM, since it uses ﬁxed-eﬀect study weights in
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the ﬁrst step and random-eﬀects study weights in the second. Other estimators were
recommended over PMDLin two previous simulation studies [3, 64], but neither sim-
ulated meta-analyses with large diﬀerences in study size and neither reported the
mean squared error of heterogeneity variance estimates.
There are two main advantages to the design of this simulation study over previous
studies. First, a comprehensive set of heterogeneity variance estimators are compared
in a wide range of scenarios and reported a wide range of performance measures. Pre-
vious simulation studies gave conﬂicting recommendations because their results only
gave a limited picture. Second, meta-analyses were simulated using τ 2 parameter
values that varied between scenarios and deﬁned such that meta-analyses represent
a consistent and wide range of I2 values. Results suggest that properties of hetero-
geneity variance estimators are more comparable between scenarios with the same
I2, rather than the same τ 2. The I2 statistic also takes into account the 'typical'
within-study variances and is a measure of inconsistency between studies. Previous
simulation studies set τ 2 parameter values in many cases with little knowledge of
whether they constitute low, moderate or high levels of heterogeneity.
The limitations of this simulation study are as follows. First, only a subset of all
conﬁdence interval methods for the summary eﬀect are included. Results show the
Hartung-Knapp method is a more robust than the Z-type method to changes in the
heterogeneity variance estimator, but no conclusive recommendations can be made
going forward. Other methods exist such as the proﬁle likelihood method [37], which
has also been shown as a better alternative to the Z-type method in simulated meta-
analysis data [45] and recommended elsewhere [20]. Second, a continuity correction
of 0.5 was applied wherever simulated studies with a binary outcome contained zero
events, but other better-performing methods are available [113]. This choice may
have impacted the results in scenarios where the event is rare, but was chosen in
this study because it is widely used. For each scenario, the probability that a study
has zero events was calculated retrospectively and shown in the table F.4 of the
appendix. Finally, the ﬁve distributions from which sample sizes were drawn can't
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be considered representative of all distributions observed in practice; study sample
sizes are unlikely to conform to a deﬁned distribution.
Summarising the properties of a comprehensive list of heterogeneity variance es-
timators, compared over many combinations of parameter values was the biggest
challenge of this study. By simulating meta-analyses from a wide range parameter
values, inevitably there are scenarios that reﬂect meta-analyses rarely observed in
practice. For example, most meta-analyses contain very few studies [21], but meta-
analyses with up to 100 studies were simulated in order to show results over the full
range of possible meta-analysis sizes. When interpreting results and drawing con-
clusions, equal consideration was given to rare and common scenarios. In the next
chapter, results from a secondary analysis of the simulation data is presented using
novel analysis methods that take into account the characteristics of meta-analyses
in the Cochrane Database of Systematic Reviews (CDSR).
7.7 Conclusions
The DerSimonian-Laird two-step estimator (PMDL) and REML have similar prop-
erties in both standardised mean diﬀerence and odds ratio two-stage meta-analyses.
REML is recommended over PMDL on the basis of these results because it's already
widely known, available in most statistical software packages, and rarely fails to
converge using Fisher's scoring algorithm. PMDL is recommended as an alternative
when convergence fails. The Hartung-Knapp conﬁdence interval for the summary
eﬀect is generally recommended over other Wald-type and t-distribution methods
compared in this study, but other methods not included may have better coverage in
meta-analyses with rare events. To be consistent, we recommend the same REML
estimate of the heterogeneity variance to calculate this conﬁdence interval. However,
this is inconsequential given how robust this conﬁdence interval is to changes in the
heterogeneity variance method in most scenarios. REML, or indeed any other single
estimate of heterogeneity, should not be relied on to gauge the extent of heterogen-
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eity in most meta-analyses. However, this single estimate can be used calculate a
reliable Hartung-Knapp conﬁdence interval for the summary eﬀect.
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Chapter 8
Properties of heterogeneity variance
estimators in meta-analyses of
Cochrane reviews
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8.1 Introduction
In the last chapter, I simulated meta-analysis data that represented a wide range of
meta-analyses occurring in practice. Results from all these simulations were presen-
ted and considered when drawing conclusions. However, this analysis approach did
not account for the possibility that some simulation scenarios may be more rep-
resentative of real meta-analyses than others. Those that represent meta-analyses
more frequently occurring in practice should arguably have more bearing on the
conclusions.
In this chapter, I implement a novel and systematic method of focusing more on
these scenarios representative of real meta-analyses. I combine the ﬁndings from
my simulated meta-analysis data with empirical data from the Cochrane Database
of Systematic Reviews (CDSR) [21]. This CDSR dataset was used to perform an
empirical comparison of heterogeneity variance estimators in chapter 4. I include the
same 12,894 meta-analyses as I did in chapter 4. Recall that CDSR meta-analyses
containing fewer than three studies are excluded; studies in these 'meta-analyses'
are unlikely to have been synthesised and therefore it's unlikely an estimate of the
heterogeneity variance was presented.
The principle aim of this analysis is to provide a clear and concise summary of the
simulation results to lead into the concluding chapter. I also aim to: (1) describe the
absolute performance of heterogeneity variance estimators in meta-analyses in prac-
tice; (2) distinguish between the heterogeneity variance estimators that I identiﬁed
in the last chapter as having reasonable but similar properties; and (3) show the po-
tential consequence of using heterogeneity variance estimators with poor properties.
8.2 Methods
To summarise the performance of heterogeneity variance estimators expected in
CDSR meta-analyses, analysis was carried out in three steps. First, I mapped each
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CDSR meta-analysis to a simulated scenario with the closest matching character-
istics. The methods for this process are detailed in the next section. Second, I
calculated the total number of CDSR meta-analyses matched to each scenario. Fi-
nally, by combining these frequencies and the simulation results, I derive a predicted
distribution of each estimators performance in CDSR meta-analyses. The perform-
ance measures included in this chapter are given in section 8.2.2, the heterogeneity
variance estimators included are detailed in section 8.2.3 and analysis methods are
in section 8.2.4.
8.2.1 Mapping empirical to simulated meta-analyses
I mapped every included CDSR meta-analysis to a simulated scenario with the closest
matching characteristics. Six meta-analysis characteristics are considered in this
process: (1) the type of outcome measure, (2) the number of studies, (3) the level of
inconsistency between study eﬀects (estimated by I2), (4) the summary eﬀect, (5)
the distribution of study sample sizes and (6) the average event probability in each
study (binary outcome meta-analyses only). I mapped all meta-analyses to scenarios
with normally distributed study eﬀects because results show that all heterogeneity
variance estimators are robust to non-normal eﬀects. CDSR meta-analyses with a
binary outcome were matched with one of 2,560 simulated scenarios of OR meta-
analyses. Those with a continuous outcome were matched with one of 160 simulated
scenarios of SMD meta-analyses. Matching criteria for all other characteristics are
given in table 8.1.
I used the Sidik-Jonkman (SJ) estimate of I2 in CDSR meta-analyses (see section
2.3.2). SJ was chosen because it only produces positive heterogeneity variance estim-
ates, which is advantageous for two reasons. First, the distribution of SJ estimates
of I2 is likely to be more realistic of the underlying distribution, given that truncated
methods produce an unrealistic proportion of zero estimates (see chapter 4). Second,
it minimises the number of meta-analyses matching with scenarios where I2 = 0%.
The reason this is beneﬁcial is made clear in section 8.3.2.
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Parameter Parameter value/distribution Empirical matching criteria
Number of
studies in the
meta-analysis
(k)
2, 3, 5, 10, 20, 30, 50, 100 The closest value. When k is
equidistant between two scenarios
(i.e. if k = 4), the meta-analysis is
matched to one of the two closest
at random.
Mean I2 for
each scenario
0%, 30%, 60%, 90% The closest I2 estimate. SJ is used
to estimate I2 in CDSR
meta-analyses using formula 1.6 for
I2 (chapter 1). e.g. SJ estimates of
I2 from 15% to 45% mapped to the
scenario with I2 = 30%
Summary
eﬀect (θ)
In SMD meta-analyses, θ = 0.5. In
log-odds ratio meta-analyses,
θ = 0, 0.5, 1.1, 2.3
The closest absolute θ estimate. All
SMD meta-analyses matched to
θ = 0.5.
Distribution of
true study
eﬀects (θi)
(a) Normal distribution, (b) normal
distribution with moderate skew and
(c) normal distribution with high skew
All CDSR meta-analyses matched
to scenario (a).
Study sample
sizes (n1i,
n2i)*
(a) Small studies: n1i = 20 n1i + n2i < 50 for all studies
(b) Small to medium sized studies:
n1i ∼ U (20, 200)
n1i + n2i < 500 for all studies; and
n1i+n2i < 50 for at least one study
(c) Medium sized studies: n1i = 200 50 ≤ n1i + n2i < 500 for all studies
(d) Small and large studies:
n11, ..., n1m = 20 and
n1m, ..., n1k ∼ U (1000, 2000) where m is
the integer half way between 1 and k
(when k is odd, one study is be
generated from one of the two
distributions at random)
n1i + n2i ≥ 500 for at least one
study; and
n1i+n2i < 50 for at least one study
(e) Large studies: n1i ∼ U (1000, 2000) n1i + n2i ≥ 50 for all studies; and
n1i + n2i ≥ 500 for at least one
study
Parameters only applying to odds ratio meta-analyses
Average event
probability in
study (pi)
(a) pi = 0.5 pi ≥ 0.1 and sd(pi) < 0.05 ** 
(b) pi ∼ U (0.1, 0.5) pi ≥ 0.1 and sd(pi) ≥ 0.05 ** 
(c) pi = 0.05
0.025 ≤ pi < 0.1 **
(d) pi = 0.01
pi < 0.025 **
Table 8.1: Matching criteria for simulated and empirical CDSR meta-analysis
data
*In all scenarios, sample sizes are equal between groups (n1i = n2i)
** In CDSR meta-analyses, pi is estimated by the proportion of events in both groups combined
(i.e. pi = (ai + ci) / (n1i + n2i) using the notation from section 1.3.2 in the introduction chapter)
 The cut-oﬀ value of 0.05 for the standard deviation is roughly half way between the standard
deviations of scenarios (a) and (b) respectively172
Study sample sizes and event probabilities are simulated from various distributions,
so matching CDSR meta-analyses to these is more diﬃcult. Empirical study sample
sizes are unlikely to come from some natural distribution and I generated study
sample sizes from a limited number of distributions. I took a pragmatic approach
to address this issue and deﬁne matching criteria in table 8.1. These criteria were
simple to implement and I believe lead to reasonably unbiased results. Nevertheless,
I applied caution when interpreting the results because of the limitations of these
methods.
8.2.2 Performance measures
I predict the performance of CDSR meta-analyses according to four of the ﬁve per-
formance measures reported in the previous chapter of simulation results, namely:
 Proportional bias of heterogeneity variance estimates
 Proportional mean squared error (MSE) of heterogeneity variance estimates
 Mean bias of the summary eﬀect estimates
 Coverage of 95% conﬁdence intervals of the summary eﬀect
Performance measures relating directly to the heterogeneity variance parameter are
presented on the proportional scale so that results can be combined between scenarios
with diﬀerent parameter values. The scenarios with homogeneous study eﬀects (i.e.
τ 2 = 0) cannot be presented on the proportional scale, so they are excluded from the
analysis of these measures. Coverage is presented for all conﬁdence interval methods
included in the previous chapter of simulation results; Wald-type, t-distribution and
Hartung-Knapp methods. The proportion of zero estimates of the heterogeneity
variance is not reported in this analysis but was reported in the previous chapter.
I excluded this measure because results would be analogous with the proportion of
observed of zero estimates from CDSR meta-analyses in chapter 4.
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8.2.3 Included estimators of the heterogeneity variance
I compared six heterogeneity variance estimators in this analysis that were chosen
based on simulated results in the last chapter. DerSimonian-Laird (DL), Paule-
Mandel (PM), the two step Paule-Mandel (PMDL) and restricted maximum likeli-
hood (REML) were included because they have the best properties overall. Sidik-
Jonkman (SJ) and maximum likelihood (ML) were also included because these pro-
duce heterogeneity variance estimates with the most positive and negative bias re-
spectively. SJ and ML were included to show the potential consequence of using
estimators with poor properties and highlight the added beneﬁt of using estimators
with more reasonable properties.
8.2.4 Analysis methods
I present the results in two parts. First, I summarise how many CDSR meta-analyses
are matched to each scenario based on the criteria deﬁned in section 8.2.1. This
summary is in the form of a heat map that highlights the key scenarios that are
likely to be most representative of CDSR meta-analyses. The heat map is presented
in such a way that it can be directly compared with results tables 7.1 and 7.2 in
the last chapter. These tables summarise the scenarios that cause problems with
heterogeneity variance estimation.
Second, I present the distribution of performance in CDSR meta-analyses accord-
ing to each of the included four measures. These could alternatively be described
as a weighted distribution of performance, with weights deﬁned as the number of
CDSR meta-analyses matched to each scenario. Distributions were derived for the
six heterogeneity variance estimators and compared in the same plot and results of
OR and SMD meta-analyses are presented separately. These distributions are not
naturally smooth given the ﬁnite number of scenarios they are based on. Therefore,
to plot them clearly, I deﬁned appropriate intervals for each measure and calculate
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the proportion of CDSR meta-analyses mapped to scenarios within each interval.
The proportion in each interval are shown on the y-axis of each plot. Performance
measures are presented on the x-axes on appropriate log-scales to focus on the region
that represents optimal performance (e.g. where MSE is close to zero).
8.3 Results
I present the number of CDSR meta-analyses matched to each scenario in section
8.3.1 to show which simulated scenarios are most representative of real meta-analyses.
The main results of the analysis follow in section 8.3.2 onwards.
8.3.1 The proportion of CDSRmeta-analyses matched to each
simulated scenario
The proportion of CDSR meta-analyses that match to each simulated scenario are
given in ﬁgure 8.1 in the form of a heat map. Each combination of sample size
distribution and probability of event (in OR meta-analyses only) are presented in
separate blocks. Within each block I present combinations of simulated I2 values
(I2 = 0%, 30%, 60%, 90%) and numbers of studies (3,5,10,20,30). Scenarios of meta-
analyses containing 2 studies are excluded because these empirical meta-analyses
were from the results (as they were in chapter 4, when the same data was used).
Scenarios of meta-analyses containing 50 and 100 studies were excluded because
they only account for 0.5% of SMD and OR meta-analyses. The number of meta-
analyses matched to each summary eﬀect parameter are not presented in the heat
map to make the ﬁgure more concise. Overall, 4092 (45.6%) odds ratio meta-analyses
were matched to θ = 0, 3354 (37.4%) to θ = 0.5, 1249 (13.9%) to θ = 1.1 and 284
(3.2%) to θ = 2.3.
CDSR meta-analyses are distributed fairly uniformly between scenarios with mean
I2 values of 0%, 30%, 60% and 90%. However, fewer meta-analyses are matched
175
Study sizes: Small 
Small-to-
medium 
Medium 
Small and 
large 
Large 
Number of studies: 3 5 10 20 30 3 5 10 20 30 3 5 10 20 30 3 5 10 20 30 3 5 10 20 30 
S
M
D
  
m
et
a-
an
al
y
si
s 
 
 
𝐼2 = 0% 
𝐼2 = 30% 
𝐼2 = 60% 
𝐼2 = 90% 
O
R
 m
et
a-
an
al
y
se
s 
w
it
h
 e
v
en
t 
p
ro
b
ab
il
it
y
: 
0
.5
 
 
𝐼2 = 0% 
𝐼2 = 30% 
𝐼2 = 60% 
𝐼2 = 90% 
0
.1
 t
o
 0
.5
  
𝐼2 = 0% 
𝐼2 = 30% 
𝐼2 = 60% 
𝐼2 = 90% 
0
.0
5
 
 
𝐼2 = 0% 
𝐼2 = 30% 
𝐼2 = 60% 
𝐼2 = 90% 
0
.0
1
 
 
𝐼2 = 0% 
𝐼2 = 30% 
𝐼2 = 60% 
𝐼2 = 90% 
Figure 8.1: A heat map of CDSR meta-analyses falling into each simulated
scenario
Percentages represent the proportion of meta-analyses matched to each block, out of
the total of SMD or OR meta-analyses.
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with scenarios where I2 = 0% (i.e. where the SJ method produces I2 < 15%)
because the Sidik-Jonkman only produces positive heterogeneity variance estimates;
1911 (21.3%) OR meta-analyses and 727 (18.6%) SMD meta-analyses are matched
to these scenarios. I2 are estimated in CDSR meta-analyses, so this is only a rough
representation of the distribution of underlying I2.
In the last chapter of results, I found that all heterogeneity estimation methods
have considerable negative bias in meta-analyses with rare events, except where all
study sizes are large. The heat map shows these scenarios represent 2,094 (23.3%)
odds ratio meta-analyses (as shown in blocks 16-19 and 21-24 on the heat map).
229 (2.6%) of odds ratio meta-analyses are matched to scenarios with small studies
and common events (blocks 6 and 11), where heterogeneity variance estimators have
considerable negative bias when there is a high level of inconsistency between study
eﬀects. The remaining scenarios represent all 3,915 (100%) SMD meta-analyses and
6,656 (74.1%) OR meta-analyses, where most heterogeneity variance estimators have
low bias, at least when the eﬀect size is not extreme and there are suﬃcient numbers
of studies. However, of these meta-analyses, 1650 (42.1%) SMD meta-analyses and
2739 (39.8%) OR meta-analyses are represented by the scenarios with only three
studies. All heterogeneity variance estimates are imprecise and most have small to
moderate positive bias in these scenarios.
8.3.2 Performance of heterogeneity variance estimators in CDSR
meta-analyses
In this section, I present the predicted distributions of performance in CDSR meta-
analyses. I present proportional bias and MSE of the heterogeneity variance estim-
ators in sections 8.3.2.1 and 8.3.2.2. For these analyses, I excluded scenarios where
I2 = 0% as results cannot be presented on the proportional scale. Only a small
number of CDSR meta-analyses matched with these scenarios, as shown in section
8.3. I present bias of the summary eﬀect in section 8.3.2.3 and coverage of 95%
177
conﬁdence intervals of the mean eﬀect in section 8.3.2.4.
8.3.2.1 Predicted bias of the heterogeneity variance
Figure 8.2 shows the predicted distribution of proportional bias of heterogeneity
variance estimators in CDSR meta-analyses. The x-axis is plotted on a log scale so
that it expands around the point where bias is zero, i.e. the optimal bias. Results
for other performance measures in this analysis are presented with x-axes on similar
scales.
Figure 8.2 predicts that reasonably unbiased estimates of the heterogeneity variance
are produced in few CDSR meta-analyses using any of the estimators compared.
DL, PMDL and REML are likely to produce the highest proportion of reasonably
unbiased estimates; these methods are predicted to derive estimates with less than
10% bias (positive or negative) in roughly 40% of OR meta-analyses and 60% of
SMD meta-analyses. Slightly fewer PM estimates are predicted to have bias under
10%; 35.9% of OR meta-analyses and 48.5% of SMD meta-analyses. However, these
results suggest PM would produce the least negatively biased estimates of these four
estimators in OR meta-analyses. This is because PM has marginally less bias in
scenarios with rare events, where it is not recommended to rely on a single estimate
of heterogeneity.
As expected from the results of the last chapter, results predict that ML and SJ have
considerable bias in most CDSR meta-analyses. results predict that ML estimates
are negatively biased by more than 10% in 95.9% of OR meta-analyses and 90.8%
of SMD meta-analyses. Similarly, SJ is predicted to be positively biased (>10%) in
82.2% of OR meta-analyses and 70.4% of SMD meta-analyses.
Results predict that all estimators except ML would produce a much higher propor-
tion of positively biased estimates than negatively biased. These estimators have
positive bias in meta-analyses containing few studies, which represent most CDSR
meta-analyses. It is widely noted that DL has negative bias in certain scenarios,
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but the ﬁgure shows that in OR meta-analyses, 40.4% of DL estimates would be
positively biased and only 15.2% negatively biased by more than 10%. Less than 1%
of DL estimates in SMD meta-analyses have negative bias more than 10%.
8.3.2.2 Predicted mean squared error of the heterogeneity variance
The predicted distributions of proportional MSE are given in ﬁgure 8.4 for each of
the six included heterogeneity variance estimators. The means of these distributions
are given in table 8.2. The proportional MSE of heterogeneity variance estimates
in OR meta-analyses is typically around 0.4-0.5, which shows estimates in these
meta-analyses are usually imprecise. The proportional MSE in OR meta-analyses is
typically four times higher than in SMD meta-analyses; given the diﬀerence in scale
between OR and SMD outcome measures, they are expected to be only 1.81 times
higher [15]. This 'additional' error can be attributed to scenarios with rare events.
These results conﬁrm what was already noted in the last chapter; methods that
produce a higher proportion of negatively biased heterogeneity variance estimates
(i.e. ML and to a lesser extent DL) have a lower MSE. Of the four estimators included
with reasonable properties (DL, PM, PMDL and REML), PM has the highest MSE
because it produces the least negatively biased estimates.
8.3.2.3 Predicted bias of summary eﬀect estimates
Figure 8.3 shows the predicted distribution of bias of the summary eﬀect in CDSR
meta-analyses. Recall, the summary eﬀect represents a log odds ratio in binary
outcome meta-analyses and a standardised mean diﬀerence in continuous outcome
meta-analyses. As expected from the results of the last chapter, bias of the summary
eﬀect is consistent between all heterogeneity variance estimators compared. Results
predict that roughly 10% of OR meta-analyses produce summary eﬀects that have
small to moderate bias towards the null value. All SMD meta-analyses produce
reasonably unbiased summary eﬀect estimates.
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Figure 8.2: Predicted distribution of proportional bias of the heterogeneity
variance estimators
x-axis presented on the log scale for bias >0 and the reverse-log scale for bias<0.
Log scales are in base 10.
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Figure 8.4: Predicted distribution of proportional MSE of heterogeneity
variance estimates
x-axis presented on the log scale with base 10.
Heterogeneity variance estimator
Outcome type DL PM PMDL REML SJ ML
OR 0.358 0.500 0.429 0.408 0.638 0.203
SMD 0.103 0.129 0.118 0.118 0.133 0.060
Table 8.2: The average proportional MSE of heterogeneity variance estimates
in CDSR meta-analyses
These summary statistics are derived from the same results as in ﬁgure 8.4
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Figure 8.3: Predicted distribution of bias of the summary eﬀect (θ)
x-axis presented on the log scale for bias >0 and the reverse-log scale for bias<0.
Log scales are in base 10.
8.3.2.4 Predicted coverage of 95% conﬁdence intervals of the summary
eﬀect
Coverage of 95% conﬁdence intervals of the summary eﬀect are shown in ﬁgure 8.5.
Conﬁdence intervals are calculated by Wald-type, t-distribution and Hartung-Knapp
methods are presented in the same ﬁgure, separately for OR and SMD meta-analyses.
Figure 8.5 shows the Wald-type conﬁdence interval method rarely produces conﬁd-
ence intervals with coverage close to 95%. ML produces a lower Z-type coverage than
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Figure 8.5: Predicted distribution of the coverage of summary eﬀect
conﬁdence intervals; Wald-type, t-distribution and Hartung-Knapp.
x-axis presented on the log scale for coverage >95% and the reverse-log scale for
coverage<95%. Log scales are in base 5.
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SJ because of a large diﬀerence in bias between these methods. All other included
heterogeneity variance estimators with reasonable properties (DL, PM, PMDL and
REML) show almost identical results. For these estimators, coverage is between
93% and 97% in 30% of OR meta-analyses and 35% of SMD meta-analyses. Cover-
age is below 93% in 57% of OR meta-analyses and 67% of SMD meta-analyses and
substantially low (less than 85%) in 6.3% of OR meta-analyses and 11.4% of SMD
meta-analyses. As shown in the last chapter of results, low Z-type coverage tends to
come from meta-analyses with low numbers of studies and high underlying I2.
For t-distribution conﬁdence intervals, the predicted distribution of coverage is also
similar between the heterogeneity variance estimators compared. Most meta-analyses
produce t-distribution conﬁdence intervals far above the nominal 95% level. 68% of
OR meta-analyses and up to 65% of SMD meta-analyses have coverage above 97%.
High coverage of the t-distribution conﬁdence interval is observed in meta-analyses
with low numbers of studies (as shown in the last chapter).
Hartung-Knapp conﬁdence intervals typically perform much better than the other
two conﬁdence interval methods. Coverage is almost identical for the four heterogen-
eity variance estimators. 88% of OR meta-analyses and 95% of SMD meta-analyses
have coverage between 93% and 97%. A small proportion of OR meta-analyses have
coverage below 93%; these results come from scenarios with small studies and rare
events.
8.4 Discussion
One of the main criticisms of the DL method is that it produces negatively biased
heterogeneity variance estimates. This has been shown in the last chapter and in
previous simulation studies identiﬁed in chapter 5. Results from this analysis sug-
gests this negative bias is of concern in many meta-analyses from Cochrane reviews.
However, less expectedly, the DL method is is predicted to be positively biased in
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twice as many meta-analyses; results show 40% of CDSR meta-analyses have charac-
teristics that produce DL heterogeneity variance estimates with positive bias of more
than 10%. This is because DL is positively biased in meta-analyses containing few
studies and these simulated scenarios constitute most CDSR meta-analyses. The
predicted bias of other heterogeneity variance methods is only marginally better.
I included three other methods in this analysis that showed reasonable properties
in the last chapter; Paule-Mandel (PM), two-step DerSimonian-Laird (PMDL) and
REML. These methods would produce heterogeneity variance estimates with only
marginally improved properties in meta-analyses in practice.
I compared heterogeneity variance estimators in terms of bias of the summary eﬀect
and my conclusions are in agreement with those in the last chapter. The predicted
level of bias is consistent between all included heterogeneity variance estimators.
Results suggest that summary eﬀect estimates are approximately unbiased in all
CDSR meta-analyses with a SMD outcome measure. 12% of meta-analyses with a
log odds ratio outcome measure have negative bias greater than 0.1.
Finally, I compared heterogeneity variance estimators in terms of coverage of 95%
conﬁdence intervals of the summary eﬀect, where conﬁdence intervals were calculated
from Wald-type, t-distribution and Hartung-Knapp methods. Predicted coverage is
fairly consistent between heterogeneity variance estimators for all three conﬁdence
interval methods. Coverage of Wald-type and t-distribution conﬁdence intervals are
typically much further from the nominal 95% than anticipated in the last chapter.
Wald-type conﬁdence intervals are predicted to have coverage below 85% in up to 15%
of SMD meta-analyses and up to 8% of OR meta-analyses. This conﬁdence interval
method typically performs better in OR meta-analyses, perhaps because more of
these meta-analyses were matched to simulated meta-analyses with larger studies.
t-distribution conﬁdence intervals are predicted to have very poor performance in
most CDSR meta-analyses, with coverage of over 97%. Hartung-Knapp conﬁdence
intervals showed results that were anticipated from the last chapter; they would
perform well in most meta-analyses but should be used with caution in OR meta-
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analyses with small studies and rare events.
This analysis provides a clear summary or the simulation results but can never
replace the comprehensive exploration of results in chapter 7. The analysis method
I used here can be considered practical and pragmatic but not without criticisms.
First, matching the CDSR distributions of study sample sizes and event probabilities
to simulation scenarios was problematic. It is unlikely that the simulations are
representative of the CDSR meta-analyses in this respect. Second, by presenting
bias and MSE of heterogeneity variance estimates on the proportional scale, I made
the following implausible assumption: the consequence of a heterogeneity variance
estimate with 100% error is the same regardless of the underlying parameter value.
Finally, I excluded scenarios where studies were homogeneous (τ 2 = 0) because
results could not presented on the proportional scale. This is likely to have lead to an
underestimate of the proportion of positively biased heterogeneity variance estimates.
Furthermore, ML performs well in meta-analyses with homogeneous study eﬀects,
so these results will have exaggerated MLs negative bias. These issues are not likely
to have aﬀected my conclusions, given that I made them while also considering my
results from the last chapter. Limitations of the simulation study in chapter 7 also
apply here, given it is based on the same data. Most notably, I used a continuity
correction of 0.5 for odds ratio meta-analyses with zero events, though other methods
have been shown to perform better [113]. Other continuity corrections or methods
could have improved the predicted performance of heterogeneity variance estimators
in these results.
8.5 Conclusions
The REML heterogeneity variance estimator, recommended based on the results
from the last chapter, has a similar predicted performance to the other three estim-
ators with reasonable properties (DL, PM and PMDL). The overriding conclusion of
this analysis is that heterogeneity variance estimates in meta-analyses of Cochrane
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reviews are most likely imprecise and biased. Meta-analyses rarely have character-
istics in practice that allow for a single reliable point estimate of the heterogeneity
variance. A more substantial improvement in the 95% conﬁdence interval of the sum-
mary eﬀect is usually possible if the Hartung-Knapp method is used over Wald-type
or t-distribution methods. The method used to calculate the heterogeneity variance
estimate is unlikely make a substantial impact on coverage of the Hartung-Knapp
conﬁdence interval. A single estimate of the summary eﬀect and its random-eﬀects
conﬁdence interval is usually suﬃcient even in meta-analyses with few studies and
sensitivity analysis is usually not required in this respect. In random-eﬀects meta-
analyses, conclusions should not be drawn directly from a single point estimate of
heterogeneity without ﬁrst considering its uncertainty and likely level of bias.
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Chapter 9
Discussion and conclusions
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9.1 Introduction
There is often heterogeneity across studies in a meta-analysis that cannot be ex-
plained by known study characteristics. It is therefore common to assume a random-
eﬀects model, which includes an additional study variance component known as the
heterogeneity variance parameter. This parameter is commonly estimated by the
DerSimonian-Laird method [25]. Prior to conducting this research, simulation stud-
ies found that DerSimonian-Laird produces negatively biased estimates in certain
scenarios [78, 79, 102, 124]. This estimator continues to be the default method
for random-eﬀects meta-analysis, partly because there is no consensus over which
method, if any, should be used in its place. In this thesis, I reviewed available
methods for heterogeneity variance estimation, investigated their properties in em-
pirical and simulated meta-analysis data and made recommendations for future meta-
analyses in health research.
A chapter-by-chapter summary of the content and main ﬁndings of this thesis is
given in section 9.2. In section 9.3, I discuss the applicability of the ﬁndings from
my research and its limitations. I make ﬁnal conclusions in section 9.5.
9.2 Thesis summary
Chapters 1 to 3 are introductory chapters that detail all statistical methods for
random-eﬀects meta-analysis that are relevant to the rest of the thesis. In chapter
1, I introduced the concept of meta-analysis and methods for statistically combin-
ing studies to provide a summary eﬀect. In chapter 2, I presented a comprehensive
methodological review of heterogeneity variance estimators. I drew attention to
methodological connections between methods and, in the case of Paule-Mandel and
empirical Bayes, found they are identical and only expressed in diﬀerent terms. In
chapter 3, I introduced a number of methods for estimating the conﬁdence interval of
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the mean eﬀect; it was deemed relevant to introduce these methods because I com-
pare heterogeneity variance estimators in terms of their impact on these conﬁdence
intervals in many later chapters.
After collating and reviewing the relevant methods, I investigated empirically whether
choosing a method other than DerSimonian-Laird signiﬁcantly changes the hetero-
geneity variance estimate and conclusions of a meta-analysis. I compared a wide
selection of methods in 12,894 meta-analyses from the Cochrane Database of Sys-
tematic Reviews (CDSR). Results showed high discordance between heterogeneity
variance estimates between most methods, with diﬀerences on the scale of the I2
statistic of up to 50%. I investigated whether meta-analysis characteristics, such as
study sizes and sparsity of data, could have an impact on these diﬀerences. I found
no convincing patterns, which suggests that diﬀerences are related to diﬀerences in
the methods that apply regardless of the meta-analysis characteristics. Estimated
summary eﬀects derived from diﬀerent heterogeneity estimation methods showed
a much higher level of agreement. However, there was discordance in the level of
statistical signiﬁcance of the mean eﬀect between methods in a small percentage of
meta-analyses. Findings from this empirical analysis gave motivation for the rest of
the thesis.
Next, in chapter 5, I presented the results of a systematic review of simulation
studies that compare heterogeneity variance estimators. I identiﬁed twelve simula-
tion studies that matched the inclusion criteria, but only four could be considered
comprehensive and unbiased [78, 79, 96, 124]. The other eight simulation studies
recommended their own newly proposed estimator and often compared them with
very few other methods. I found the Paule-Mandel (PM) estimator performed well in
both binary and continuous outcome meta-analyses and was recommended based on
the ﬁndings of three simulation studies [3, 78, 79]. However, inconsistency between
recommendations of other simulation studies, and a number of limitations in their
designs, meant that a new simulation study was justiﬁed.
The design of a new simulation study is presented in chapter 6 and addresses the
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limitations found in other previous simulation studies. To minimise the conﬂict of
interest that was present in many previous studies, many collaborators gave input
into the study design and only pre-existing estimators are compared. The main
results of this simulation study are presented in chapter 7. Findings conﬁrm the
DerSimonian-Laird is negatively biased in binary outcome meta-analyses with rare
events and/or where meta-analyses contain small studies; within-study variances
are imprecise and often biased in these scenarios. The Paule-Mandel estimator,
recommended most frequently in previous simulation studies, has better properties
than DerSimonian-Laird overall and is negatively biased only in the most extreme
cases where all methods perform poorly. However, results of this study revealed that
Paule-Mandel estimates have higher positive bias in meta-analyses with moderate
to large diﬀerences in study size. This can be attributed to Paule-Mandel's random-
eﬀects study weights, which can assign a relatively large weight to small studies. The
two-step DerSimonian-Laird estimator or REML are a good compromise between
these two methods.
A secondary analysis of the simulated data is presented in chapter 8. Results of
this analysis predicted the likely properties of heterogeneity variance estimators in
meta-analyses from the CDSR dataset. Findings from this analysis suggest that
heterogeneity variance estimates are likely to be biased and imprecise in most meta-
analyses in practice regardless of which method is used. The two-step DerSimonian-
Laird estimator oﬀers only a minimal improvement over DerSimonian-Laird. More
promisingly, in most meta-analyses, estimates of the mean eﬀect are unbiased and
its Hartung-Knapp conﬁdence interval has coverage close to the nominal 95%.
9.3 Discussion
I consider my thesis to have thoroughly examined the properties of heterogeneity
variance estimators in frequentist meta-analyses. I assessed their properties in a wide
range of scenarios in both binary and continuous outcome data, summarised using
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odds ratio and standardised mean diﬀerence measures respectively. These measures
make up only 37% and 24% of binary and continuous outcome CDSR meta-analyses
respectively (see chapter 4), but I believe my ﬁndings apply to other measures. The
relative risk is used in 62% of CDSR meta-analyses with a binary outcome, and my
review of previous simulation studies (chapter 5) suggests properties in these meta-
analyses are comparable with odds ratio meta-analyses. My ﬁndings can also apply
to meta-analyses that use a (unstandardised) mean diﬀerence measure, which make
up 76% of continuous outcome CDSR meta-analyses. Viechtbauer [124] conducted
a simulation study of both standardised and unstandardised mean diﬀerence meta-
analyses and found properties were reasonably consistent between the two measures.
Findings in this thesis may suggest how heterogeneity variance estimators perform
in meta-analyses of other types of data. For time-to-event outcomes, study results
may be expressed in terms of hazard ratios, which can be interpreted as the relative
risk of an event occurring per unit of time [112, 118]. Therefore, they share many of
the same properties of relative risks in non-time-to-event data [65]. Standard errors
of hazard ratios are large when few events are observed and therefore, the size of the
study is correlated with the hazard ratio. It is not possible to identify the number
of meta-analyses in the CDSR dataset with time-to-event outcomes, however, Davey
et al. [21] suggests the proportion could be up to 4%. It is possible that the issues
identiﬁed for odds ratio meta-analyses with rare events, as observed in my simulation
study, are also present for meta-analyses of hazard ratios. A new simulation study
would be required to conﬁrm this.
Methods for meta-analyses of diagnostic accuracy studies are more diverse because
test performance depends on the deﬁned threshold value [23, 112]. However, for a
given threshold, study results can be presented as a binary 2x2 contingency table
that includes the number of true and false-positives and negatives [23]. Likelihood
ratios or diagnostic odds ratios can be derived from these tables. Findings in this
thesis from binary outcome meta-analyses may be applied to meta-analyses of these
summary statistics. Studies can be summarised in other ways, such as sensitivity,
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speciﬁcity, or through the whole Receiver Operating Curve (ROC), in which proper-
ties of the heterogeneity variance are likely to be diﬀerent. The number of diagnostic
accuracy meta-analyses in the CDSR dataset is likely to be small [70]. No simulation
studies that compare heterogeneity variance estimators in time-to-event or diagnostic
accuracy meta-analyses were identiﬁed in the systematic review in chapter 5.
I compared methods to estimate the heterogeneity variance in meta-analyses of ag-
gregate data throughout this thesis. Individual participant data (IPD) can also be
combined in a meta-analysis in one or two stages. A two-stage approach calculates
study-level aggregate data from IPD, so my results can trivially be applied in this
setting. Other IPD meta-analyses use a one-stage approach [104], which involves
multi-level modelling and the calculating the heterogeneity variance simultaneously
with all other parameters in the model. This may be preferred over the aggregate
two-stage approach because it allows subject-level covariates to be added into the
model and a more thorough investigation into the causes of heterogeneity [105]. Of
the heterogeneity variance estimators mentioned in this thesis, only the maximum
likelihood, REML and Bayesian methods can be applied in this setting. Methods
are also available to combine study-level 2x2 contingency tables in binary outcome
meta-analyses [103, 121], which generally use REML methods for heterogeneity vari-
ance estimation. This approach may lead to improved estimates of the heterogeneity
variance in meta-analyses with sparse data, but there currently been little simulation
research in this area.
I introduced a number of Bayesian approaches to heterogeneity variance estimation
in chapter 2. Those that require a subjective prior distribution were not compared
in further chapters because of diﬃculties in deﬁning them in simulated data and
empirical meta-analysis data out of context. Bayesian methods naturally avoid zero
heterogeneity variance estimates and may also increase precision in meta-analyses
with few studies, which constitute most meta-analyses in Cochrane reviews. Turner
et al. [120] and Rhodes et al. [88] deﬁne informed prior distributions for binary and
continuous outcome meta-analyses respectively. These priors are based on previous
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meta-analyses from the CDSR dataset and deﬁned separately for each disease area.
A full Bayesian approach is likely to lead to improved estimates of the heterogeneity
variance when reliable and informative priors are available. However, this is not
always the case, particularly in disease areas with few previous meta-analyses [88].
Random-eﬀects meta-analysis, and most heterogeneity variance methods, are built on
the assumption of normally distributed eﬀects [48]. However, my simulation results,
and those from Kontopantelis et al. [64], show heterogeneity variance methods are
robust to all but the most extreme distributions of study eﬀects. Publication bias is
potentially more of an issue for heterogeneity variance estimation. In meta-analyses
with publication bias, the size of the study eﬀects are correlated with study size.
This issue was deemed beyond the scope of this thesis. Assessing the properties of
heterogeneity variance methods in simulated meta-analyses with publication bias is
problematic. Studies could be systematically excluded to simulate publication bias
but this would not preserve the parameters of the underlying distribution. Methods
will inevitably perform poorly in the presence of signiﬁcant publication bias, but this
is understandable.
A continuity correction of 0.5 was applied to all binary outcome meta-analyses with
zero events in my simulation study. This correction factor was chosen because it's
widely used and the default method in the software Revman [87]. Other methods
for dealing with zero events are available [10, 30]. In particular, a one-stage logistic
regression modelling approach has been shown to produce less biased odds ratio
estimates than the methods I used [113]. The decision to use this correction factor
may have aﬀected results in scenarios with rare outcomes. However, it is unlikely
that using a diﬀerent correction factor would have aﬀected conclusions, particularly
in scenarios with extremely rare events where all heterogeneity variance estimates
had considerable negative bias.
Table 9.1 summarises the heterogeneity variance estimation methods available in
the main statistical software packages at the time of writing. I include the four
estimators that have the most reasonable properties (DerSimonian-Laird, two-step
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DerSimonian-Laird, Paule-Mandel and REML) and full Bayes. WinBUGS [87] is the
only software in which the DerSimonian-Laird estimator is not available; this is only
because WinBUGS is software that specialises in Bayesian methods. DerSimonian-
Laird is the only available estimator in Revman [87] and is the software used to
conduct all Cochrane systematic reviews. The two-step DerSimonian-Laird estimator
(PMDL) is not readily available in any statistical software. The packages meta [99]
and metafor [126] in R [85] can produce PMDL estimates only by restricting the
Paule-Mandel iterative process to two steps. PMDL is not available in any software
package because it is widely considered as a simpliﬁed version of Paule-Mandel, and
therefore assumed to have inferior properties.
9.4 Further work
I have identiﬁed several limitations that came to light during the conduct of my
research and discussed them in the last section. They were not addressed in this
thesis mainly because of time and length constraints and were arguably inevitable
given the scale of the problem of heterogeneity variance estimation in meta-analysis. I
now suggest potential areas for further research to address many of these limitations.
9.4.1 Logistic regression models for meta-analysis
I discussed logistic regression methods in the last section that can be used to com-
bine 2x2 contingency table data in binary outcome meta-analyses [103, 121]. This
method makes full use of study data that is often readily available from these study's
published results. There are a limited number of heterogeneity variance estimation
methods available for use in combination with this method, but one of which is
REML, which I showed has reasonable properties in aggregate data meta-analyses.
A simulation study would be of beneﬁt to compare the properties heterogeneity
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variance estimates derived from this method (using REML) and aggregate data es-
timation methods (using REML and the two-step DerSimonian-Laird heterogeneity
variance estimators).
9.4.2 Distributions of study size
In the simulation study in chapters 6 - 8, meta-analyses were generated with study
sizes derived from ﬁve diﬀerent distributions representing a variety of sizes and also
a wide variety of diﬀerences in study size. These could not be considered a compre-
hensive selection of distributions, but had a substantial impact on the the properties
of estimators. A new simulation study would be of beneﬁt for further exploration
in a wider variety of distributions. Distributions that are yet to be explored and
may reveal interesting results include; (1) few small studies and many large studies,
(2) many large studies and few small studies, (3) uniformly distributed from small
to large, (4) negatively skewed (producing more large studies than small), and (5)
positively skewed (producing more small studies than large).
9.4.3 Wider strategies for heterogeneity variance estimation
in problem meta-analyses
I showed in the last chapter that heterogeneity variance estimates are usually im-
precise and biased in meta-analyses in practice. Therefore, we can rarely rely on a
single estimate when making inference on the degree of heterogeneity and a wider
strategy in these scenarios is required. I recommend sensitivity analysis in these
meta-analyses, but further research may be required to investigate the potential
impact of diﬀerent sensitivity analysis strategies.
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9.4.4 Conﬁdence intervals for the heterogeneity variance
Finally, it is imperative that conﬁdence intervals for the heterogeneity variance are
reported as standard in meta-analyses to express the uncertainty around their estim-
ates. Many conﬁdence intervals are available for this purpose [122], so a systematic
review may be required to ﬁnd if there is consensus over which conﬁdence interval
method has the best properties. Recommendations from this research would form
part of the wider strategy for addressing the issue imprecise estimates, as I mentioned
above.
9.4.5 Implementation in statistical software
Finally, to encourage the use of the two-step DerSimonian-Laird estimator in future
meta-analyses, its code must be implemented into statistical software packages and
ideally be the default option. My recommendation diﬀers from the recommendations
of other comprehensive simulation studies [78, 79, 124], and an editorial letter to Co-
chrane [123]; these recommend the iterative Paule-Mandel estimator and/or REML
for use in practice. Therefore, it may take time for the dissemination of my research
to impact on meta-analysis methods in statistical software.
9.5 Conclusion
DerSimonian-Laird is the most commonly used method to estimate the heterogeneity
variance in meta-analysis, and produces negatively biased estimates in meta-analyses
of binary data with rare events and/or meta-analyses containing only small studies.
The Paule-Mandel estimator produces estimates with negative bias only in extreme
cases where all meta-analysis method fail, and where conducting the meta-analysis at
all is questionable. However, Paule-Mandel produces estimates with a higher positive
bias than DerSimonian-Laird in meta-analyses with moderate to large diﬀerences in
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study size. The two-step DerSimonian-Laird estimator and REML are shown in my
simulation study to have the best properties of both these methods. I recommend
REML given that it is already widely known and available in most statistical software
packages. I recommend the Hartung-Knapp conﬁdence interval for the summary
eﬀect and advise caution when making inference on this only in binary outcome
meta-analyses with rare events.
More importantly, heterogeneity variance estimates derived from any method in a
two-stage meta-analysis are usually imprecise and either negatively or positively
biased in practice. I recommend the reporting of conﬁdence intervals for the hetero-
geneity variance estimate and I2. Recent studies have found these conﬁdence inter-
vals are rarely reported in practice [56], which can mislead researchers into thinking
the level of heterogeneity is known. I recommend sensitivity analyses, particularly if
the researcher believes conclusions could change solely based on a change is the level
of heterogeneity present. Sensitivity analysis are rarely required for inference on the
the summary eﬀect alone if the Hartung-Knapp conﬁdence interval method is used.
My thesis has demonstrated many of the problems inherent in estimating hetero-
geneity in a meta-analysis. The DerSimonian-Laird approach has been criticised in
the past, and I recommend that the REML or two-step DerSimonian-Laird estim-
ators be used instead. The use of the Hartung-Knapp conﬁdence interval could also
provide a more realistic interpretation of uncertainly of the summary eﬀect in het-
erogeneous meta-analyses. None of these methods are perfect however, and caution
should always be exercised when estimating heterogeneity or I2, particularly when
there are few studies or events are rare. In such circumstances comparing several
estimates of heterogeneity may be useful. This work highlights the fact that our
response to heterogeneity should not begin and end with performing a single ran-
dom eﬀects analysis; we should always seek to investigate potential causes of any
identiﬁed heterogeneity.
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Recommendations:
 There is no method likely to produce an accurate estimate of the heterogeneity
variance in most two-stage meta-analyses in Cochrane reviews. Therefore, a
conﬁdence interval for this estimate should always be reported.
 REML heterogeneity variance estimates generally have the most reasonable
properties, so this method is recommended. Two-step DerSimonian-Laird is a
good alternative when iteration for REML fails to converge.
 The Hartung-Knapp conﬁdence interval method for the summary eﬀect is re-
commended over Wald-type methods.
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Appendix A: Supplementary material
from chapter 2
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A.1 Search strategy
The following search criteria was designed to identify methods to estimate the het-
erogeneity variance parameter and its conﬁdence interval in Veroniki et al. [122]. My
thesis does not compare conﬁdence interval methods for this parameter, so papers
that relate solely to these methods were excluded from my review. PubMed was
searched to identify research articles and references of each article were scanned for
additional relevant literature. The following search criteria was used:
((heterogen*[Title/Abstract]) OR (*consisten*[Title/Abstract]) OR (between
- study variance*[Title/Abstract]) OR (between - trial variance*[Title/Abstract]))
AND (meta - analys*[Title/Abstract]) AND ((random eﬀect*[Title/Abstract])
OR (mixed eﬀect*[Title/Abstract]) OR (meta - regress*[Title/Abstract]))
AND ((distribution) OR ( prior) OR (prediction) OR (estimat*) OR
(overall treatment eﬀect*) OR (summary treatment eﬀect*) OR (pooled
eﬀect*) OR (conﬁdence interval*) OR (bias*) OR (error*) OR (power)
OR (simulation*) OR (coverage probability*) OR (mean square* AND
error*))
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Appendix B: Supplementary material
from chapter 4
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Figure B.1: Bland-Altman scatter plots comparing I2 estimates from diﬀerent
heterogeneity variance methods excluded from the main results
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Figure B.2: Bland-Altman scatter plots comparing τ2 estimates from diﬀerent
heterogeneity variance methods.
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Appendix C: Supplementary material
from chapter 5
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C.1 Search strategy
We searched MEDLINE and the Web of Science core collection using the following
strategy:
1. meta-* OR heterogen* [Title]
2. random eﬀect* OR random-eﬀect* OR mixed eﬀect* OR meta-regress* OR
sequential meta-analys* [Title/Abstract]
3. compar* OR simulat* OR mean square* OR bias* OR estimat* [Title/Ab-
stract]
4. between-trial OR (between-study OR heterogen* OR *consisten* OR DerSi-
monian* [Title/Abstract]
5. cancer OR stroke OR blood OR arthritis OR alcohol OR depress* OR infect*
OR diabetes OR disease* OR illness* OR surviv* OR smok* OR risk OR
vitamin* OR therapy OR surgery [Title]
6. (#1 AND #2 AND #3 AND #4) NOT #5
To reduce the number of applied meta-analyses from the search results, publications
with selected common medical terms in the title were excluded (#5). The search
strategy needed to be adapted for JSTOR for two reasons: (1) There is a limit to
the number of search terms that can be used and (2) Only 10% of publications in
the database include abstracts and so "Title/Abstract" terms were searched within
the full text instead. The JSTOR search strategy was as follows:
1. meta anal* [Title]
2. random eﬀect* [Full Text]
3. compar* OR simulat* OR mean square* OR bias* [Full Text]
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4. heterogen* [Full Text]
5. #1 AND #2 AND #3 AND #4
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C.2 Performance measures in simulated data
Measure Notation Details
Measures relating to τ2
Bias bias
(
τˆ2
)
E
[
τˆ2
]− τ2
MSE MSE
(
τˆ2
)
E
[(
τˆ2 − τ2)2]
Variance V ar
(
τˆ2
)
E
[(
τˆ2 − E [τˆ2])2]
Eﬃciency e
(
τˆ2
)
I
−1−
F
var (τˆ2)
where I
−1−
F is Fishers information:
I
−1−
F = 2
[
k∑
i=1
1(
τ2 + σ2i
)]−1
Proportion of
zero estimates
P (τˆ2 = 0) The proportion of zero estimates of τˆ2
Measures relating to θ
Bias bias
(
θˆ
)
E
[
θˆ
]
− θ
MSE MSE
(
θˆ
)
E
[(
θˆ − θ
)2]
Measures relating to conﬁdence intervals for θ
Coverage cov (CIx) The proportion of conﬁdence intervals for xˆ that contain x
Error interval
estimation
EI (CIx) A ratio between the observed and the true conﬁdence interval
widths. For example, in the case when x = θ, then
EI (CIθ) =
upperCIθ − lowerCIθ
3.92
√(∑k
i=1
(
τ2 + σˆ2i
)−1)−1
Table C.1: Performance measures in simulated data
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Appendix D: Supplementary material
from chapter 6
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D.1 Tables of τ 2 parameter values
Outcome
measure
Study sizes
Event
prob
I
2
=
1
5
%
I
2
=
3
0
%
I
2
=
4
5
%
I
2
=
6
0
%
I
2
=
7
5
%
I
2
=
9
0
%
I
2
=
9
5
%
τ2
OR small 0.5 0.067 0.178 0.344 0.633 1.33 4.5 15.6
small-to-medium 0.5 0.0144 0.0333 0.0655 0.122 0.244 0.78 1.67
medium 0.5 0.0067 0.0174 0.0333 0.056 0.122 0.367 0.78
small and large 0.5 0.0025 0.0066 0.0144 0.023 0.0756 0.356 0.78
large 0.5 0.0001 0.0023 0.00456 0.0082 0.0166 0.045 0.01
small 0.1 to 0.5 0.0944 0.233 0.445 0.856 1.89 20 -
small-to-medium 0.1 to 0.5 0.0178 0.0433 0.0855 0.1545 0.322 1.11 2.3
medium 0.1 to 0.5 0.0089 0.0233 0.0433 0.078 0.156 0.45 1.11
small and large 0.1 to 0.5 0.0036 0.0084 0.0178 0.0356 0.0945 0.456 1.22
large 0.1 to 0.5 0.0012 0.0023 0.00589 0.0107 0.0222 0.0645 0.134
small 0.05 0.422 1.156 2.56 7.56 - - -
small-to-medium 0.05 0.0755 0.189 0.378 0.745 1.78 - -
medium 0.05 0.034 0.0967 0.189 0.356 0.756 3.44 -
small and large 0.05 0.0144 0.0345 0.0745 0.167 0.433 2.3 -
large 0.05 0.0053 0.0133 0.0255 0.0445 0.089 0.23 0.56
small 0.01 2.78 14.5 - - - - -
small-to-medium 0.01 0.378 1.11 2.45 6.7 - - -
medium 0.01 0.12 0.45 1.067 2.44 7.8 - -
small and large 0.01 0.0656 0.178 0.34 0.1 3.67 - -
large 0.01 0.0245 0.0622 0.122 0.233 0.478 1.78 -
SMD small - 0.0178 0.0444 0.0845 0.156 0.322 0.1 2.44
small-to-medium - 0.0035 0.00856 0.0156 0.023 0.056 0.12 0.34
medium - 0.0018 0.00444 0.00844 0.01545 0.0311 0.089 0.12
small and large - 0.0007 0.00156 0.00344 0.00744 0.0189 0.089 0.12
large - 0.0002 0.0006 0.0011 0.0021 0.0042 0.0133 0.0256
Table D.1: τ2 parameter values for each simulated scenario.
τ 2consistent between numbers of studies and distributions of study eﬀects. I2 = 0%
is not included in this table, because it always corresponds to τ 2 = 0. Parts of the
table marked with a dash are where there is no such τ 2 that produces meta-analyses
with the given mean I2
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Outcome
measure
Study sizes
Event
prob
I
2
=
1
5
%
I
2
=
3
0
%
I
2
=
4
5
%
I
2
=
6
0
%
I
2
=
7
5
%
I
2
=
9
0
%
I
2
=
1
9
5
%
90% reference range of underlying I2
OR small 0.5 14 - 15 30 - 31 44 - 46 59 - 61 73 - 76 88 - 92 91 - 97
small-to-medium 0.5 10 - 20 20 - 36 33 - 53 48 - 67 64 - 81 86 - 93 92 - 96
medium 0.5 15 - 15 30 - 30 45 - 45 59 - 60 74 - 75 90 - 90 95 - 95
small and large 0.5 1 - 20 3 - 40 6 - 58 13 - 75 27 - 88 63 - 97 78 - 99
large 0.5 14 - 17 27 - 32 42 - 48 57 - 63 72 - 77 89 - 91 94 - 95
small 0.1 to 0.5 12 - 17 25 - 34 40 - 49 54 - 65 69 - 80 60 - 97 -
small-to-medium 0.1 to 0.5 9 - 20 20 - 36 32 - 54 48 - 68 62 - 81 84 - 93 92 - 97
medium 0.1 to 0.5 12 - 17 26 - 34 40 - 49 55 - 64 70 - 78 88 - 92 93 - 96
small and large 0.1 to 0.5 1 - 22 3 - 40 6 - 59 10 - 74 24 - 88 59 - 97 78 - 99
large 0.1 to 0.5 12 - 18 24 - 34 39 - 50 53 - 65 70 - 79 87 - 92 94 - 96
small 0.05 13 - 16 25 - 34 35 - 52 28 - 72 - - -
small-to-medium 0.05 10 - 19 19 - 36 34 - 53 47 - 68 60 - 82 - -
medium 0.05 15 - 16 29 - 31 43 - 47 58 - 62 71 - 77 84 - 93 -
small and large 0.05 1 - 20 3 - 39 6 - 57 12 - 75 25 - 88 58 - 98 -
large 0.05 13 - 17 27 - 33 42 - 49 57 - 63 72 - 77 89 - 92 93 - 96
small 0.01 10 - 19 3 - 45 - - - - -
small-to-medium 0.01 9 - 19 18 - 38 28 - 55 30 - 74 - - -
medium 0.01 14 - 16 27 - 32 38 - 50 47 - 67 47 - 84 - -
small and large 0.01 1 - 20 3 - 40 6 - 58 12 - 77 19 - 91 - -
large 0.01 13 - 16 27 - 33 41 - 48 56 - 63 70 - 78 86 - 92 -
SMD small - 15 - 15 29 - 30 44 - 46 60 - 61 74 - 76 89 - 91 94 - 96
small-to-medium - 9 - 19 20 - 36 33 - 53 46 - 67 64 - 80 85 - 93 92 - 96
medium - 15 - 15 30 - 30 45 - 45 60 - 60 75 - 75 89 - 90 95 - 95
small and large - 1 - 21 3 - 39 6 - 57 12 - 74 26 - 88 63 - 97 79 - 99
large - 13 - 16 27 - 33 42 - 48 57 - 63 73 - 77 89 - 91 94 - 95
Table D.2: 90% reference range of underlying I2 values for each simulated
scenario.
τ 2consistent between numbers of studies and distributions of study eﬀects. I2 = 0%
is not included in this table, because it corresponds only to τ 2 = 0. Parts of the
table marked with a dash are where there is no such τ 2 that produces meta-analyses
with the given mean I2
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D.2 R code for all heterogeneity variance estimators
#######################################################################
# R code for calculating all heterogeneity estimates in one function #
#######################################################################
#######################################
#list of arguments and their meanings #
#######################################
#xi - vector of effect estimates for each study. If the outcome is
# odds ratio (for example), we assume that xi is already converted to
# log odds -ratios. log argument can be used to convert output back onto
# the original scale after all heterogeneity estimates have been
# calculated
#
#sei - vector of standard errors for each study.
#
#hetest - vector of heterogeneity estimators that you would like to be
# calculated. The default is NULL , which means all estimates are
# calculated.
#
#signiftau2 - number of significant figures to round tau2 estimates
# (inc confidence intervals)
#
#maxit - maximum number of iterations allowed where the process of
# estimating tau2 involved iteration
#
#output - TRUE if output is displayed , FALSE otherwise (stops too much
# output when we are running the program iteratively)
#
#tau2.0 - starting value of iterative estimators
#
### PARAMETERS SPECIFIC TO AB... note that 2 out of 3 are required to
# calculate the estimate:
#eta - shape parameter of the prior distribution
#lambda - spread parameter of the prior distribution
#tau2prior - prior estimate of heterogeneity
#
### PARAMETERS SPECIFIC TO HS2
#Ntot - total sample size in meta -analysis (over both treatment groups)
#
### PARAMETERS SPECIFIC TO IPM (nci and nti are also used for the MBH
### estimator)
#nci - sample size of the control group
#nti - sample size of the treatment group
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#eci - number of events in the control group
#
### PARAMETERS SPECIFIC TO DLp
#DLpos - truncation value as an alternative to zero with the original
# DL estimator
#
### PARAMETERS SPECIFIC TO DLb
#bsamp - number of bootstrap samples
#
#PARAMETERS SPECIFIC TO MBH
#corrbias - corrects xi for bias if TRUE , only functional for MBH
# estimator (using the method of Malzahn et al 2000)
#
#######################################
#list of estiamtors and their acornyms#
#######################################
##### General MoM approaches
#CA - Cochran 's ANOVA
#DL - DerSimonian -Laird
#PM - Paule Mandel
#CA2 - Two step PM with CA initial estimate
#DL2 - Two step PM with DL initial estimate
#IPM - Improved Paule -Mandel (binary outcome data only) - uses arguments
# eci , nci and nti
#DLp - Positive DerSimonian -Laird estimate , with truncation at 0.01
#DLb - bootstrap version of DerSimonian -Laird
#### Other approaches
#HM - Hartung Makambi
#HS - Hunter Schmidt (original estimator using FE weightings)
#SJ - Sidik Jonkman
#SJ2 - An improvement on Sidik Jonkman
#MBH - Malzahn , Bohning and Holling (from original paper Malzahn 2000)
#### Maximum Likelihood approaches
#ML - Maximum Likelihood
#REML - Restricted Maximum Likelihood
#ARML - Approximate Restricted Maximum Likelihood
#### Bayesian Approaches
#EB - Empirical Bayes
#AB - Approximate Bayes
#B0 - Rukhin Bayes with zero prior (with correction for sum(n))
#BP - Rukhin Bayes with simple prior
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hetest <- function(xi=lSS , sei=seSS , Ntot=NULL , nci=NULL , nti= NULL ,
eci=NULL , eta=NULL , lambda=NULL , tau2prior=NULL , DLpos =0.01,
bsamp =5000, SMD=FALSE , hetest=NULL , signiftau2 =6, maxit =100,
tau2 .0=NULL , trunc=TRUE , output=TRUE) {
#if no specific set of estimates is required , calculate them all...
if (is.null(hetest )) hetest <- c("CA","DL","PM","IPM","CA2",
"DL2","DLp","DLb","HM","HS","SJ","SJ2","MBH","ML","REML",
"ARML","AB","B0","BP")
#clear the variables that may have been defined previously when this
#function was run so that we can start again fresh
CA_est <-DL_est <-PM_est <-IPM_est <-CA2_est <-DL2_est <-as.numeric(NA);
DLp_est <-DLb_est <-HM_est <-HS_est <-SJ_est <-SJ2_est <-as.numeric(NA);
MBH_est <-ML_est <-REML_est <-ARML_est <-AB_est <-B0_est <-as.numeric(NA);
B0K_est <-BP_est <-as.numeric(NA);
#assume equal sample sizes in arms
if (!is.null(Ntot) & is.null(nci) & is.null(nti)) {
Ntot <- nci + nti
}
if (!is.null(Ntot) & is.null(nci) & is.null(nti)) {
nci <- nti <- round(Ntot/2,digits =0)
}
Kest <- length(hetest) # number of estimates to be calculated
esti <- 1
#^a counter so that we can create a dataset with a separate estimate
#on each row the first specified estimate will be in row 1 ... etc.
#### specifying all output vectors before replacing the values with
#### actual estimates.
name <- rep(NA,Kest)
tau2 <- rep(NA,Kest)
#theta not needed for output , just for the process of calculating some
#of the tau2 estimates
theta <- rep(NA ,Kest)
#bias correction if the meta -analysis has an SMD outcome measure
#keep unadjusted SMDs for MBH estimator
if (SMD) {
xi_unadj <- xi
sei_unadj <- sei
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J <- 1- (3/(4*( Ntot -2) - 1))
xi <- xi*J
sei <- sqrt((sei ^2)*(J^2))
}
K <- length(xi) #K=number of studies in the meta -analysis
vi <- sei^2 #variance of each study
wFEi <- 1/vi
FEtheta <- sum(xi*wFEi)/sum(wFEi)
#DerSimonian Laird
if ('DL ' %in% hetest) {
name[esti] <- "DL"
DLw <- 1/vi
theta[esti] <- sum(xi*(DLw))/ sum((DLw))
DLtausq1 <- sum(DLw*((xi-theta[esti ])^2)) - (sum(DLw*vi)) +
(sum((DLw ^2)*vi)/sum(DLw))
DLtausq2 <- sum(DLw) - (sum(DLw ^2)/ sum(DLw))
if (trunc) DL_est <- tau2[esti]<- max(0,DLtausq1/DLtausq2)
else DL_est <- tau2[esti]<- DLtausq1/DLtausq2
esti <- esti + 1
}
#DerSimonian Laird
if ('DLp ' %in% hetest) {
name[esti] <- "DLp"
DLw <- 1/vi
theta[esti] <- sum(xi*(DLw))/ sum((DLw))
DLtausq1 <- sum(DLw*((xi-theta[esti ])^2)) - (sum(DLw*vi)) +
(sum((DLw ^2)*vi)/sum(DLw))
DLtausq2 <- sum(DLw) - (sum(DLw ^2)/ sum(DLw))
if (trunc) DLp_est <- tau2[esti]<- max(DLpos ,DLtausq1/DLtausq2)
else DLp_est <- tau2[esti]<- DLtausq1/DLtausq2
esti <- esti + 1
}
#DerSimonian Laird
if ('DLb ' %in% hetest) {
name[esti] <- "DLb"
DLw <- 1/vi
theta[esti] <- sum(xi*(DLw))/ sum((DLw))
#number of possible combinations given the number of studies
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#if K=9 then there are 24310 possible combinations , much more
#samples than would ever be needed. so no need to calculate perm
if (K<9) perm <- factorial (2*K - 1) / (factorial(K)* factorial(K-1))
else perm <- bsamp -1
#if the number of combinations is small , then no need to do all
#bootstraps , just take complete sample ...
if (perm <= bsamp) {
comb_DLb <- combinations(n=K, r=K, repeats.allowed=TRUE)
no_samples <- perm
}
#if the number of combinations is large then just do a sample ...
else {
comb_DLb <- t(replicate(bsamp ,sample (1:K,K,replace = TRUE )))
no_samples <- bsamp
}
DLb_est2 <- rep(NA,times=no_samples)
for (i in 1: no_samples) {
studycomb <- comb_DLb[i,]
theta_b <- sum(xi[studycomb ]*( DLw[studycomb ]))/
sum((DLw[studycomb ]))
DLtausq1_b <- sum(DLw[studycomb ]*((xi[studycomb]-theta_b )^2)) -
(sum(DLw[studycomb ]*vi[studycomb ])) +
(sum((DLw[studycomb ]^2)*vi[studycomb ])/ sum(DLw[studycomb ]))
DLtausq2_b <- sum(DLw[studycomb ]) - (sum(DLw[studycomb ]^2)/
sum(DLw[studycomb ]))
if (trunc) DLb_est2[i] <- max(0, DLtausq1_b/DLtausq2_b)
else DLb_est2[i] <- DLtausq1_b/DLtausq2_b
}
DLb_est <- tau2[esti]<- mean(DLb_est2)
esti <- esti + 1
}
#Cochran ANOVA
if ('CA ' %in% hetest | 'ML' %in% hetest | 'REML ' %in% hetest) {
#to calculate REML , we need a starting value of tau2_ML , or else
#there may be more than 1 solution.
CAw <- rep(1/K,times=K)
theta[esti] <- sum(xi*CAw)/sum(CAw)
CAtausq1 <- sum(CAw*((xi-theta[esti ])^2)) - (sum(CAw*vi)) +
(sum((CAw ^2)*vi)/sum(CAw))
CAtausq2 <- sum(CAw) - (sum(CAw ^2)/ sum(CAw))
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CA_est <- max(0,CAtausq1/CAtausq2)
if ('CA ' %in% hetest ){
if (trunc) tau2[esti]<- max(0,CAtausq1/CAtausq2)
else tau2[esti]<- CAtausq1/CAtausq2
name[esti] <- "CA"
esti <- esti + 1
}
}
#Paule Mandel
if ('PM ' %in% hetest) {
quant <- df <- K-1
#degrees of freedom and expected mean under the fixed effects
#assumption
PMtau2out <- 1
# just set an initial value for PM estimate for output
if (is.null(tau2 .0)) PMtausq <- 0 #initial estimate of tau2
else PMtausq <- tau2.0
PMit <- 1 #iteration number
PM_F <- 1 #just to get the iteration started. F=0 => convergence
while (PM_F !=0){
#first calculate the the pooled effect based on present
#estimate of tausq
PMw = 1/(sei^2+ PMtausq)
PMyW = sum(xi*PMw)/sum(PMw)
#equation comes from DerSimonian and Kacker 2007
Q1 <- sum(PMw*(xi -PMyW )^2) #generalised Q statistic
Q2 <- sum((PMw ^2)*(xi-PMyW )^2) #denominator from delta
#quant=statistic coming from the chisq dist regardless of data.
#mean/CI bound etc
if (trunc) PM_F <- max(Q1 -quant ,0)
else PM_F <- Q1-quant
delta <- PM_F/Q2 #what to add onto the next tausq estimate
if (PM_F !=0) PMtausq <- PMtausq + delta
PMit <- PMit + 1
if (PM_F ==0) {
PMtau2out <-PMtausq
}
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if (PMit== maxit) {
PM_F <- 0
if (output ==TRUE)
cat("PM estimator: Maximum Number of iterations reached
without convergence\n")
}
}
name[esti] <- "PM"
if (PMit== maxit) PM_est <- tau2[esti] <- NA
else PM_est <- tau2[esti] <- PMtau2out
PMw <- 1/(vi + tau2[esti])
theta[esti] <- sum(xi*PMw)/sum(PMw)
esti <- esti + 1
}
#Paule Mandel (with improved standard errors)
if ('IPM ' %in% hetest) {
quant <- df <- K-1
#degrees of freedom and expected mean under the
#fixed effects assumption
if (is.null(tau2 .0)) IPMtausq <- 0 #initial estimate of tau2
else IPMtausq <- tau2.0
IPMdiff <- 1
IPMit <- 1 #iteration number
#counter for number of negative estimates
negcount <- 0
#calculations needed to calculate standard errors , but that don 't
#change for each iteration
oddsc <- log(eci/(nci -eci)) # odds in control group
thetaCA <- sum(xi)/K # un-weighted average
while (IPMdiff !=0){
IPMtausq_prev <- IPMtausq
#first calculate the standard errors according to the alternative
#formula proposed by Bhaumik (depends on tau2 estimate so needs to
#be calculated for each iteration)
sei_IPM <-
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((exp(-oddsc - thetaCA + (IPMtausq /2)) + 2 +
exp(oddsc + thetaCA + (IPMtausq /2)))/( nci + 1)) +
((exp(-oddsc) + 2 + exp(oddsc ))/( nti + 1))
#calculate the the pooled effect based on present estimate of
#tausq
IPMw = 1/( sei_IPM ^2+ IPMtausq)
IPMyw = sum(xi*IPMw)/sum(IPMw)
#equation comes from DerSimonian and Kacker 2007
Q1 <- sum(IPMw*(xi-IPMyw )^2) #generalised Q statistic
Q2 <- sum(IPMw*( sei_IPM ^2)) - (sum((IPMw ^2)*( sei_IPM ^2)) /
sum(IPMw))
Q3 <- sum(IPMw) - (sum(IPMw ^2) / sum(IPMw))
IPMtausq <- (Q1 - Q2) / Q3
if (trunc) {
if(IPMtausq >=0) IPMdiff <- round(abs(IPMtausq - IPMtausq_prev),
digits=signiftau2)
else {
negcount <- negcount + 1
#if iteration is negative more than once then REML=0
#final est
if (negcount >=2) IPMdiff <-0
IPMtausq <-0
}
}
else IPMdiff <- round(abs(IPMtausq - IPMtausq_prev),
digits=signiftau2)
IPMit <- IPMit + 1
if (IPMit==maxit) {
IPMdiff <- 0
if (output ==TRUE)
cat("IPM estimator: Maximum Number of iterations reached
without convergence\n")
}
}
name[esti] <- "IPM"
if (IPMit ==maxit) IPM_est <- tau2[esti] <- NA
else IPM_est <- tau2[esti] <- IPMtausq
IPMw <- 1/(vi + tau2[esti])
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theta[esti] <- sum(xi*IPMw)/sum(IPMw)
esti <- esti + 1
}
#Cochran ANOVA initial estimate with PM weightings
if ('CA2 ' %in% hetest) {
name[esti] <- "CA2"
if (trunc) CAtau2 <- max( 0 , (1/(K-1))* sum((xi -(sum(xi)/K))^2) -
(1/K)*sum(vi) )
else CAtau2 <- (1/(K -1))* sum((xi -(sum(xi)/K))^2) - (1/K)*sum(vi)
CA2w <- 1/( CAtau2 + vi)
theta[esti] <- sum(xi*CA2w)/sum(CA2w)
CA2wtausq1 <- sum(CA2w *((xi -theta[esti ])^2)) - (sum(CA2w*vi)) +
(sum((CA2w ^2)*vi)/sum(CA2w))
CA2wtausq2 <- sum(CA2w) - (sum(CA2w ^2)/ sum(CA2w))
if (trunc) CA2_est <- max(0,tau2[esti]<- CA2wtausq1/CA2wtausq2)
else CA2_est <- tau2[esti]<- CA2wtausq1/CA2wtausq2
esti <- esti + 1
}
#DerSimonian Laird initial estimate with PM weightings
if ('DL2 ' %in% hetest) {
name[esti] <- "DL2"
DLw <- 1/(vi)
DLtheta <- sum(xi*DLw)/sum(DLw)
if (trunc) DLtau2 <- max( 0 , (sum(DLw*((xi -DLtheta )^2)) - K + 1)/
( sum(DLw) - (sum(DLw ^2)/ sum(DLw)) ) )
else DLtau2 <- (sum(DLw*((xi -DLtheta )^2)) - K + 1) /
( sum(DLw) - (sum(DLw ^2)/ sum(DLw)) )
DL2w <- 1/( DLtau2 + vi)
theta[esti] <- sum(xi*DL2w)/sum(DL2w)
DL2tausq1 <- sum(DL2w *((xi -theta[esti ])^2)) - (sum(DL2w*vi)) +
(sum((DL2w ^2)*vi)/sum(DL2w))
DL2tausq2 <- sum(DL2w) - (sum(DL2w ^2)/ sum(DL2w))
if (trunc) DL2_est <- max(0,tau2[esti]<- DL2tausq1/DL2tausq2)
else DL2_est <- tau2[esti]<- DL2tausq1/DL2tausq2
esti <- esti + 1
}
#Hartung Makambi
if ('HM ' %in% hetest) {
name[esti] <- "HM"
HMQ <- sum ((1/vi)*((xi-FEtheta )^2))
HM_est <- tau2[esti] <- (HMQ^2) / ((2*(K-1)+ HMQ)*( sum(1/vi)-
(sum ((1/vi)^2)/ sum(1/vi))))
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esti <- esti + 1
}
#Hunter Schmidt (original estimator using FE weightings)
if ('HS ' %in% hetest) {
name[esti] <- "HS"
if (trunc) HS_est <- tau2[esti] <- max(0 ,
(sum(wFEi*(xi - FEtheta )^2) - K) / (sum(wFEi)) )
else HS_est <- tau2[esti] <- (sum(wFEi*(xi - FEtheta )^2) - K) / (sum(wFEi))
esti <- esti + 1
}
#Sidik Jonkman
if ('SJ ' %in% hetest) {
name[esti] <- "SJ"
#### ESTIMATE OF TAU2
#calculate the pooled estimate
SJtheta_0 <- sum(xi)/K
#Cochrans equally weighted estimate of the pooled result
SJtau2_0 <- (1/K)*sum((xi - SJtheta_0 )^2)
#if all estimates are identical then we cannot go any further in
#the calculation and our estimate is zero
if (SJtau2_0 >0) {
#SJ weightings based on initial estimate of tau2 (SJtau2_0)
SJw <- 1/( (vi/SJtau2_0 )+1)
#Random effects pooled estimate based on the above weightings
SJtheta_1 <- sum(xi*SJw)/sum(SJw)
SJ_est <- tau2[esti] <- (1/(K -1)) * sum( SJw * (xi-SJtheta_1 )^2 )
}
else SJ_est <- tau2[esti] <- 0
#pooled effect estimate
SJw2 <- 1/( (vi/tau2[esti ])+1)
theta[esti] <- sum(SJw2 * xi) / sum(SJw2)
esti <- esti + 1
}
#Improved Sidik Jonkman
225
if ('SJ2 ' %in% hetest) {
name[esti] <- "SJ2"
#### ESTIMATE OF TAU2
#calculate the pooled estimate
SJ2theta_0 <- sum(xi)/K
#if all estimates are identical then tau2 is zero
if (sum((xi - SJ2theta_0 )^2) >0) {
#variance components method (general form of hedges olkin)
SJ2tau2_0 <- max( 0.01 , ((1/(K -1))*( sum((xi - SJ2theta_0 )^2))) -
((1/K)*(sum(vi))) )
#SJ2 weightings based on initial estimate of tau2 (SJ2tau2_0)
SJ2w <- 1/( (vi/SJ2tau2_0 )+1)
#Random effects pooled estimate based on the above weightings
SJtheta_1 <- sum(xi*SJ2w)/sum(SJ2w)
SJ2_est <- tau2[esti] <- (1/(K -1)) *
sum( SJ2w * (xi -SJtheta_1 )^2 )
}
else SJ2_est <- tau2[esti] <- 0
#pooled effect estimate
SJ2w2 <- 1/( (vi/tau2[esti ])+1)
theta[esti] <- sum(SJ2w2 * xi) / sum(SJ2w2)
esti <- esti + 1
}
#Malzahn , Bohning , Holling estimator (as given in the original
#Malzahn et al 2000 paper) only for SMD effects
if ('MBH ' %in% hetest) {
name[esti] <- "MBH"
if (SMD) {
Ni <- nci + nti - 2
Hi <- sqrt(Ni/2)*( gamma ((Ni/2) -0.5)/ gamma(Ni/2))
di <- xi/Hi
thetaMBH <- sum(di)/K #equal weighted mean effect
Ki <- 1 - ((Hi )^2*((Ni -2)/Ni))
MBH_est <- (sum((1-Ki)*((di-thetaMBH )^2))/(K-1)) -
((1/K)*sum((nci + nti)/(nci*nti ))) -
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((1/K)*sum(Ki*(di ^2)))
if (trunc) MBH_est <- tau2[esti]<- max(0,MBH_est)
else tau2[esti]<- MBH_est
} else MBH_est <- tau2[esti] <- NA
esti <- esti + 1
}
#Maximum Likelihood
if ('ML ' %in% hetest) {
name[esti] <- "ML"
#difference between this iteration and previous to assess when we
#have convergence set MLdiff !=0 initially to get the process of
#iteration going
MLdiff <- 1
#counter for number of iterations
MLit <-0
#counter for number of negative estimates
negcount <- 0
#first set initial estimate of tau2 and theta
#(fixed effect estimates)
if (is.null(tau2 .0)) MLtau2 <- CA_est
else MLtau2 <- tau2.0
MLtheta <- sum(xi*wFEi)/sum(wFEi)
while(MLdiff !=0){
#estimate of between study heterogeneity
MLtau2_prev <- MLtau2 #record of previous step
if (-min(vi)>=MLtau2) MLtau2 <- -min(vi)+(10^ - signiftau2)
MLtau2 <- sum( ((xi-MLtheta )^2 - vi) / (vi+MLtau2 )^2 ) /
sum( 1 / (vi+MLtau2 )^2 )
#estimate for pooled effect
MLtheta_prev <- MLtheta #record of previous step
MLtheta <- sum( xi / (vi+MLtau2) ) / sum( 1 / (vi+MLtau2) )
if (trunc) {
if(MLtau2 >=0) MLdiff <- round(abs(MLtau2 - MLtau2_prev),
digits=signiftau2)
else {
negcount <- negcount + 1
227
# if iteration is negative more than once then REML=0 final est
if (negcount >=2) MLdiff <-0
MLtau2 <-0
MLtheta <-sum(xi*wFEi)/sum(wFEi)
}
}
else MLdiff <- round(abs(MLtau2 - MLtau2_prev),digits=signiftau2)
MLit <- MLit + 1
if (MLit== maxit) {
MLdiff <- 0
if (output ==TRUE)
cat("ML estimator: Maximum Number of iterations reached
without convergence\n")
}
}
if (MLit== maxit) ML_est <- tau2[esti] <- NA
else ML_est <- tau2[esti] <- MLtau2
#pooled effect estimate
MLw2 <- 1/( (vi/tau2[esti ])+1)
theta[esti] <- sum(MLw2 * xi) / sum(MLw2)
esti <- esti + 1
}
#Restricted Maximum Likelihood
if ('REML ' %in% hetest) {
name[esti] <- "REML"
#first set initial estimate of tau2 and theta
#(fixed effect estimates)
if (is.null(tau2 .0)) REMLtau2 <- CA_est
else REMLtau2 <- tau2.0
REMLtheta <- FEtheta
#difference between this iteration and previous to assess when we
#have convergence set diff !=0 initially to get the process of
#iteration going
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REMLdiff <- 1
#counter for number of iterations
REMLit <- 0
#counter for number of negative estimates
negcount <- 0
#process of iteration , stop when there is no difference between the
#last two steps
while(REMLdiff !=0){
#estimate of between study heterogeneity
REMLtau2_prev <- REMLtau2 #record of previous step
tau2_p1 <- sum ((1/(( vi+REMLtau2_prev )^2))*(((xi-REMLtheta )^2)-vi))
tau2_p2 <- sum (1/(( vi+REMLtau2_prev )^2))
tau2_p3 <- sum (1/(vi+REMLtau2_prev ))
REMLtau2 <- (tau2_p1/tau2_p2 )+(1/ tau2_p3)
if (trunc) {
if(REMLtau2 >=0) REMLdiff <- round(abs(REMLtau2 - REMLtau2_prev),
digits=signiftau2)
else {
negcount <- negcount + 1
#if iteration is negative more than once then REML=0 final est
if (negcount >=2) REMLdiff <- 0
REMLtau2 <- 0
REMLtheta <- FEtheta
}
}
else REMLdiff <- round(abs(REMLtau2 - REMLtau2_prev),
digits=signiftau2)
REMLit <- REMLit + 1
if (REMLit ==maxit) {
REMLdiff <- 0
if (output ==TRUE)
cat("REML estimator: Maximum Number of iterations reached
without convergence\n")
}
#this is just to update theta , rather than because this has
#anything to do with convergence of this outcome
#estimate for pooled effect
REMLtheta_prev <- REMLtheta #record of previous step
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REMLtheta <- sum( xi / (vi+REMLtau2) ) / sum( 1 / (vi+REMLtau2) )
}
if (REMLit ==maxit) REML_est <- tau2[esti] <- NA
else REML_est <- tau2[esti] <- REMLtau2
#pooled effect estimate
theta[esti] <- REMLtheta
esti <- esti + 1
}
#Approximate Restricted Maximum Likelihood
if ('ARML ' %in% hetest) {
name[esti] <- "ARML"
#first set initial estimate of tau2 and theta
#(fixed effect estimates)
ARMLtau2 <- 0
ARMLtheta <- FEtheta
#difference between this iteration and previous to assess when we
#have convergence
#set diff !=0 initially to get the process of iteration going
ARMLdiff <- 1
#counter for number of iterations
ARMLit <-0
#process of iteration , stop when there is no difference between
#the last two steps
while(ARMLdiff !=0){
#estimate of between study heterogeneity
ARMLtau2_prev <- ARMLtau2 #record of previous step
tau2_p1 <- sum (1/(( vi+ARMLtau2_prev )^2))
tau2_p2 <- sum( (1/((vi+ARMLtau2_prev )^2)) *
( ((K/(K-1)) * (xi-ARMLtheta )^2) - vi ) )
ARMLtau2 <- tau2_p2/tau2_p1
if (trunc) {
if(ARMLtau2 >=0) ARMLdiff <-
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round(abs(ARMLtau2 - ARMLtau2_prev),digits=signiftau2)
else {
ARMLdiff <- 0
ARMLtau2 <- 0
ARMLtheta <- FEtheta
}
}
else ARMLdiff <- round(abs(ARMLtau2 - ARMLtau2_prev),
digits=signiftau2)
ARMLit <- ARMLit + 1
if (ARMLit ==maxit) {
ARMLdiff <- 0
cat(" Maximum Number of iterations reached without
convergence\n")
}
#this is just to update theta , rather than because this has
#anything to do with convergence of this outcome
#estimate for pooled effect
ARMLtheta_prev <- ARMLtheta #record of previous step
ARMLtheta <- sum( xi / (vi + ARMLtau2) ) /
sum( 1 / (vi + ARMLtau2) )
}
ARML_est <- tau2[esti] <- ARMLtau2
#pooled effect estimate
theta[esti] <- ARMLtheta
esti <- esti + 1
}
#Approximate Bayes
if ('AB ' %in% hetest) {
#check that 2 of the prior parameters are specified , otherwise
#return an error
countarg <- 0
if (!is.numeric(lambda )) countarg <- countarg + 1
if (!is.numeric(eta)) countarg <- countarg + 1
if (!is.numeric(tau2prior )) countarg <- countarg + 1
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if (countarg ==1) {
name[esti] <- "AB"
# set up output data
require(rmeta)
require(pscl)
#calculate both eta and lambda parameters if they are not
#both specified
if (is.null(lambda )) lambda <- tau2prior *(eta -1)
else if (is.null(eta)) eta <- (lambda/tau2prior )+1
# Compute approximate Bayes estimate of heterogeneity variance
# from DerSimonian -Laird estimate and prior distribution
tau2DL <- meta.summaries(xi,sei ,method =" random ") $tau2
AB_est <- tau2[esti] <- tau2AB <-
max ((2 * lambda + K * tau2DL )/(2 * eta + K - 2), 0)
esti <- esti + 1
}
else {cat(" ERROR: AB estimate cannot be calculated as prior
parameters have been specified incorrectly \n")}
}
#Rukhin (zero prior)
if ('B0 ' %in% hetest) {
name[esti] <- "B0"
#just assume fixed effects mean , this is the way Kontopantelis
#did it also doesnt specify what n_i is given that the estimator
#is proposed in the context where there isn 't 2 treatment groups
#per study , N=nci + nti as used by Kontopantelis
#not exactly the same formula as in Rukhin 2012, because there
#is a mistake , this is the corrected
#formula similar to that used by Konto 2012
B0theta <- theta[esti] <- FEtheta
B0_est <- tau2[esti] <- ( sum((xi-B0theta )^2)/(K+1) ) -
(( (sum(nci+nti)-K)*(K-1)* sum(vi) ) /
( K*(K+1)* sum(nci+nti -K+2) ))
#this is possible if the denominator is zero (rare )...
if (is.infinite(B0_est )) B0_est <- tau2[esti] <- NA
esti <- esti + 1
}
#Rukhin (simple prior)
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if ('BP ' %in% hetest) {
name[esti] <- "BP"
#just assume fixed effects mean for now , paper doesn 't specify
BPtheta <- theta[esti] <- FEtheta
BP_est <- tau2[esti] <- sum((xi-BPtheta )^2)/(K+1)
esti <- esti + 1
}
#Bayes Modal estimator
if ('BM ' %in% hetest) {
}
#### data frame for reporting all output
#first round off the estimate to specified number of decimal
#places by signiftau2 arguament
tau2 <- signif(tau2 , digits=signiftau2)
out <-data.frame(name ,tau2)
if (output ==TRUE) print(out)
#### output that can be used after function has been run
#create an output frame that can be used when iterating through this
#function multipe times
#the above dataframe is better when only calculating estimates for
#one meta -analysis
res <- list(CA_est ,DL_est ,PM_est ,IPM_est ,CA2_est ,DL2_est ,DLp_est ,
DLb_est ,HM_est ,HS_est ,SJ_est ,SJ2_est ,MBH_est ,ML_est ,REML_est ,
ARML_est ,AB_est ,B0_est ,BP_est)
names(res) <- c("CA","DL","PM","IPM","CA2","DL2","DLp","DLb","HM",
"HS","SJ","SJ2","MBH","ML","REML","ARML","AB","B0","BP")
return(res)
#we can refer to the estimates outside of this function by <funct name >$<est name >
}
D.3 R code for conﬁdence interval methods of the
summary eﬀect
#######################################################################
# R code for calculating all confidence interval estimates #
#######################################################################
#######################################
#list of arguments and their meanings #
#######################################
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##hetests - vector of heterogeneity estimates
#xi - effect estimates of the studies in the meta -analysis
#sei - standard errors of the effect estimates
#CIest - names of the confidence intervals to be calculated
#signif - significance level set for the confidence intervals ,
# the default is 0.05 (i.e. 95% CI)
#output - if TRUE then output results into the R console
#signifCI - numer of significant figues to round off the CI bounds
#hetnames - names of the heterogeneity estimators (corresponding to
# the heterogeneity estimates in hetests argument)
#
#######################################
#list of estiamtors and their acornyms#
#######################################
#####so far just includes the CI methods that are used in the
##### simulation study
#
#Z - Z-type confidence interval
#T - t-distribution confidence interval
#HK - Hartung -Knapp confidence interval
#make sure I keep this update and consistent with the estimators
#available in the het_est.R program
CIests <- function(hetests , xi, sei , CIest=c("Z","T","HK"),
signif =0.05 , output=TRUE , signifCI=4, hetnames=c("CA","DL","PM",
"IPM","CA2","DL2","DLp","DLb","HM","HS","SJ","SJ2","MBH","ML",
"REML","ARML","AB","B0","BP")) {
if (length(hetests )!= length(hetnames ))
stop(" Number of tau2 estimator names doesn 't match the number
of estimates given ")
#calculate mean effects
thetaests <- rep(NA,times=length(hetests ))
for(i in 1: length(hetests )) {
thetaests[i] <- sum(xi*(1/( sei^2 + hetests[i])))/
sum (1/( sei^2 + hetests[i]))
}
#number of studies
nostudies <- length(sei)
#create a blank matrix where all the results will go...
CImat <-matrix(NA,nrow=length(CIest)*2,ncol=length(hetnames ))
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colnames(CImat) <- hetnames
#define row names ...
rownammat <- rep(NA,times=nrow(CImat))
for (i in 1:nrow(CImat )) {
#if i is even
if (i %% 2 == 0) rownammat[i] <- paste(CIest[i/2],"_ub",sep ="")
else rownammat[i] <- paste(CIest[(i/2)+0.5] ," _lb",sep ="")
}
rownames(CImat) <- rownammat
#Z-type CI
if ('Z' %in% CIest) {
for (i in 1: length(hetnames )) {
CImat["Z_lb",hetnames[i]] <- thetaests[i] -
qnorm(1-( signif /2))* sqrt (1/sum (1/( hetests[i]+( sei ^2))))
CImat["Z_ub",hetnames[i]] <- thetaests[i] +
qnorm(1-( signif /2))* sqrt (1/sum (1/( hetests[i]+( sei ^2))))
}
}
#t-type CI
if ('T' %in% CIest) {
for (i in 1: length(hetnames )) {
CImat["T_lb",hetnames[i]] <- thetaests[i] -
qt(1-( signif /2), df=nostudies -1)*
sqrt (1/sum (1/( hetests[i]+(sei ^2))))
CImat["T_ub",hetnames[i]] <- thetaests[i] +
qt(1-( signif /2), df=nostudies -1)*
sqrt (1/sum (1/( hetests[i]+(sei ^2))))
}
}
#Hartung -Knapp CI
if ('HK ' %in% CIest) {
for (i in 1: length(hetnames )) {
varHK <- sum ((1/( hetests[i]+(sei ^2)))*((xi -thetaests[i])^2))/
((nostudies -1)* sum (1/( hetests[i]+(sei ^2))))
CImat["HK_lb",hetnames[i]] <- thetaests[i] -
qt(1-( signif /2), df=nostudies -1)* sqrt(varHK)
CImat["HK_ub",hetnames[i]] <- thetaests[i] +
qt(1-( signif /2), df=nostudies -1)* sqrt(varHK)
}
}
if (output ==TRUE) print(CImat)
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CImat <<- round(CImat ,digits=signifCI)
}
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Appendix E: Simulation study
protocol
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Protocol amendments
 Generic meta-analyses are no longer included because the results are almost
identical to SMD meta-analyses. The only diﬀerence between the two meta-
analysis types is that within-study variances are based on the underlying study
eﬀects, as opposed to the observed study eﬀects.
 I simulate 5,000 meta-analyses per scenario, not 10,000 as stated in the original
protocol.
 Scenarios 4 and 5 for the study sample size distributions have been changed.
Originally, these two scenarios were:
(4) n1 = 20 and n2, ..., nk ∼ U (1000, 2000)
(5)n1 ∼ U (1000, 2000) and n2, ..., nk ∼ 20.
I changed them to:
(4) Small and large studies: n11, ..., n1m = 20 and n1m, ..., n1k ∼
U (1000, 2000) where m is the integer half way between 1 and
k (when k is odd, one study is be generated from one of the
two distributions at random)
(5) Large studies: n1i ∼ U (1000, 2000)
I took this decision because the original mixture distributions were de-
pendent on the number of studies k.
 The analysis plan originally stated Typical conﬁdence intervals for τ 2 will also
be presented, which will help show scenarios where τ 2 estimates are imprecise.
This will not be included as there is no way of eﬀectively displaying these on
the graphs and would divert attention away from the main results.
The protocol that follows in this appendix is the original protocol agreed between
collaborators.
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Background
Heterogeneity is an important consideration in any meta-analysis, as its presence can
have a considerable impact on the conclusions reached. All meta-analyses should ex-
amine the extent of heterogeneity across studies. There are various ways of doing
this, and of addressing heterogeneity in the statistical synthesis. A common ap-
proach, often advocated when an adequate explanation cannot be identiﬁed for a
moderate amount of between-study variation, is to use a random-eﬀects model. As
part of a random-eﬀects meta-analysis, a heterogeneity variance parameter (τ 2) is
estimated. This parameter may be used to quantify heterogeneity even if a synthesis
is not performed.
Several methods have been proposed to estimate τ 2, the most commonly used be-
ing the DerSimonian- Laird method [25]. However, simulation studies suggest this
method underestimates heterogeneity variance in dichotomous outcome meta-analyses
[78, 102]. Other heterogeneity estimation methods include Paule-Mandel's method
[24, 80], which falls under the same method of moments approach as DerSimonian-
Laird. Estimators have also been proposed based on maximum-likelihood (ML) [37]
and restricted maximum likelihood (REML) [124] approaches. These estimators al-
low for negative estimates of heterogeneity variance and must be truncated to zero
in such cases. Hartung-Makambi [40], Sidik-Jonkman [101] and the improved Sidik-
Jonkman [102] estimators are designed to provide only positive estimates so that
truncation is not required.
A recent empirical study (at the Centre for Reviews and Dissemination in York)
on meta-analyses from the Cochrane Database of Systematic Reviews (CDSR) com-
pared ﬁve methods including DerSimonian-Laird method, Paule-Mandel, Hartung-
Makambi, Sidik-Jonkman and REML [67]. For each method, I2 statistics were cal-
culated as an estimate of the level of heterogeneity using the generalised formula
proposed by Higgins and Thompson [47]. The study found that estimates of I2
derived from diﬀerent methods can be highly discordant. Diﬀerences between τ 2
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estimates can lead to I2 values that diﬀer in absolute terms by more than 50%.
Discrepancies between heterogeneity variance estimates can also lead to discordant
conclusions on the summary eﬀect; the empirical study showed that 7.4% of Cochrane
meta-analyses have discordant statistical signiﬁcance at the 5% level depending on
which heterogeneity estimation method is used (out of ﬁve methods that were com-
pared). The disagreement between heterogeneity variance estimates can be partly
attributed to the low number of studies typically found in meta-analyses of health-
care interventions: those in the Cochrane Database of Systematic Reviews contain
a median of just 3 studies (inter-quartile range 2 to 6)(Davey et al., 2011). When
conducting a meta-analysis, it is therefore important to make an informed decision
when choosing which heterogeneity estimation method to use and whether to rely
on one point estimate alone.
Twelve simulation studies assessing the performance of heterogeneity variance es-
timators have been identiﬁed from a preliminary review of the literature, which are
summarised in chapter 5. Of these studies, four compare a wide selection of estim-
ators over a wide range of simulated scenarios (Novianti et al., 2014, Viechtbauer,
2005, Sidik and Jonkman, 2007, Kontopantelis et al., 2013). One study (Viecht-
bauer, 2005) recommends REML, one study (Novianti et al., 2014) recommend
Paule-Mandel and Sidik and Jonkman (Sidik and Jonkman, 2007) recommend their
own methods. Kontopantelis et al. suggested that the bootstrap alternative to the
standard DerSimonian-Laird method performs better but mainly recommends con-
ducting sensitivity analyses; in most meta-analyses, there is insuﬃcient data to rely
on one estimate of heterogeneity alone. DerSimonian-Laird, Cochran's ANOVA and
REML were the only estimators included in all four of the main studies. The study
by Kontopantelis et al. [64] was the only main study to include Bayesian estimators
from Rukhin [93]. Only the study by Novianti et al. [78] included the Paule-Mandel
method in its comparisons. Aside from the four most comprehensive studies, other
simulations have been identiﬁed in the literature in which only a small selection of
heterogeneity variance estimators are compared [2, 3, 11, 61, 74, 79, 93, 96, 101].
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Previous simulation studies have made conﬂicting recommendations for heterogen-
eity estimation and as such there is currently no overall consensus. This can be
partly attributed to diﬀerences between studies in the eﬀect sizes used to determine
what makes a good heterogeneity variance estimator. Performance of heterogeneity
variance estimators in previous studies have been assessed mainly in terms of bias,
variance or some measure of precision. Bias is a measure of how much the heterogen-
eity parameter is under or overestimated. Measures of precision include the mean
squared error (MSE) and eﬃciency, which quantify the expected deviation from the
true parameter value. Recommendations made by Viechtbauer [124] were based a
trade-oﬀ between minimising bias and maximising eﬃciency, as is the case in most
other simulation studies. In contrast, the study by Novianti et al. [78] made recom-
mendations based only on which method has the lowest bias. Previous studies have
aimed to provide a simple recommendation that can easily be applied in practice,
yet their results suggests no estimator is clearly best under all conditions.
Comprehensive simulation studies are needed to examine methods for estimating het-
erogeneity variance and for incorporating these into random-eﬀects meta-analyses.
The current study primarily addresses the ﬁrst part of this, namely the choice of
variance estimator. There are conﬂicting recommendations about this issue in the
current literature, and a number of speciﬁc questions need answering to inform a
consensus recommendation. Existing simulation studies compare the performance
of heterogeneity variance estimators mainly on meta-analyses with uniformly dis-
tributed study sample sizes. No simulation study compares multiple distributions
of study sample sizes. IntHout et al. [55] suggests the performance of heterogeneity
methods in meta-analysis varies depending on the distribution of study sizes. Re-
search where true treatment eﬀects are simulated from a non-normal distribution is
also limited to a comparison between eﬀect (θ) estimation methods, but not speciﬁc-
ally heterogeneity variance estimators [62, 63]. The two main limitations of current
recommendations are: (1) they are only based on a comparison of a small subset of all
heterogeneity estimation methods available (2) they do not address suﬃciently the
practical situation that in many meta-analyses all heterogeneity variance estimates
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are very imprecise.
This study aims to address the limitations of the current research, comparing the
performance of heterogeneity variance estimators using simulated meta-analysis data
that resemble conditions that may occur in practice. Empirical meta-analysis data
taken from a 2008 snapshot of the Cochrane Database of Systematic Reviews (CDSR)
will be used to inform parameter values for simulations [21]. A comprehensive selec-
tion of heterogeneity estimation methods will be compared, as identiﬁed in a recent
review yet to be published [122].
Aims
The principal aim of this study is to make clear recommendations for meta-analyses
in a wide range of realistic situations about which heterogeneity variance estimator
(if any) is most appropriate to use. Recommendations will be informed by how
heterogeneity variance estimators perform in simulated meta-analyses and agreed
between collaborators of the study. Parameter values used to simulate meta-analyses
through a random-eﬀects model will cover the full range of possible scenarios observed
in practice. The study will answer the following questions:
 In what situations do all estimators perform poorly, where relying on one point
estimate of heterogeneity is not recommended?
 In what situations does one estimator outperform all others and perform well
enough to provide a reasonable point estimate of heterogeneity?
 In what situations do most heterogeneity variance estimators perform equally
well?
 Are there any estimators that we can exclude entirely?
 Are there characteristics of the meta-analysis that explain the poor estimation?
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Heterogeneity variance estimators
Methods for estimating the heterogeneity variance (τ 2) in a random-eﬀects model
were identiﬁed from a comprehensive review of heterogeneity methods [122]. For
each simulated meta-analysis, estimates of τ 2 will be calculated from the following
14 methods:
 Cochran's ANOVA [18] (also known as Hedges-Olkin [42])
 DerSimonian-Laird [25]
 Paule-Mandel [80]
 Two-step DerSimonian-Laird [24]
 Two-step Cochran's ANOVA [24]
 Hunter-Schmidt [53]
 Maximum likelihood [37]
 Restricted maximum likelihood [124]
 Hartung-Makambi [40]
 Sidik-Jonkman [101]
 Improved Sidik-Jonkman [102]
 Rukhin with zero prior [93]
 Rukhin's simple estimator [93]
Details of how to estimate τ 2 from all these methods are given in chapter 2. A small
number of methods were excluded, as listed on page113 with reasons for exclusion.
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Conﬁdence intervals for the summary eﬀect
In order to perform a comprehensive comparison of heterogeneity variance estimat-
ors, their performance must be evaluated not only as a point estimate of heterogeneity
(τ 2). This study also investigates the impact using a given heterogeneity variance es-
timator to calculate a summary eﬀect and conﬁdence interval of the summary eﬀect.
Many methods of calculating the conﬁdence interval have been proposed. Because
inference on the mean of the random-eﬀects distribution is not the main focus of the
simulation study, only a small subset of conﬁdence interval methods available will
be included:
 Wald-type [25]
 t-distribution (with number of studies -1 degrees of freedom) [28]
 Hartung-Knapp [38]
All these methods are independent of the choice of heterogeneity variance estim-
ator. Therefore, any combination of methods can be applied in practice and all
combinations are considered in this simulation study. 95% conﬁdence intervals will
be calculated for all analyses. Details of each conﬁdence interval method are given
in chapter 3.
Many methods are also available to calculate a conﬁdence interval for τ 2. These
methods will not be considered as the scope of this study is limited to the impact of
using point estimates of heterogeneity.
Performance measures
Heterogeneity variance estimators will be compared in terms of the following 11
performance measures:
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 Median and mean absolute bias in estimate of τ 2 *
 Median and mean squared error of estimate of τ 2 *
 Proportion of zero estimates of τ 2
 Mean absolute bias in estimate of the mean treatment eﬀect }
 Mean squared error of estimate of the mean treatment eﬀect }
 Coverage of the 95% conﬁdence interval for the mean treatment eﬀect** (i.e.
the proportion of times the underlying mean treatment eﬀect falls inside the
95% conﬁdence interval)
 Power to detect a signiﬁcant summary eﬀect
 Mean and variance of the error-interval estimation of eﬀect 
*Previous studies have used the mean squared error to measure performance, but
τ 2 and estimation errors do not conform to the normal distribution. Performance
measures based on the mean make heterogeneity variance estimators with negative
bias appear better as underestimates are more likely to be negative and therefore
truncated at zero. Therefore, median bias and squared errors will also be presented.
} Mean treatment eﬀect calculated by the weighted inverse variance method
**Conﬁdence interval coverages will also be compared against the coverage of each
conﬁdence interval method based on the true value of the heterogeneity variance.
 Error-interval estimation is a ratio between the width of the estimated conﬁdence
interval and the true conﬁdence interval, as deﬁned by a previous simulation study
[64]. The formula is given in the original paper.
A good estimator is unbiased, has a low MSE and a summary eﬀect conﬁdence
interval with coverage close to 95%. Details of how to calculate all performance
measures are given in appendix C.2
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Simulation methods
Analysis will be undertaken using simulated data produced from the following steps:
1. A meta-analysis dataset is generated for speciﬁed parameter values using the
methods outlined on page 248.
2. Heterogeneity variance estimates are calculated for the given meta-analysis
using methods on page 244.
3. Steps 1 and 2 are repeated 10,000 times and performance measures are calcu-
lated (see page 245)
4. Steps 1-3 are repeated for all combinations of parameter values. The parameter
values are given on page 252.
All steps will be carried out in R [85]. The metafor package in R [126] will be
used to calculate estimates of heterogeneity from methods coded in this package,
and bespoke code for those that are not. Methods available in metafor to estimate
τ 2 include Cochran's ANOVA, DerSimonian-Laird, Hunter-Schmidt, Sidik-Jonkman,
maximum likelihood and REML. Wald-type and Hartung-Knapp conﬁdence interval
methods for the mean treatment eﬀect are also available in metafor. Heterogeneity
methods will be compared using the same simulated datasets to eliminate some of the
sampling error. Maximum likelihood and REML heterogeneity variance estimators
are iterative and fail to converge to a solution in a small number of cases [64],
but this is primarily due the chosen iteration algorithm rather than the estimator
[126]. In this study, the default iteration algorithm in metafor will be used - Fishers
scoring method with Cochran's ANOVA the initial estimate [126]. Simulated meta-
analyses that cause such failures will not be replaced, and instances recorded so that
the characteristics of the simulated data can be examined. Heterogeneity variance
estimates for each meta-analysis and performance measures for each combination of
parameter values will be stored for the analysis. The simulation code has already
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been written according to the methods described in this version of the protocol and
is available on request.
Simulating meta-analyses
For studies i = 1, . . . , k in each meta-analysis, true treatment eﬀects (θi such as a log
odds ratio or standardized mean diﬀerence), are simulated from some distribution
D1:
θi ∼ D1
(
θ, τ 2
)
where θ is the mean parameter and τ 2 the heterogeneity variance parameter of D1
Deﬁned distributions for D1 with parameter values θ and τ
2 used to simulate meta-
analyses are detailed on page 252. For each θi sampled from D1, estimates of θi
(denoted by θˆi) are then generated to simulate within-study sampling error. The
process for doing so depends on the type of outcome of studies in each meta-analysis.
In this study, three types of meta-analyses will be simulated: (1) Generic eﬀect sizes
with known variance; (2) continuous outcome meta-analyses with a standardised
mean diﬀerence eﬀect measure; and (3) dichotomous outcome meta-analyses with an
odds ratio eﬀect measure, as detailed on pages 248 to 250.
Generic eﬀect sizes (with known variance)
Estimates of θi are simulated from a normal distribution:
θˆi ∼ N(θi, σ2i )
where θi is the mean parameter and σ
2
i is the sampling variance parameter.
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σ2i are calculated based on the sample size of each study. We assume equal sample
sizes between intervention groups and denote the sample size for each group by ni:
σ2i =
2
ni
+
θ2i
4ni
ni are generated from one of a number of distributions as detailed on page 252. The
formula for σ2i above is the approximate variance of a standardised mean diﬀerence
with sample sizes equal between arms and θ = 0 [8]. By using this formula to derive
σ2i , simulation results from outcome-independent meta-analyses can be directly com-
pared with standardised mean diﬀerence meta-analyses where ni are simulated from
the same distributions. Results from outcome-independent meta-analyses will rep-
resent the performance of heterogeneity variance estimators under ideal conditions,
where standard errors are known and performance is not aﬀected by the choice of
eﬀect measure.
Standardised mean diﬀerence meta-analyses
For each study i with simulated true eﬀect θi:
1. Generate sample sizes for each intervention group, denoted by ni, from one of
a number of distributions as detailed on page 252.
2. Generate ni observations from N(0, σ
2
T i) and ni observations from N(θi, σ
2
Ci),
to represent patient-level data in the treatment and control groups respectively.
Without loss of generality, we set σ2T i = σ
2
Ci = 1.
3. Calculate the sample mean and standard deviation of these observations for
the treatment and control groups.
4. Calculate the sample SMD and standard error of the study, denoted by θˆi,
using Hedge's g method [8]:
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θˆi =
ZT i − ZCi
si
J
where si is the pooled variance and J is an adjustment to correct for bias:
si =
√
(ni − 1) sˆd2T i + (ni − 1) sˆd2Ci
2ni − 2
J = 1− 3/ (8nI − 9)
5. Calculate the variance of θˆi:
σˆ2i =
(
2
ni
+
θˆ2i
4ni
)
· J2
Hedge's g method calculates a pooled standard deviation assuming equal variances
between treatment groups, which is the case in this simulation study.
Odds ratio meta-analyses
Meta-analyses with an odds ratio eﬀect measure are simulated for two reasons: (1)
Previous simulation studies [78] suggest heterogeneity variance estimators perform
worse in this setting compared with SMD meta-analyses and (2) the odds ratio is the
most common outcome measure in binary outcome meta-analyses [120]. It has been
suggested this is partly because σ2i are estimated poorly when the event of interest
is rare [3]. For each study i with simulated true eﬀect θi:
1. Generate the true average probability of an event across the control and treat-
ment groups, denoted by pi. pi is drawn from the distributions detailed on
page 252. pT i and pCi are found from solutions to the simultaneous equations:
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pi =
pT i + pCi
2
ORi =
pT i (1− pCi)
pCi (1− pT i)
Solving the equations leads to the following formula for pT i and pCi:
pCi =
1
2 (ORi − 1) ·
[
2piORi −ORi − 2pi − 1
−
√
(ORi − 2piORi + 2pi + 1)2 + 8pi (ORi − 1)
]
pTi = 2pi − pCi
2. Generate sample sizes for each intervention group, denoted by ni, from one of
a number of distributions as detailed on page 252.
3. The numbers of events in the control and treatment groups are generated from
the binomial distributions B(nCi, pCi) and B(nT i, pT i). nCi and nT i are the
sample sizes of the treatment and control groups and will be assumed equal for
this study (nCi = nT i = ni). Cell counts in a 2x2 contingency table can then
be derived.
4. Add 0.5 to all cell counts if there is any zero in the table. If there are zero
events in both arms then exclude this study from the synthesis. If there are
fewer than 2 studies remaining after exclusions then the meta-analysis will be
withdrawn from the simulations without replacement.
5. Calculate the sample OR on the log scale, θˆi and its variance [8].
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Parameter values
Performance of the heterogeneity variance estimators will be assessed for all com-
binations of parameter values and distributions given in table E.1 for outcome-
independent, standardised mean diﬀerence and odds ratio meta-analyses. There
will be a total of 840 simulated scenarios for outcome-independent meta-analyses,
840 standardised mean diﬀerence meta-analyses and 3360 simulated scenarios for OR
meta-analyses. Each scenario will have 10,000 simulated datasets. It is estimated
that each scenario will take 5 minutes to simulate given the computing power avail-
able and a total of 17 days to simulate all data. Justiﬁcation of each parameter and
distribution is given in this section.
Parameter values were chosen to represent the range of values observed in published
meta-analyses.
(1) Figure E.1 is taken from a recent empirical study at the Centre for Reviews and
Dissemination (CRD) in York and shows the number of studies in meta-analyses from
the Cochrane Database of Systematic Reviews up to 2008. Note, the ﬁgure excludes
meta-analyses with fewer than 3 studies, calculating an estimate of heterogeneity
was considered inappropriate in meta-analyses with two studies. The distribution
in ﬁgure E.1 was used to inform parameter values for k. The number of studies per
meta-analysis in simulations will range between 2 and 100, although 95% of meta-
analyses in the Cochrane database contain fewer than 16 studies; this is to account
for meta-analyses with a higher number of studies in other ﬁelds.
(2) Parameter values of τ 2 were chosen based on the distribution of τ 2 predicted in
meta-analyses from Cochrane reviews. Two empirical studies used Bayesian methods
derive a distribution for τ 2 based on meta-analyses with an odds ratio outcome
[120] and standardised mean diﬀerence outcome [88]. The studies showed similar
distributions of τ 2 between the two outcomes types. Therefore, the same parameter
values will be used to simulate meta-analyses of all outcomes. Using these predictive
distributions for τ 2 is more appropriate than a distribution of τ 2 estimates which
252
Parameter Value/distribution
1 k Number of
studies in
the meta-
analysis
2, 3, 5, 10, 20, 30, 50, 100
2 I2 Level of het-
erogeneity
0%, 15%, 30%, 45%, 60%, 75%, 90%, 95%
3 θ Mean of the
random-
eﬀects
0.5
4 θi Distribution
of true
study eﬀects
(1) θi ∼ N (θ, τ 2)(standard random-eﬀects
model)
(2) Normal distribution with moderate
skew: θi ∼ SN (θ, τ 2, γ = 0.7)
(3) Normal distribution with high skew:
θi ∼ SN (θ, τ 2, γ = 0.95)
τ 2 takes parameter values that satisfy the
I2 values above and θ = 0.5
5 ni Sample size
in each
intervention
group (1:1
allocation
ratio)
(1) ni = 20
(2) ni ∼ U (20, 200)
(3) ni = 200
(4) n1 = 20 and n2, ..., nk ∼ U (1000, 2000)
(5)n1 ∼ U (1000, 2000) and n2, ..., nk ∼ 20
In all scenarios, sample sizes are equal
between groups (n1i = n2i)
Parameters only applying to odds ratio meta-analyses
6 pi Average
probability
of event
across
treatment
and control
groups
(1) pi = 0.5
(2) pi ∼ U (0.1, 0.5)
(3) pi = 0.05
(4) pi = 0.01
Table E.1: Set of parameter values and distributions to simulate
meta-analyses
is more dependent on which heterogeneity estimation method is used. Preliminary
simulations show that the chosen parameter values for τ 2 result in generic meta-
analyses with I2 values that span the full I2 range from 0% up to nearly 100%. This
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dataset of Cochrane reviews is described in detail elsewhere [21].
Figure E.1: Histogram of the numbers of studies in meta-analyses in the
Cochrane Database of Systematic Reviews (CDSR)
(3) To reduce the number of scenarios, we will only simulate meta-analyses where
θ = 0.5. The choice is immaterial for simulation of generic eﬀect sizes, and previous
simulation studies have suggested that the parameter value chosen for true summary
eﬀect (θ) has little bearing on performance measures including bias and variance of
heterogeneity variance estimators [78, 102].
(4) True treatment eﬀects θi will be generated from three distributions. In all scen-
arios, θi are sampled from distributions with mean θ and variance τ
2. First, θi will be
generated from the normal distribution which is assumed in the standard random-
eﬀects model and represents optimal conditions where estimators may perform best
(scenario 1). Some heterogeneity estimation methods such as Paule-Mandel do not
assume normality of true eﬀects and therefore it is hypothesised such estimators will
be more robust under non-normal conditions [24]. Second, θi will be sampled from
a skew normal distribution (scenario 2) with a 0.8 skew parameter value; this rep-
resents a moderate negative skew as illustrated in ﬁgure E.2. A simulation study
[62, 63] previously looked at performance of heterogeneity variance estimators under
skew-normal conditions, and deﬁned this similar level of skew as `moderate'. This
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distribution is deﬁned elsewhere [68]. Third, θi will be generated from a bimodal
distribution with studies drawn from two normal distributions of unequal means;
this represents a scenario where some dichotomous factor is responsible for some of
the heterogeneity present. The means of the two normal distributions were chosen
so that the resulting mixture distribution has mean θ = 0 and variance τ 2. The level
of bi modality is dependent on the parameter value of τ 2 [98]. Kontopantelis et al.
[64] conducted a simulation study of non-normal treatment eﬀects and showed, of
the heterogeneity variance estimators compared, that the performance of methods
were moderately robust to various distributions of eﬀects.
Figure E.2: Probability density function of skew-normal distribution
Note that the variance diﬀers depending on the simulation scenario, but this is only
the scaling parameter.
(5) Study sample sizes (ni) will be generated from ﬁve diﬀerent distributions to
represent a wide range of distributions. Distributions include small equally sized
studies (scenario 1), medium equally sized studies (scenario 2), uniform variation of
small to medium size studies (scenarios 3), one large study with all other studies
small (scenario 4) and one small study with all other studies large (scenario 5). A
recent simulation study suggests that the performance of heterogeneity estimation
methods may be dependent on the distribution of study sizes; this study however,
only compared two heterogeneity methods [55]. Other previous studies simulated
sample sizes from one distribution only; namely a uniform [78, 102], normal [124] or
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χ2 distribution [64].
(6) Binary outcome meta-analyses will be generated from a range of underlying
event rates. In scenario 1, the underlying average event rate will be 0.5 to represent
the ideal scenario with event rates sampled as far from the asymmetric tails of the
binomial distribution as possible. Scenario 2 represents a situation where event rates
are variable between studies but not so rare as to be considered a big contributing
factor to poor estimates of treatment eﬀects and standard errors. Scenarios 3 and
4 represent situations where the average underlying event rate is homogeneous and
rare. It is not necessary to simulate meta-analyses where the event of interest is
extremely common (i.e. pi = 0.95 or 0.99) as the resulting odds ratios are the
inverse of those obtained with extremely uncommon event rates.
Analysis
Primary analysis
Heterogeneity variance estimators will be compared in terms of the performance
measures deﬁned on page 245 and will be presented graphically for each simulated
scenario. Graphs will be produced for each performance measure to compare the
results of the 14 heterogeneity variance estimators. For each scenario, typical I2
values will be presented to show the level of heterogeneity the scenario represents.
Typical conﬁdence intervals for τ 2 will also be presented, which will help show scen-
arios where τ 2 estimates are imprecise. 95% conﬁdence intervals will be calculated
by the Q-proﬁle method [9]. If estimators are judged to have similar performance,
they may be grouped together to simplify results. Also, if the results are similar
between diﬀerent parameter values, the results from such scenarios will be combined
together.
Maximum likelihood and REML estimators may in some meta-analyses fail to con-
verge [62, 63]. Therefore for each scenario, the percentage of failures will be tabulated
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and results of which will be taken into account when making recommendations. If
other iterative heterogeneity variance estimators fail to converge, results of such
failures will also be presented.
Secondary analysis
The range of simulation scenarios in this study aims to be representative of all meta-
analyses from Cochrane systematic reviews. A secondary analysis will identify which
scenarios from this study occur most in reviews published in the Cochrane Database
of Systematic Reviews up to 2008 [21]. This will identify the importance of results
of each scenario and also help inform recommendations. As the level of heterogen-
eity can only be estimated in real meta-analyses, we will use distributions of the
underlying level of heterogeneity derived using Bayesian techniques in two empirical
studies [88, 120] to assess how frequently each τ 2 parameter value occurs in practice.
Distributions derived from the two studies were based separately on OR outcome
[120] and SMD outcome meta-analyses [88]. Both studies assume that τ 2 = 0 are
untenable in real meta-analyses and therefore the distribution has zero probability of
such values. As a consequence, we make this assumption in our analysis. Only scen-
arios where true treatment eﬀects have been simulated from the normal distribution
will be included in this analysis (scenario 1, see page 252); identifying non-normal
eﬀects in real meta-analyses would be diﬃcult given most meta-analyses contain few
studies. Results will be presented as a list of scenarios in the order of scenarios most
likely to occur in practice to the least.
Simulated meta-analyses will be selected for further investigation where heterogen-
eity variance estimates are particularly discordant. These meta-analyses will be
explored to identify characteristics that may have caused discordance.
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Recommendations
We aim to make recommendations about the best choice of heterogeneity variance
estimator in a meta-analysis with any given observed characteristics and make re-
commendations as a general strategy. Recommendations based on the results of this
study are likely to be made mainly on a subjective compromise between the res-
ults from all performance measures and the practicality of such recommendations.
Simple estimators will be recommended over iterative estimators where the diﬀerence
in performance in negligible. An estimator will be recommended in all scenarios to
provide a point estimate of heterogeneity in the primary random eﬀects model. How-
ever, making conclusions based a single point estimate will only be recommended
when the estimate is suﬃciently precise, alternative approaches will be recommended
otherwise. A decision tree may be formulated if it is appropriate to do so that can
be used in a given meta-analysis. The process of interpreting and summarising the
results of this study will involve all collaborators to make this study as systematic
as possible. Any relevant discussions will also be documented as part of the results.
258
Appendix F: Supplementary material
from chapter 7
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Figure F.1: Proportional median bias (left-hand-side) and proportional mean
bias (right-hand-side) of the heterogeneity variance in selected scenarios to
show why median bias is excluded from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
Figure F.2: Proportional median squared error (left-hand-side) and
proportional mean squared error (right-hand-side) of the heterogeneity
variance in selected scenarios to show why median squared bias is excluded
from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
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Figure F.3: Mean squared error of the summary eﬀect in selected scenarios to
show why this measure is excluded from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
Figure F.4: Power to detect a statistically signiﬁcant summary eﬀect in
selected scenarios to show why this measure is excluded from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
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Figure F.5: Mean error of the error-interval estimation of eﬀect in selected
scenarios to show why this measure is excluded from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
Figure F.6: Variance error of the error-interval estimation of eﬀect in
selected scenarios to show why this measure is excluded from the main results.
Scenarios containing standardised mean diﬀerence meta-analyses with
small-to-medium study sizes and I2 of 0%.
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Figure F.7: Mean squared error of heterogeneity variance estimates in odds
ratio meta-analyses containing small studies and with event probability 0.1 to
0.5
Scenarios with an underlying summary odds ratio of 1.65 (A1-A4), 3 (B1-B4) and
10 (C1-C4).
MSE is presented on the proportional scale only when τ 2 > 0.
There was no such τ 2 that produced a mean I2 of 90% when θ = 2.3, so these
scenarios are not presented.
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Study sizes
small small to medium medium small and large large
N
u
m
b
e
r
o
f
st
u
d
ie
s
(k
)
2 0 (0) 0 (0) 0 (0) 4.2 (<0.01) 0 (0)
3 0 (0) 0 (0) 0 (0) 4.2 (<0.01) 0 (0)
5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
10 0 (0) 4.2 (<0.01) 2.1 (<0.01) 0 (0) 0 (0)
20 0 (0) 8.3 (<0.01) 0 (0) 0 (0) 0 (0)
30 0 (0) 2.1 (<0.01) 0 (0) 0 (0) 0 (0)
50 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
100 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Table F.2: The percentage of scenarios and meta-analyses in which ML failed
to converge
Numbers outside the round brackets represent the percentage of scenarios where at
least one meta-analysis failed to converge to a ML estimate (out of a total of 48).
Numbers inside the round brackets represent the percentage of failed ML
convergence in scenarios that contain failures.
Study sizes
small small to medium medium small and large large
N
u
m
b
e
r
o
f
st
u
d
ie
s
(k
)
2 0 (0) 0 (0) 0 (0) 31 (0.02) 0 (0)
3 0 (0) 6 (<0.01) 2 (<0.01) 83 (0.02) 0 (0)
5 2 (<0.01) 2 (<0.01) 0 (0) 15 (<0.01) 0 (0)
10 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
20 0 (0) 4 (<0.01) 0 (0) 0 (0) 0 (0)
30 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
50 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
100 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Table F.3: The percentage of scenarios and meta-analyses in which REML
failed to converge
Numbers outside the round brackets represent the percentage of scenarios where at
least one meta-analysis failed to converge to a REML estimate (out of a total of
48). Numbers inside the round brackets represent the percentage of failed REML
convergence in scenarios that contain failures.
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Performance
measure
Reason for exclusion Figures of
selected results
Median bias of the
heterogeneity variance
estimate
The median is not meaningful
in the many scenarios when
>50% of heterogeneity variance
estimates are zero.
Figure F.1, shown in
comparison with
results of mean bias.
Median squared error
of the heterogeneity
variance estimate
Figure F.2, shown in
comparison with
results of mean
squared error.
Mean squared error of
estimate of the
summary eﬀect
Preliminary analysis showed
all heterogeneity variance
estimators have almost
identical mean squared
errors. Therefore, the only
observation that can be made
is that mean squared error
decreases as the number of
studies/size of studies
increase, but this is to be
expected and trivial.
Figure F.3
Power to detect a
signiﬁcant summary
eﬀect
Preliminary analysis showed
all heterogeneity variance
estimators have almost
identical power. Therefore,
the only observation that can
be made is that power
increases as the number of
studies/size of studies
increase, but this is to be
expected and trivial.
Figure F.4
Mean of the
error-interval
estimation of eﬀect
Preliminary analysis showed
this measure is highly
correlated with mean squared
error of the heterogeneity
variance. This is perhaps
because a high mean squared
error causes more variability
in conﬁdence interval widths.
Figure F.5
Variance of the
error-interval
estimation of eﬀect
Figure F.6
Table F.1: Excluded performance measures and reasons for exclusion
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Abbreviations
CDSR Cochrane Database of Systematic Reviews
FDA Food and Drug Administration
HK Hartung-Knapp (conﬁdence interval method)
IPD Individual Participant Data
MD Mean Diﬀerence
NICE National Institute for Clinical Excellence
OR Odds Ratio
RD Risk Diﬀerence
ROC Receiver Operating Curve
RR Relative Risk
SMD Standardised Mean Diﬀerence
The following are abbreviations used for heterogeneity variance estimation methods:
CA Cochran's ANOVA
DL DerSimonian-Laird
DLP Positive DerSimonian-Laird
PM Paule-Mandel
PMCA Two-step Cochran's ANOVA
PMDL Two-step DerSimonian-Laird
HM Hartung-Makambi
HS Hunter-Schmidt
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SJ Sidik-Jonkman
SJCA Improved Sidik-Jonkman
ML Maximum Likelihood
REML Restricted Maximum Likelihood
ARML Approximate Restricted Maximum Likelihood
FB Full Bayes
AB Approximate Bayes
BM Bayes modal
B0 Rukhin (zero prior)
BP Rukhin (simple)
SB Rukhin (alternate)
DLB Bootstrap DerSimonian-Laird
MBH Malzahn, Böhning and Holling
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